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Background: Emerging evidence suggest that peptides from fish have several 
beneficial health effects in the human body. A huge part of the world’s population are 
affected by life-style diseases related to overweight and obesity, leading to impaired 
glucose metabolism and other adverse metabolic impairments. In addition, around one 
out of ten individuals are affected by irritable bowel syndrome (IBS), a diagnosis that 
most often is only partly controlled by dietary changes and/or pharmacological 
treatment and cause reduced quality of life. A dietary supplement contributing to 
increased utilization of residual material from the fishing industry, capable of improve 
health outcomes related to metabolism and gastrointestinal function, can arguably be 
regarded valuable both for those individuals affected as well as contribute to a more 
sustainable industry. 
 
Aim: To investigate the effects of a supplement with cod protein hydrolysate (CPH) on 
glucose metabolism and appetite in healthy subjects, and on gut health in patients with 
IBS.  
 
Method: Three randomized double-blinded clinical intervention studies were 
conducted. Study 1 was a crossover trial in 41 healthy, middle-aged to elderly adults, 
and included two study days, with 4-7 days wash out in between. The intervention 
consisted of 20 mg of CPH (or control) per kg body weight, given before a standardized 
breakfast meal. Study 2 was a dose-range study in 31 healthy, older subjects receiving 
four different doses of CPH equivalent to 10, 20, 30 or 40 mg/kg body weight in random 
order, each dose taken daily for one week, with a week of wash-out in between. Primary 
outcome in both studies was postprandial response in glucose metabolism, measured by 
samples of serum glucose, insulin and plasma glucagon-like peptide 1 (GLP-1) (Paper 
I and III), and secondary outcomes (Study 1) were postprandial acylated ghrelin 
concentration and sensations associated with appetite (Paper II). Study 3 included 28 
patients with IBS randomly allocated to daily supplementation with 2.5 g CPH (n=13) 
or placebo (n=15) for 6 weeks. Outcomes were evaluated at baseline and after six weeks. 
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Primary outcomes were symptom severity evaluated by IBS Severity Scoring System 
(IBS-SSS) and quality of life. Secondary outcomes included gut integrity markers 
(zonulin, lipopolysaccharide-binding protein, intestinal fatty acid binding protein) and 
pro-inflammatory cytokines in serum, fecal calprotectin and fecal fermentation 
measured by concentration of short-chain fatty acids (SCFAs) (Paper IV).  
 
Results: No differences were observed between CPH and control for postprandial 
concentrations of glucose, GLP-1, acylated ghrelin or sensation related to appetite, but 
the postprandial insulin concentration was significantly lower after CPH compared to 
control (Study 1). No differences in estimated postprandial maximum level of glucose, 
insulin or GLP-1 were observed when comparing the dose of 10 mg/kg body weight of 
CPH to 20, 30 or 40 mg/kg body weight, but the estimated maximum value of glucose 
and insulin was lower for the 40 mg/kg body weight dose than the 10 mg/kg body weight 
dose (Study 2). Total IBS-SSS scores were reduced in both the CPH group and the 
placebo group, with no significant differences between intervention and placebo 
treatment. Concentrations of serum markers and SCFAs did not change for any of the 
groups (Study 3). 
 
Conclusion: Study 1 demonstrated that a single dose of CPH before a breakfast meal 
reduced the postprandial insulin concentration, without affecting blood glucose 
response, GLP-1 levels, concentrations of acylated ghrelin or sensations related to 
appetite in healthy individuals. Study 2 demonstrated that serum glucose and insulin 
concentrations tended to be reduced with increasing doses of CPH, however no 
significant effects were observed. Study 3 suggested that 2.5 g of CPH taken daily by 
IBS patients for six weeks did not affect symptom severity, gut integrity markers, 
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1.1 Fish – A great source of high-quality protein 
 
1.1.1 Fish consumption and health effects 
The Norwegian Health Authorities recommend a fish intake of 300-450 g a week, 
corresponding to two to three dinner meals.1 The Norwegian population eat on average 
less fish and more red meat than recommended.2 According to all the well-known 
benefits of reducing meat intake, an increase in fish intake will in most western 
populations arguably be beneficial both in regards to human health, environmental 
footprint and sustainable food production.3,4    
 
Fish contains 20-30% protein, a varying amount of fat and is a good source of 
micronutrients such as vitamin D, vitamin B12, iodine and selenium. Besides being a 
good source of high-quality protein, fish is considered the main source of the essential 
long chain omega-3 polyunsaturated fatty acids (PUFAs) such as eicosapentaenoic acid 
(EPA) and docosahexaenoic acid (DHA).5 It is classified according to the content of fat, 
and fish species containing less than 2% fat is considered lean fish, species containing 
2-5% fat is considered to be medium fatty fish, whereas species with a fat content above 
5% is classified as fatty fish.5  
 
Currently, the Norwegian Health Authorities recommend a weekly intake of 200 g fatty 
fish.1 However, a comprehensive risk-assessment from the European Food Safety 
Authorities (EFSA) published in November 2018, evaluating the health risk of exposure 
to dioxins and dioxin-like polychlorinated biphenyls (PCBs) from foods, led to a 
drastically reduction in the tolerable weekly intake (TWI) for dioxins and PCBs.6 As 
fatty fish is one of the main dietary sources to these detrimental substances, a new risk-
benefit evaluation regarding consumption of fatty fish is needed to evaluate whether the 






The great interest in the health effects of fish consumption have escalated from the 
1970s, when it was observed that the Greenland Eskimos, a population with a high 
intake of fish, had a low prevalence of cardiovascular disease (CVD) and type 2 diabetes 
(T2D).8 This observation is considered the first indication of the positive health effects 
of marine omega-3 PUFAs and has generated comprehensive investigations of the 
relationship between fish consumption and the beneficial effect of omega-3 PUFAs.  
Later observational studies have found fish consumption to be associated with reduced 
risk of coronary heart disease and stroke,9-12 but the effect on diabetes is more 
inconsistent.13-18 Consumption of fatty fish with a high concentration of omega-3 
PUFAs is associated with a reduction of circulating triglycerides, but the effect on 
cholesterol is more inconclusive.19 Regular fish consumption is associated with 
decreased levels of inflammatory markers related to CVD, hence is thought to have an 
anti-inflammatory effect.20 Although the mechanisms behind the anti-inflammatory 
effect is not fully understood, it has been suggested that it is a result of a reduced 
production of pro-inflammatory eicosanoids derived from arachidonic acids and 
increased conversion of EPA and DHA to eicosanoids with anti-inflammatory 
properties.21 
 
1.1.2 Health effects of lean fish intake 
The beneficial health effects of regular fish consumption have traditionally been 
attributed the content of marine long-chain omega-3 PUFAs and their importance for 
cardiovascular health. Interestingly, emerging evidence from studies reporting on the 
effects of lean fish and fish proteins in particular, eliminates the unique effect of the 
omega-3 PUFAs and suggests that other fish components besides the healthy fatty acids 
may improve health.22 Several observational studies in humans have indicated that 
intake of lean fish may beneficially influence metabolic and cardiovascular health. 
Consumption of lean fish has been associated with beneficial changes in body 
composition, glucose regulation and lipid metabolism23,24, in addition to reduced risk of 
metabolic syndrome and T2D.14-17,25 These associations are supported by several animal 
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studies reporting on beneficial effects of cod protein on glucose regulation and insulin 
sensitivity,26-28 lipid metabolism29 and hypertention.30  
 
In addition, promising results are reported in several clinical trials in humans, 
investigating health effects of an intervention with lean fish, however the overall results 
are conflicting. Most studies have compared lean fish with fatty fish or a non-seafood 
diet, containing equal amounts of proteins from lean meat, eggs, chicken and dairy 
products. A beneficial effect of lean fish consumption on lipid status has been reported 
in some interventions in healthy individuals,31,32 whereas no effect or a negative effect 
on lipid concentrations has been reported in others.33-36 Two studies have reported a 
beneficial effect of lean fish on glucose metabolism in normal-weight and overweight 
individuals,37,38 whereas one study in overweight and obese individuals reported a 
beneficial effect of salmon, but not cod.39 Lean fish has been reported to reduce blood 
pressure in CVD patients,40 but the same effect was not seen in a group of overweight 
and obese individuals.41  
 
Overall, existing literature point towards several beneficial health effects of consuming 
lean fish, however the limited number of clinical trials emphasize the need for more 
research to better understand the potential mechanisms generating these beneficial 
health outcomes.  
 
1.1.3 Fish and protein quality  
It is well established that an adequate amount of proteins in the diet is important to 
maintain a healthy body. The recommended daily protein intake for healthy adults is 
between 0.8-1.5 g per kg body weight, dependent on age and level of physical activity.42 
The nutritional value of proteins in different foods is dependent on several factors, 
including primary structure, susceptibility to enzymatic digestion, chemical changes 
during processing, the composition of amino acids and the overall content of essential 
amino acids. Essential amino acids are amino acids the human body are not capable of 





essential. Foods regarded as a source to high-quality proteins holds a high content of the 
essential amino acids.43  
 
Fish and marine resources, such as by-products from the fishing industry, are great 
sources of high-quality protein.44 Fish proteins contains all the essential amino acids, 
with a particularly high content of lysine and leucine. Of the non-essential amino acids, 
aspartic, glutamic acid and alanine are present in quite high amounts in proteins from 
fish. In addition, fish holds a high content of the amino acid-derived organic acid 
taurine.45 Most seafood proteins have a high digestibility, normally above 90%, thus the 
exploitation of the available amino acids in the protein source is good.43  
 
1.1.4 Utilization of marine resources: Fish protein hydrolysates 
Given the increased global demand for sources of high-quality protein, as well as the 
requirement for sustainable processing and production in the industry, it is an increasing 
interest in extraction of nutrients from by-products from the fishing industry. Better 
utilization of protein rich residual material from the industry can arguably be regarded 
both environmentally friendly, sustainable and cost-effective.44 Additionally, in coast 
located countries with an established fishing industry, such as Norway, a special interest 
is given the potentially biologically active effect of peptides generated from hydrolyzing 
fish by-products.44  
 
Various biotechnological approaches are currently investigated aiming to extract 
valuable nutrients and bioactive compounds from fish and fish by-products, capable of 
enhancing human health. Proteins from fish can be broken down to fish protein 
hydrolysates by enzymatic conversion of intact protein into peptides. Usually, these 
protein fragments, referred to as peptides, contains less than 20 amino acids.44 
Intervention studies evaluating the possible health effects of lean fish, have this far 
mostly focused on the possible health effects of cod filet, which in dry weight accounts 
for 50-70% of the whole fish. The remaining part of the fish is not suitable for human 
consumption as is, and is referred to as residual- or waste-material. Recently, improved 
processing technologies enable better utilization of this protein-rich residual material, 
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which after freeze drying contains approximately 70% protein.46 Peptides isolated from 
fish proteins by hydrolysis can be derived from both muscle, skin, scale, bones and other 
tissue, and can with right processing become high-quality protein powders suitable for 
human consumption.47 Existing literature have reported using several different enzymes 
utilized for food-processing in the industry, such as trypsin and Corolase®, among 
others, in the production of fish protein hydrolysates.48,49 These fish protein hydrolysates 
are of commercial interest, due to their good nutritional composition, beneficial amino 
acid profiles and possible bioactive properties.50 Accordingly, if peptides derived from 
hydrolysis of residual material from the fishery industry is found to be suitable for 
human consumption and capable of improving different health outcomes, it will 
innovate both human health and the industry.  
 
1.1.5 Fish proteins as a source of bioactive peptides 
In addition to being a good source of amino acids and energy, some dietary proteins are 
suggested to have a number of other important effects beyond nutrient supply, most 
often linked to the effects of possible bioactive peptides.51 Bioactive peptides can be 
formed naturally from dietary proteins by digestion and enzymatic degeneration in the 
gut or by microbial fermentation, or they can be delivered in the diet as already 
hydrolyzed proteins. Bioactive peptides tend to have 2 to 20 amino acid residues, present 
as di- and tripeptides with low molecular mass.52 Bioactivity is linked to the presence of 
different combinations of amino acid sequenced, with a possibly unique potential to 
beneficially modulate different metabolic pathways and thereby contribute to disease 
modulation. 
 
Different metabolic properties have been linked to different amino acid sequences 
present in fish peptides.44 Some are suggested to reduce hypertension by inhibit 
angiotensin-1 converting enzyme (ACE), some to beneficially alter the blood glucose 
metabolism through different mechanisms, such as inhibiting dipeptidylpeptidase-4 
(DPP-4), and some are suggested to affect the gut microbiota by contributing to 





generating a local effect directly in the gastrointestinal (GI) tract, or after entering the 
circulation by absorption in the gut.54 Some of the suggested effects of bioactive 
peptides from fish are depicted in Figure 1.  
 
The use of natural bioactive products has for a long time been used for prevention and 
treatment of a wide spectrum of conditions, but based on current evidences the scientific 
validity of such products is limited. However, it is sufficient preliminary data to indicate 
that bioactive compounds may potentially be valuable for clinical use, thus further 
clinical trials investigating these effects are of great need.55  
 
 
Figure 1. Suggested metabolic effects of bioactive peptides from fish. Peptides holding 
amino acid sequences with potential bioactive effects are suggested to influence different 
pathways involved metabolic regulation. Bioactive peptides can be formed after ingestion 
of food proteins by degeneration by enzymes in the gut or microbial fermentation (1) or 
they can be added in the diet as a nutrition supplement containing hydrolyzed protein (2). 
Reprinted from Dale et al 201922 with approval from publisher. ACE: Angiotensin-1 
converting enzyme, DPP-4: dipeptidylpeptidase-4. 
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1.1.6 Results from animal studies with fish protein hydrolysates 
Several animal studies have investigated the effect of fish protein hydrolysates on 
different metabolic outcomes, using hydrolysates based on different fish species. Most 
studies have compared the effect of fish protein hydrolysates with whole casein. 
 
A protein hydrolysate from salmon have been reported to improve the lipid profile in 
rats by reduce total plasma cholesterol, increase the high-density lipoprotein 
(HDL):total cholesterol ratio and lowering acyl-CoA-cholesterol acyltransferase 
activity, when compared to protein from casein.56 Additionally, a study including rats 
fed a high-fat diet with either casein or salmon protein hydrolysate as source of protein, 
reported that the rats fed fish protein hydrolysate became resistant to high fat diet-
induced obesity.57  In addition, they found the rats fed fish protein hydrolysate to have 
reduced postprandial plasma glucose and triglycerides levels, as well as lower 
triglycerides levels accumulated in the liver compared with the casein fed rats.57 A 
similar effect has been reported from a study in rats investigating a fish protein 
hydrolysate from saithe, where the fish protein hydrolysate (reported to have a high 
content of taurine and glycine) was found to reduce visceral adipose tissue mass and 
elevate fasting bile acids compared to casein.58 These findings are supported by a later 
study, reporting that a protein hydrolysate from salmon beneficially altered the fatty acid 
composition in liver and adipose tissue in a mouse model of chronic inflammation.52 
 
In contrast, more conflicting results are presented in a study investigating the effect of 
two different fish protein hydrolysates, based on either herring or salmon.59 In this study, 
the herring-fed rats presented lower serum HDL- and low-density lipoprotein (LDL)-
cholesterol, as well as higher triglycerides than the casein/whey-fed rats, implying a 
negative effect of herring on lipid status. The salmon-fed rats gained more weight and 
had improved postprandial blood glucose regulation than the casein/whey-fed rats.59 
The same fish protein hydrolysates were later reported to contain several peptide 
sequences with possible ACE-inhibiting activities,60 supported by another study 
reporting that a diet with cod residual proteins prevented hypertension in rats.30 The 





suggested that the cod residual proteins might contain amino acid sequences with ACE 
and/or renin inhibitory effects, capable of effecting the blood pressure regulating renin-
angiotensin system.30  
 
Overall, the findings from animal studies investigating the metabolic effects of different 
fish protein hydrolysates report several beneficial effects of these peptides, however the 
results are somehow conflicting, and it is a lack of knowledge regarding the mechanistic 
effects causing these potential beneficially alterations.  
 
1.1.7 Results from human interventions with fish protein supplements 
Several clinical interventions have investigated the potential effects of supplements with 
low doses of fish proteins or fish protein hydrolysates in humans on different outcome-
measures related to metabolic and gastrointestinal health. The relevant studies are 
presented in Table 1. 
 
Three studies have evaluated the effect of a supplement with fish proteins or fish protein 
hydrolysates on glucose and lipid metabolism in overweight and obese 
individuals.47,61,62 Vikøren et al. reported 8 weeks of supplementation with 3 or 6 g cod 
protein hydrolysate in 34 overweight/obese adults to result in lower values for fasting 
glucose, lower postprandial glucose concentration, lower LDL cholesterol, reduced 
body fat and increased muscle mass compared to baseline.61 Vildmyren et al. reported 8 
weeks of daily supplementation with 6 g protein from cod residual material to 
beneficially alter the postprandial serum concentrations of non-esterified fatty acids in 
42 healthy overweight or obese adults, when compared to placebo.47 Hovland et al. 
compared the effects of 8-weeks supplementation with 2.5 g of either cod protein, 
herring protein hydrolysate, salmon protein hydrolysate or milk proteins (90% casein 
and 10% whey) in 77 overweight/obese adults.62 They reported the cod protein 
supplement to reduce postprandial glucose concentration within the group, but no 
significant differences were observed when compared to the salmon- or herring 
hydrolysate groups.  
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Table 1. Overview of studies investigating the effect of supplementation with low doses of fish proteins 
and fish protein hydrolysates on different health outcomes related to metabolism and risk markers for 
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RCT: Randomized controlled trial, w: weeks, d: days, PH: Protein hydrolysate, LDL: Low-density lipoprotein, 
NEFA: Non-esterified fatty acids, CCK: Cholecystokinine, GLP-1: Glucagon-like peptide-1, MCP-1: Monocyte 







No differences were observed from baseline to after intervention for either insulin or 
lipid concentrations. The authors concluded that 2.5 g of fish proteins a day may be 
sufficient to improve glucose regulation.62 Taken together, the results from these three 
studies indicate that supplementation with relatively low doses of fish proteins- and 
hydrolysates are capable of beneficially alter glucose and lipid metabolism in 
overweight and obese subjects.  
 
Two studies have reported on the effects of fish protein hydrolysate supplements on 
body weight and appetite.63,64 Nobile et al. investigated the effect of a 13 weeks 
intervention with either 1.4 g or 2.8 g fish protein hydrolysate from saithe in 120 
overweight individuals, and reported both doses to reduce body weight, body mass index 
(BMI) and fat mass, as well as waist-, thighs- and hip circumference when compared to 
placebo.63 The fact that the effect was equal for both of the intervention dosages, points 
towards a beneficial metabolic effect of hydrolysates from fish, also when administered 
in low does. This is supported by a crossover study by Zaïr et al. investigating the effect 
of a 2-week intervention with 2 g fish protein hydrolysate from blue whiting a day in 15 
overweight women, reporting that the fish hydrolysate significantly suppressed appetite 
when compared to placebo. Postprandial measures of glucose concentrations and self-
reported sensations related to appetite showed that sweet-carvings, as well as plasma 
glucose levels, were reduced after the fish protein hydrolysate intervention.64  
 
One study have reported beneficial effects of a fish protein hydrolysate on blood 
pressure.65 Kawasaki et al. investigated a sardine muscle hydrolysate containing a 
suggested bioactive valyl-tyrosine motif. The hydrolysate was supplemented to 29 mild 
hypertensive subjects daily for 4 weeks and was reported to reduce blood pressure and 
increase plasma angiotensin I when compared to placebo.65  
 
A feasibility pilot study performed in twenty-four nursing home residents investigated 
the effects of six weeks supplementation with 5.2 g protein from blue whiting compared 
to placebo on parameters related to inflammation and glucose metabolism.66 They 
reported decreased serum concentrations of monocyte chemoattractant protein-1 (MCP-
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1) and increased C-reactive protein (CRP) in the intervention group compared to 
placebo, and no observed effect on glucose metabolism.66 
 
A few studies have reported on the effects of fish protein hydrolysates on gut health. It 
has been suggested after in vitro observations that hydrolysates from fish may have an 
immune-modulating effect with several beneficial properties in the intestine.69 This 
hypothesis is supported by a small clinical trial reporting that a fish protein hydrolysate 
may prevent injuries caused by the use of non-steroid anti-inflammatory drugs 
(NSAIDs), change permeability and possibly prevent injurious conditions in the gut.67 
Also, a cod skin peptide has been shown to reduce chemotherapy-induced toxicity and 
hence improve the quality of life in gastric cancer patients.68 These findings pose novel 
questions on whether a protein hydrolysate from fish can improve gut health, that needs 
further investigations before conclusions can be made.  
 
The last literature search for publications related to health effects of fish protein- and 
fish protein hydrolysate supplements in animal and human trials relevant for this thesis 





1.2 Body weight and metabolic implications 
 
1.2.1 Overweight and obesity  
Health challenges related to an unhealthy lifestyle have increased in a great extent the 
last decade. Overweight and obesity affects today in total over a third of the world´s 
population, with the prevalence constantly increasing.70 Overweight and obesity is 
defined by the World Health Organization (WHO) as abnormal or excessive fat 
accumulation that may impair health.71 BMI is the weight-for-height index used to 
classify overweight and obesity in adults, measured as weight in kilograms divided by 
the square of height in meters. Overweight is defined as BMI ³ 25 kg/m2 and obesity as 
BMI ³ 30 kg/m2.72 Individuals with increased body weight are at higher risk for the 
development of lifestyle related diseases, such as CVD and T2D.73 Metabolic syndrome 
is an increasingly common clinical condition, defined as a cluster of risk factors for the 
development of CVD and T2D. The condition is recognized by metabolic abnormalities 
such as abdominal obesity and elevated waist circumference, dyslipidemia (with 
elevated triglycerides and/or reduced HDL cholesterol), hypertension and insulin 
resistance.74   
 
The global increasing obesity problem calls for new nutritional strategies including both 
preventive and treatment options.75 Weight loss is theoretically easy; the energy intake 
has to be less than the energy expenditure. However, the practical implementation is 
challenging, and continue to lack compliance.71 One of the most obvious challenges in 
weight loss is hunger, which makes it difficult to maintain the dietary control.76 Appetite 
is regulated by tuned interactions between the GI tract, the adipose tissue and 
hypothalamus, and is controlled by several different hormones promoting or inhibiting 
the feeling of satiety.77 Ghrelin, a small appetite-stimulating peptide secreted from 
neuroendocrine cells in the stomach, is this far the only identified hormone known to 
stimulate hunger.78 This quality has created the idea that compounds capable of 
inhibiting the act of ghrelin may be effective in the prevention and/or treatment of 
overweight and obesity.79  
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1.2.2 Glucose metabolism 
In a fasting state and under normal physiological conditions, the plasma glucose levels 
are normally maintained within the narrow range from 4.0 to 6.0 mmol/L. The tight 
blood glucose control is balanced by glucose absorption from the intestine, production 
by the liver and uptake and metabolism of glucose by muscle and adipose tissue, 
regulated by the two hormones insulin and glucagon.80  
 
Insulin is the primary regulatory hormone essential for regulation of blood glucose 
concentration. The hormone is produced by the pancreatic b-cells and increase the 
glucose uptake in peripheral tissue, as well as inhibit the production of glucose from the 
glycogen stores in the liver. In addition, insulin stimulate cell growth and differentiation, 
as well as promote the storage of substrates in the liver, muscle and fat tissue by 
stimulating lipogenesis and protein synthesis and inhibit lipolysis and protein 
breakdown.80 
  
Increased glucose levels in the blood after ingestion of food triggers secretion of insulin. 
Insulin increase the glucose uptake in the cells by stimulating translocation of the 
glucose-transporter type 4 (GLUT4) from intracellular sites to the plasma membrane of 
the cell.81 GLUT4 is stored in vesicles inside the cell that continuously cycles from the 
intracellular stores to the cell surface. The insulin receptor is part of a subfamily of the 
tyrosine kinases, that also includes the insulin receptor-related receptor (IRR) and the 
insulin-like growth factor (IGF)-1 receptor. These tyrosine kinase receptors are proteins 
with two a- and two b-units, that undergo autophosphorylation and catalyzes the 
phosphorylation of intracellular proteins.80 At least nine intracellular proteins of the 
insulin/IGF-1 receptor kinases have been identified, of which four belongs to the 
insulin-receptor substrate (IRS) family. Upon phosphorylation by tyrosine, these 
intracellular IRS proteins interact with signal molecules involved in a series of signal 
pathways. The act of insulin on cells in peripheral tissue involves the activation of 
several different kinases, including phosphatidylinositol 3-kinase (PI3K), protein kinase 






The muscle is responsible for approximately 90% of the insulin-stimulated glucose 
uptake and stores the glucose as glycogen. Although the adipose tissue only counts for 
10% of the insulin-stimulated glucose uptake, this fraction is important for the control 
of the energy homeostasis in the whole body.81 The adipose tissue play an important 
part in metabolic regulation and insulin resistance. In the adipose tissue, the energy is 
stored as triglycerides, and free fatty acids (FFAs) released from adipocytes reduce the 
uptake of glucose in muscle cells as well as the insulin secretion from b-cells in the 
pancreas. In addition, the FFAs induce glycogenolysis in the liver, leading to elevated 
blood glucose concentrations. In addition, the adipocytes secrete adipokines such as 
leptin and adiponectin, hormones involved in the regulation of food intake, energy 
expenditure and insulin sensitivity.80  
 
1.2.3 Insulin resistance  
Insulin resistance or deficiency, as seen in metabolic syndrome and diabetes, results in 
dysregulation of the blood glucose concentrations leading to elevated fasting and 
postprandial blood glucose concentration.80 T2D is a chronic metabolic disorder 
characterized by increased plasma glucose levels, due to a defect in the ability of muscle 
and adipose tissue to appropriately respond to insulin. The insulin resistance of obesity 
and T2D is characterized by defects in many levels of the glucose metabolism and 
involves a decrease in the deposition of glucose to peripheral tissues, an overproduction 
of glucose in the liver as well as a functional damage of the pancreatic B-cells 
responsible for insulin production.82 Mechanisms suggested to be involved in insulin 
resistance caused by excess of adipose tissue (as seen in overweight and obesity), 













Figure 2. (1) Excess of energy intake compared to energy expenditure over time leads to an 
increase in adipose tissue, and potentially overweight and obesity. An increase in adipose 
tissue as seen in overweigh/obesity leads to (2) increased circulating concentrations of free 
fatty acids (FFAs), an event that is suggested to contribute to several adverse metabolic 
implications in pathways involved in the blood glucose metabolism, such as (3) reduced 
insulin production/secretion and increased insulin resistance in pancreas, (4) increased 
insulin resistance and decreased glucose uptake in skeletal muscles, (5) increased insulin 
resistance and glucose uptake in the liver and (6) increased receptor sensitivity to ghrelin 
action, potentially generating (7) increased appetite. Taken together, these adverse metabolic 
events contribute to increased concentration of glucose in the blood (8), known as 
hyperglycemia. The medical images are taken from Smart Servier Medical Art. Figure by 








Insulin sensitivity is influenced both by genetic and acquired factors. Increased adipose 
tissue due to overweight and obesity is the primary risk factor for insulin resistance, as 
the increase in adipose tissue results in elevated levels of circulating FFAs as well as 
inflammatory cytokines like tumor necrosis factor-alfa (TNF-a), interleukin-1 (IL-1) 
and interleukin-6 (IL-6). The elevated FFAs in the circulation contribute to insulin 
resistance by inhibit the uptake of glucose, glyconeogenesis and oxidation of glucose as 
well as increase the glycogenolysis in the liver and thereby the hepatic glucose output.80 
Additionally, it occurs a reduction of the enzyme activity of important enzymes involved 
in the normal insulin signaling pathway, such as PI3K and protein kinase B (Akt). When 
insulin resistance is combined with defects in the glucose-stimulated secretion of insulin 
from the pancreatic b-cells it will lead to the development of impaired glucose tolerance, 
hyperglycemia and eventually T2D.83  
 
Translocation of GLUT4 to the cell surface is crucial for the uptake of glucose, and this 
translocation, among other mechanisms, is impaired in T2D and contribute to the 
increased blood glucose concentration.81 In the muscle cell, the translocation of GLUT4 
is dependent on mTOR. It is shown that stimulation of this pathway improve glucose 
tolerance in animal models of T2D, but whether activation of the mTOR-pathway can 









1.3.1 Neuroendocrine regulation of appetite 
The energy homeostasis and regulation of appetite involves a complex network of 
peripheral and hypothalamic signals.79 Hypothalamus is the main regulatory organ of 
the endocrine system in humans, integrating peripheral signals about dietary intake and 
energy expenditure from the brainstem and other centers in the brain.85 Hypothalamus 
contains a number of different nuclei connected to the circulatory energy-homeostasis-
regulating system, of which the arcuate nucleus (ARC) play the most important role in 
regulation of appetite. When food is ingested, sensory information is sent from the GI 
tract to the central nervous system (CNS) and the ARC, either by the Vagus nerve or by 
GI hormones through the bloodstream. This feedback communication between the GI 
tract and the regulatory appetite centers within the CNS is part of the pathway referred 
to as the “Gut-brain-axis”.85  
 
1.3.2 Gut hormones 
Several gut hormones are known to be involved in the regulation of appetite. These 
includes ghrelin, insulin-like peptide 5 (ISL5), glucagon like-peptide-1 (GLP-1), 
glucose-dependent insulinotropic polypeptide (GIP), cholecystokinin (CCK) and 
peptide-tyrosine-tyrosine (PYY), among others.86,87 These GI hormones are normally 
referred to as incretins. They are secreted precisely to regulate appetite and satiety 
according to composition and size of a meal. Hormones produced in the GI tract have 
either an appetite stimulating (orexigenic) or appetite suppressing (anorexigenic) effect 
on food intake.86 An overview of some of the important hormones known to be involved 
in the regulation of appetite and released from the GI tract, is shown in Figure 3. 
 
Ghrelin is a small appetite-stimulating peptide consisting of 28 amino acids, secreted 
mainly from neuroendocrine D/P1-cells in the submucosal layer of the proximal part of 







Figure 3. Overview of the production and release of some of the different appetite regulating 
gastrointestinal hormones produced in the stomach and the intestines. The medical images 
are taken from Smart Servier Medical Art. Figure by Dale 2019.  
 
 
The circulating concentration of ghrelin decreases with food intake and increase with 
hunger.90 The hormone exists in the circulation both as an acylated and non-acylated 
form. The enzyme responsible for the acylation of ghrelin is ghrelin O-acyltransferase 
(GOAT).91 The acylated form of ghrelin act as a natural ligand of the growth hormone 
secretagogue receptor, also called the ghrelin receptor, and is therefore capable of 
stimulate the secretion of growth hormones, reduce the insulin secretion and impair the 
glucose metabolism.78 Due to its properties, ghrelin has become a target in appetite 
control and treatment of obesity, but a substance inhibiting the action of ghrelin, and 




Insulin-like peptide 5 (ISL5), a hormone produced by enteroendocrine L-cells in colon 
and rectum, has been identified as the second orexigenic hormone, thought to promote 
appetite during conditions of energy deprivation.87 However, nor the exact physiological 
mechanism or the orexigenic properties of this novel hormone has yet been defined. 
 
The two incretins GLP-1 and GIP, are peptide hormones secreted from the gut right after 
the ingestion of food, contributing to rapid distribution of nutrients postprandially by 
stimulating the release of insulin.92 These incretins are released from the gut by a 
glucose-stimulated response and are thought to account for 50-70% of total insulin 
secretion postprandially. GLP-1 is released from the L-cells in the small intestines as 
well as colon, whereas GIP is primarily released from K-cells in the small intestine. 
GLP-1 promotes lipolysis, slows the gastric emptying, inhibit glucagon secretion in a 
glucose-dependent manner, and is shown to improve postprandial glycemic control in 
patients with T2D, as well as promote satiety.85,92 GIP promotes energy storage in 
adipose tissue and enhance the formation of bone by stimulating osteoblast 
proliferation.92 GIP and GLP-1 are rapid degenerated by the enzyme dipeptidyl 
peptidase-4 (DPP-4), a discovery leading to the development of degradation-resistant 
GLP-1 receptor agonists and DPP-4 inhibitors for the treatment of T2D.92  
 
CCK is released from type I enteroendocrine cells in the mucosa of duodenum and 
jejunum immediately after the intake of nutrients, mostly after the intake of meals high 
in lipids and proteins. CCK has an anorexigenic effect, and once released in response to 
food intake it acts by activating the CCK receptor located in the vagal nerves in the GI 
tract.93 In addition to inhibit food intake by induce increased feeling of satiety, CCK 
interacts with the other incretins in order to regulate the energy balance.94  
 
PYY is another anorexic hormone released from enteroendocrine L-cells found 
predominantly in the distal GI tract.95 PYY is released from the gut in a caloric-
dependent manner in connection with a meal, and is shown to reduce the appetite and 
hence the intake of food.94 As with CCK, meals high in fat and protein are shown to 





Recently, it has been shown that bariatric surgery leads to significant modifications in 
the composition of gut hormones, facilitating further weigh loss.97 Whether the same 
beneficial alterations in gut hormone composition can be achieved by diet-induced 
weight loss or other dietary interventions is still not clear, and promote interesting 




1.4 Irritable bowel syndrome 
 
1.4.1 Definition 
Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder 
(FGID), assumed to affect between 10 and 20% globally, with a higher prevalence 
reported in women than men.98 The condition is characterized by a combination of 
symptoms including abdominal pain, bloating, distention, flatulence and disturbed 
bowel habits seen as constipation (IBS-C), diarrhea (IBS-D) or a combination of both 
(IBS-mixed).99 Besides the GI symptoms, many of those suffering from IBS normally 
experience a broad spectrum of extra-intestinal symptoms, such as fatigue, 
fibromyalgia, poor social functioning and reduced emotional well-being. IBS is shown 
to have severe impact on the quality of life.100,101 
 
1.4.2 Etiology and pathogenesis 
The ethology of the disease is not fully understood, but it is evidence that the condition 
involve a dysfunction in one or more of the control systems that contributes to the 
regulation of bowel function, including the central nervous system, the enteric nervous 
system, the enteroendocrine system, the enteric immune system and the gut 
microbiota.102,103 Suggested mechanisms includes alterations in the gut-brain axis, low-
grade inflammation, visceral hypersensitivity, abnormalities in the GI endocrine cells, 
changes in the GI motility, post infectious changes, bacterial overgrowth, malabsorption 
of carbohydrates, abnormalities in serotonin metabolism, gene interactions and 
alterations in the gut microbiota composition.100,104-107 An overview of suggested 














Figure 4. Overview of suggested mechanisms and factors involved in irritable bowel 
syndrome (IBS). CNS: Central nervous system, GI: Gastrointestinal, FODMAPs: 
Fermentable oligo-, di, monosaccharides and polyols, SCFAs: Short-chain fatty acids. 
The figure is made in Lucidchart, Dale 2019.  
 
 
1.4.3 Gut microbiota and IBS 
The human microbiota includes the entire collection of microorganisms living on the 
surface and inside our bodies. The microbiota living in the gut constitute by far the 
greatest portion, and it is estimated that over 70% of all the microbes in the human body 
is colonized in the colon, and constitute a cell mass equivalent to 1-2 kg of body 
weight.108,109 Over 1000 different species have been identified in the human gut, all 
belonging to a small number of phyla. The most abundant phylas are Firmicutes, 
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Bacteroidetes and Acinobacteria, while Proteobacteria, Fusobacteria, Cyanobacteria 
and Verrucoicrobia are usually present in lower amounts.110 While the gut microbiota 
is the present community of microorganisms, the gut microbiome refers to the entire set 
of genomic elements decisive for the microbiota in the gut.111 A healthy composition of 
the gut microbiome is essential for a broad range of physiological functions, as the gut 
microbial genes is decisive for the bacterial richness in the gut and hence the activity of 
the gut microbiota.110 Microbial richness, seen as bacterial diversity, is usually 
considered an indicator of good health. In contrast, reduced bacterial diversity and 
imbalance of the gut microbiota, referred to as dysbiosis, has been associated with 
impaired metabolism, obesity and broad range of diseases, such as T2D, immune-related 
diseases and inflammatory diseases, including inflammatory bowel disease 
(IBD).109,112,113 
 
Disturbances in the gut microbiota has been increasingly linked to the pathophysiology 
of IBS.114 Observations of increased risk of IBS onset after a gastroenteritis and 
associations between IBS and prior use of antibiotics highlights the importance of a 
disturbance in the gut microbiota in IBS.115,116 In addition, a broad range of studies have 
reported that the gut microbiota profiles in subjects with IBS differs to the gut 
microbiota profiles of healthy controls.117-120  
 
It is growing evidence that the altered gut microbiota in IBS not only explains the 
abdominal IBS symptoms, but also the psychiatric co-morbidity occurring in 
considerable number of patients.121 Recent years, the interaction between diet, gut 
microbiota composition and IBS symptom severity has gained a lot of attention. This is 
currently considered an important pathophysiological basis for treatment of the 











IBS is a functional disorder, and up to date no biomarkers have been identified to 
confirm the diagnosis. Thus, the diagnosis of IBS is based on clinically symptoms and 
consistency and frequency of stool, in addition to exclusion of other GI disorders, such 
as coeliac disease, IBD and microscopic colitis.102 The diagnostic criteria for IBS has 
evolved since 1978, when the first criteria was published by Manning et al.123 The 
changes includes the development of the diagnostic Rome guidelines, currently 
available in the IV edition.99 The Rome IV criteria for diagnosis of IBS and the different 
subtypes are presented in Table 2. For an accurate diagnosis, a classification of IBS 
subtype according to the Bristol Stool Form Scale is recommended.99 
 
Table 2. Rome IV criteria for the diagnosis of IBS. Modified from Mearin et al. 2016.99 
 
Rome IV diagnostic criteria for IBS 
Recurrent abdominal pain on average at least 1 day per week in the last 3 months, associated with two or 
more of the following: 
1. Related to defecation 
2. Associated with a change in stool frequency 
3. Associated with a change in form (appearance) of stool 
Symptoms must have started at least 6 months before diagnosis. 
IBS with predominant 
constipation (IBS-C) 
25% of bowel movements with Bristol stool form types 1 or 2 
AND < 25% of bowel movements with Bristol stool form types 6 or 7 
IBS with predominant 
diarrhea (IBS-D) 
>25% of bowel movements with Bristol stool form types 6 or 7 
AND < 25% of bowel movements with Bristol stool form types 1 or 2 
IBS with mixed bowel 
habits (IBS-M) 
>25% of bowel movements with Bristol stool form types 1 or 2 
AND > 25% of bowel movements with Bristol stool form types 6 or 7 
IBS unclassified  
(IBS-U) 
Patients who meet diagnostic criteria for IBS but whose bowel habits cannot 





The treatment of IBS aims to target the most predominant symptoms. A central part of 
the treatment is to educate the patients by explaining the condition and the different 
treatment options, as well as provide reassurance about the symptoms as non-harmful 
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events.99 Non-pharmacological treatment options are preferably the first-choice, as 
available drugs are most likely to target only the predominant symptom. Of note, 
antidiarrheals, laxatives, antispasmodics and anti-depressants are used in some cases. 
Currently, some of the most common drugs targeting the specific subtype-symptoms of 
IBS includes the guanylate cyclase C antagonist linaclotide (Constella) for patients with 
IBS-C and the mixed opioid agonist/antagonist eluxadoline (Truberzi) for patients with 
IBS-D and/or M. However, due to the broad diversity of symptoms experienced by most 
patients, drug treatment is often perceived as inadequate and do not lead to total control 
of symptoms.99 A multidisciplinary approach is the preferred and recommended 
treatment option. A better understanding of the disease, combined with life-style 
interventions including diet, exercise and breathing techniques, is proven to be effective 
for reducing symptom severity in IBS patients.100 In addition, psychological and 
behavioral treatment like cognitive behavioral therapy and hypnotherapy has also been 
shown to reduce IBS symptoms and improve quality of life.124   
 
1.4.6 IBS and diet 
Diet composition and food intake has been shown to play an important role in the 
generation of symptoms in patients diagnosed with IBS, and most patients claims that 
their symptoms can be related to the consumption of different foods.125 Several 
modifications in the diet are shown to improve symptom severity in IBS. The first line 
dietary treatment for IBS patients is to follow the dietary guidelines from the modified 
NICE (National Institute for Health and Care Excellence) diet, as recommended by the 
British Dietetic Association.126 The NICE-diet highlight the importance of regular 
meals, and recommend to reduce the intake of carbonated drinks, shewing gum, fatty 
and spicy foods, coffee, alcohol, onion, cabbage and beans as well as supplementing the 
diet with fibers such as psyllium husk. If these dietary modifications does not improve 
symptoms, a diet with a restricted intake of fermentable oligosaccharides, disaccharides, 
monosaccharides and polyols (FODMAPs) is shown to be effective for a reduction in 
GI symptoms, especially abdominal pain and bloating.127 Currently, the low-FODMAP 





FODMAPs are short-chained carbohydrates that are poorly absorbed in the small 
intestines, and when fermented by colonic bacteria, production of gas and osmotic 
activity causes symptoms such as bloating and diarrhea. A low-FODMAP diet is shown 
to significantly reduce symptoms in IBS patients.128 Notably, a diet with a restricted 
intake of FODMAPs is associated with distinct alterations in both function and 
composition of the gut microbiota, as well as modulations in fecal fermentation and 
production of short chain fatty acids (SCFAs).129,130 However, the long-term health 
effect of adherence to this dietary intervention is not established. The health effects of 
the changes observed in the gut microbiota composition and fecal fermentation in 
response to a diet with low content of fermentable carbohydrates is currently 
unknown,131 thus the long-term use of a strict low-FODMAP diet needs to be studied 
further in order to explore the long term effects. Novel, additional therapeutic dietary 
treatments for symptom relief in IBS patients can thus arguably be valuable.  
 
1.4.7 Potential biomarkers for IBS 
Several potential biomarkers for the diagnosis of IBS have been investigated in clinical 
trials, including non-invasive markers in both serum and feces. Overall, the results up 
to date have been disappointing, and these biomarkers are currently only used in a 
research setting.132 The suggested biomarkers tends to identify organic disease and 
hence eliminate IBS, rather than differentiate the IBS diagnosis in particular.132  
 
Pro-inflammatory cytokines 
All though the exact mechanisms behind IBS remains uncertain, several studies have 
suggested that a chronic low-grade mucosal inflammation and imbalance in the cytokine 
levels may contribute as potential etiological factors.133,134 Cytokines is a collective term 
of signal molecules with immunological functions, affecting almost all biological 
processes and produced by a broad range of human cells, including mast cells, 
macrophages and B- and T-lymphocytes, among others. The term “cytokine” 
encompasses different families, and includes interleukins, chemokines, growth factors, 
interferons, adipokines and the tumor necrosis factor family.135 Comparison of cytokine 
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levels in IBS patients compared to healthy controls have revealed altered cytokine 
production in IBS patients, and particularly mast cell activation has been suggested as a 
contributor to IBS pathogenesis.133 A broad spectrum of different cytokines have been 
investigated in IBS patients, including several of the interleukins (IL), interferon-
gamma (INF-γ)  and TNF-a, all considered functional cytokines important for the 
immune system. Elevated levels of IL-6, IL-8, IL-17 and TNF-a have been reported in 
IBS patients compared to healthy controls,136-138 and a decline in levels of IL-6 and IL-
8 has been observed in response to a low-FODMAP intervention.139 In addition, 
significantly correlations have been observed between cytokine levels, symptom 
severity and quality of life in IBS patiens.138  
 
Gut integrity markers 
In addition to low-grade inflammation, increased intestinal permeability is suggested to 
contribute to the IBS pathogenesis. Several markers related to the enterocyte function 
have been investigated in IBS populations. Zonulin is a protein serving as a physiologic 
modulator of intercellular tight junctions, assumed to be a master regulator on the 
intestinal permeability linked to development of several chronic inflammatory 
disorders. It is suggested that zonulin might serve as a marker for impaired gut-barrier 
function.140 When investigated in IBS patients compared to healthy individuals, higher 
levels of zonulin was reported in patients with IBS.141 Importantly, it was recently 
highlighted that serum zonulin might not be a valid marker for the evaluation of gut-
mucosal barrier function in GI disorders, thus zonulin values in this group of patients 
should be interpreted with caution.142  
 
Lipopolysaccharide-binding protein (LBP) is an acute-phase protein suggested as a 
marker for endotoxemia and bacterial translocation.143 Increased levels of LBP has been 
reported in patients with IBD.144 In addition, elevated concentrations has been observed 
in patients with non-coeliac wheat sensitivity, suggested to be a subgroup of IBS.145 
Serum LBP levels are thought to correlate with serum concentrations of 
lipopolysaccharide (LPS),143 When LPS was investigated in IBS-patients, the levels 





Intestinal fatty acid binding protein (iFABP) is considered a marker for intestinal 
epithelial cell damage. Lower concentrations of iFABP have been reported in IBS 
patients than in healthy controls.146 Of note, these gut integrity markers related to enteric 
function are not specific for IBS, and up to date the implications of these markers in the 




Fecal calprotectin is the most investigated fecal biomarker for inflammation. It is 
regarded a valid marker for inflammation in the GI tract and can be useful to 
discriminate between IBS and IBD.147 Calprotectin is not related to the pathogenesis of 
IBS, and levels are expected to be within the normal range in patients with FGIDs. A 
cut-off value of 150 mg/kg has by several studies been suggested to hold good diagnostic 
accuracy for the distinction between IBS and IBD.148 
 
Several recent studies have suggested that dysbiosis of the gut microbiota contributes to 
the pathogenesis of IBS, and concentrations of fecal SCFAs have been investigated as a 
marker of fecal fermentation reflecting the gut microbiota activity.130 Distinct alterations 
in fecal SCFA concentrations have been reported between IBS patients and healthy 
controls, and propionate and butyrate in particular have been suggested as possible 






1.4.8 Proteins and peptides in IBS  
Clinical experience indicate that dietary proteins normally are well tolerated in IBS 
patients, and most individuals link their symptoms to the intake of different 
carbohydrates.127 Limited evidence and knowledge exists on the impact of different 
protein sources on gut health. It has been demonstrated in healthy individuals that 
different dietary sources of protein affect the diversity and composition of the gut 
microbiota in different degree, and thereby potentially influence different health 
outcomes.150 It is growing evidence suggesting that the amino acid composition and 
digestibility of dietary proteins is determent for the gut microbiota composition.151,152 
Novel results indicate that the presence of fish proteins in the diet have impact on both 
composition and activity of the gut microbiome, affecting the human microbiota 
composition and activity.153  
 
In addition to the results highlighting proteins and peptides as possible modulators of 
the gut microbiota, it has been suggested through in vitro models that a fish protein 
hydrolysate may have an immune-modulating effect with beneficial properties in the 
intestine.154 A small clinical trial has reported that a dietary supplement containing  
hydrolyzed proteins from pacific whiting may prevent NSAID-induced injuries in the 
gut.67,69 Despite the lack of research supporting an effect of supplements with peptides 
and protein hydrolysates on gut health, several dietary supplements containing peptides 
are today sold as commercial products targeting IBS patients and those suffering from 






1.5 Rationale and hypothesis 
As described in the scientific background, emerging evidence suggest that fish protein 
hydrolysates may have several beneficial health effects, also when supplemented in low 
doses compared to the normal daily dietary protein intake. The prevalence of overweight 
and obesity is constantly increasing worldwide, and lifestyle related diseases leading to 
impaired glucose metabolism and other adverse metabolic impairments, with the need 
of treatment and prevention strategies, affect a huge part of the world’s population. In 
addition, around one out of ten individuals suffers from IBS symptoms, a diagnosis only 
partly controlled by alterations in the diet and/or pharmacological treatment, with the 
need of additional treatment strategies. A dietary supplement contributing to increased 
utilization of residual material from the fishing industry, capable of improve health 
outcomes related to metabolism and GI function, can thus arguably be valuable both for  
human health and the industry.  
 
Overall, we hypothesized that a supplement with cod protein hydrolysate (CPH) would 
beneficially affect health by improve outcomes related to glucose metabolism, appetite 
and gut health. More specific, we hypothesized that: 
 
i) A low  dose of supplement with CPH would:  
 
- beneficially affect glucose metabolism, by lowering the postprandial glucose 
and insulin concentrations in healthy subjects (Paper I)  
 
- reduce postprandial concentrations of the appetite regulating hormone 
ghrelin, hence reduce the feeling of hunger in healthy subjects (Paper II)  
 
- beneficially affect gut health and improve symptoms in IBS patients, by 
reduce degree gut permeability and inflammation, as well as modulate the 
composition of the gut microbiota and hence the fecal concentration of short 




ii) It was a dose-response relationship between different doses of CPH 
supplementation and degree of changes in the glucose metabolism in older 






2. Objectives  
 
The overall aim of the project was to investigate whether CPH produced from hydrolysis 
of residual material (muscle) from cod filet production have beneficial properties in the 
human body, leading to improvement of health outcomes related to glucose regulation 
and appetite in healthy subjects, and gut health in patients with IBS.  The work presented 
in the current thesis is based on an initiative from Firmenich Bjørge Biomarin AS, 
Ålesund, Norway, manufacturer of the specific CPH investigated in this PhD-project. 
 
Three intervention studies were included to address the effects of the CPH. Two 
intervention studies were carried out in healthy subjects to investigate the effect of CPH 
supplementation on postprandial glucose metabolism and appetite and identify the most 
effective dose for further use. The last study was designed to evaluate the effect of a 
CPH supplement in patients with IBS. The specific aims of the three studies and the four 
papers included in this PhD-thesis are listed below: 
 
Study 1 (Paper I and II):  
The primary aim was to assess the effect of a single, low dose of CPH on postprandial 
glucose metabolism in healthy adults (Paper I). The secondary aim was to evaluate the 
effect on outcomes related to appetite (Paper II).  
 
Study 2 (Paper III):  
The aim was to investigate the dose-response of increasing doses of CPH 
supplementation on glucose metabolism in older adults, to find a potential effective 
daily dose for further use in clinical studies. 
 
Study 3 (Paper IV): 
The aim was to investigate the effect of a CPH supplement on gut health in patients with 
IBS, by evaluating symptom severity, gut integrity markers and pro-inflammatory 
cytokines in serum, fecal calprotectin and fecal fermentation measured by concentration 





Methods for the three clinical studies conducted in the work with this thesis are 
described below. For a detailed description of methods used for laboratory analysis of 
the outcome measures, composition of the test material used in the three different studies 
and the implemented questionnaires, the reader is referred to the respective papers.  
 
3.1 Study population and design 
 
An overview of the recruitment flow, study design and study outcomes for the three 
randomized controlled trials included in this PhD-project is shown in Figure 5. Paper I 
and II are based on Study 1, Paper III is based on Study 2 and Paper IV is based on 
Study 3. 
 
3.1.1 Paper I and II 
Participants were recruited through advertisements on the internet and posters at 
Haukeland University Hospital and Ålesund Hospital between October 2017 and 
February 2018. Interested participants were contacted by telephone for evaluation of 
eligibility and compliance with inclusion criteria. Suitable candidates were invited to 
further screening at a hospital visit. Forty-one healthy individuals were included in the 
trial, of whom 26 were females and 15 males. Inclusion criteria were age 40-65 years 
and BMI 20-30 kg/m2. Exclusion criteria were fish/shellfish allergy and intolerance, 
pharmacologically treated diabetes mellitus, elevated blood pressure, chronic diseases 
that might affect the evaluation of the study endpoints and acute infections. Participants 
were instructed to avoid omega-3 supplementation 1 week prior to study start and while 
participating in the study, and not make any changes in their diet or level of physical 
activity. The study was designed as a double-blind crossover trial and included two 
different study days, with three to seven days wash-out period in between. On both study 
days the participants were served a test drink containing either 20 mg of CPH per kg 
body weight or casein given as control. The test material was delivered in neutral bottles, 








CPH: Cod protein hydrolysate, BW: Body weight, WO: Wash out, QoL: Quality of life 
*Results from study visit 1 with baseline postprandial measures in Study 2 is not included in the results 
reported in the manuscript based on the study (Paper III). See explanation in paragraph 6.3.2. 
 
 
Figure 5. Overview of the recruitment flow, study design and study outcomes for the 
three randomized controlled trials included in the current PhD-project. Paper I and II 
are based on Study 1, Paper III is based on Study 2 and Paper IV is based on Study 3.  
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On both study days the participants met in a fasting state at the hospital between 8 and 
9 am. Baseline blood samples were taken before they were served the test drink (CPH 
or control in random order) and a breakfast meal. The breakfast including the test drink 
provided 500 kcal and 77 g carbohydrate. Blood samples were taken in intervals of 20 
minutes until 120 minutes postprandially, with a final sample after 180 minutes.  
 
The primary outcome was response in postprandial glucose metabolism, measured by 
venous samples of serum glucose and insulin, and plasma GLP-1 (Paper I). Secondary 
outcomes were postprandial acylated ghrelin concentrations and sensations associated 
with appetite (satiety and the feeling of fullness) measured by symptom questionnaires 
(Paper II).   
 
3.1.2 Paper III 
Participants were recruited by advertisements online and at Haukeland University 
Hospital and Ålesund Hospital between March and July 2018. Subjects interested in 
participating were contacted and screened for eligibility by telephone. Suitable 
candidates meeting the inclusion criteria were invited to a baseline hospital visit 
including baseline blood chemistry and signing of the informed consent form. The 
criteria for inclusion were age between 60 and 80 years, BMI between 20-30 kg/m2 and 
signed informed consent. Criteria for exclusion were allergy and intolerances to fish 
and/or shellfish, pharmacologically treated diabetes mellitus, low and/or unstable blood 
pressure, chronic diseases or medication that were likely to interfere with the evaluation 
of the study endpoints, acute infections, substance misuse or unwillingness to comply 
with the requirements of the study. The participants were instructed not to take any 
nutritional supplements containing omega-3 fatty acids for two weeks before study 
commencement, and during the course of the study.  
 
In addition to the baseline meeting, the participants attended five study visits (Figure 5). 
The first study visit included baseline postprandial measures before the participants had 





methodological error, see further descriptions under discussion of results (paragraph 
6.3.2). The study included four different intervention cycles of one week each, with 
doses corresponding to 10, 20, 30 and 40 mg per kg body weight CPH supplement 
provided in randomized order. The participants received six bottles with powder to be 
mixed with water (test drink), to be taken each morning. On day 7 in each intervention 
period, the participants met in a fasting state at the hospital between 8 and 9 am. The 
last dose of the current intervention period (test drink) was given when fasting baseline 
blood samples were taken. Breakfast was served 10 minutes after the test drink. The 
breakfast including the test drink provided 455 kcal and 63.5 g carbohydrate. Blood 
samples were taken at 20 minutes intervals until 120 minutes postprandially, with a final 
sample after 180 minutes. The participants received six bottles for the next intervention 
week at the end of each study day. It was a wash-out period of seven days between each 
intervention week. Participants received reminders on text messages prior to each new 
intervention week, and before each study day.  
 
The primary outcome was postprandial response in glucose metabolism after the four 
different doses, measured by venous samples of serum glucose and insulin, and plasma 
GLP-1. 
 
3.1.3 Paper IV 
IBS patients were recruited through online advertisement including a digital recruitment 
form, between December 2018 and January 2019. Suitable candidates meeting the 
inclusion criteria were contacted and screened over telephone. After receiving 
information about the study and signing the informed consent form, all patients received 
a dietary record and equipment to collect a baseline stool sample by mail, prior to the 
first hospital visit. Inclusion criteria were age 20-70 years, BMI 18-30 kg/m2 and IBS 
diagnosis according to Rome IV criteria with predominant diarrhea (IBS-D) or mixed 
bowel movements (IBS-M). Exclusion criteria were fish/shellfish allergy and 
intolerance, diabetes mellitus, elevated blood pressure, chronic diseases that might 
affect the evaluation of the study outcomes, acute infections, substance abuse, 
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immunocompromised patients defined as taking immuno-suppressive medications, 
patients eating a strict low-FODMAP diet, use of antibiotics the last 4 weeks before 
inclusion or use of medications for the IBS diagnosis.  
 
The study was a double-blinded, randomized parallel group trial, and included a six-
week intervention with a drink containing 2.5 g CPH (test material) or 2.5 g maltodextrin 
(placebo). Medical data, the IBS-diagnosis and biochemical variables were assessed at 
baseline. The Rome IV criteria were used to confirm the clinical diagnosis of IBS.  
 
A 3-day dietary record was completed by all patients prior to taking the fecal sample at 
baseline and at end of the study. The patients were instructed not to make any changes 
in the diet while attending the study, and not to take any nutritional supplements 
containing omega-3 or pre- or probiotics for 6 weeks before study start, and during the 
trial. 
 
Outcomes were evaluated at baseline and at end of the study (after six weeks). Primary 
outcomes were symptom severity evaluated by IBS Severity Scoring System (IBS-SSS) 
and quality of life. Secondary outcomes included gut integrity markers (zonulin, LBP, 
iFABP) and pro-inflammatory cytokines in serum (TNF-a , INF-g, IL-4, IL-6, IL-8, IL-








3.2 Test material: The cod protein hydrolysate  
 
The fish protein hydrolysate investigated in this PhD-project was manufactured by 
Firmenich Bjørge Biomarin AS, Ålesund, Norway. A powder was made by hydrolysing 
fish muscle of Atlantic cod from the production of cod filets (cutting left overs). Fish 
muscle was hydrolysed with Protamex® (Novozymes AS) followed by spray drying of 
the soluble part of the enzyme digest.  
 
The CPH raw material contained approximately 89% protein by weight, as well as 
<0.2% fat, 0% carbohydrate, <3.0% water, 10% ash, 0.1% NaCl, 1.7% sodium and 
0.07% chloride. Free amino acids accounted for 4.77 % of total amino acids in the CPH, 
and the ratio essential amino acids/non-essential amino acids was 0.70. Analysis of the 
molecular weight distribution showed that about 90% of the peptides in the hydrolysate 
had a molecular weight of 2000 Daltons (Da) or less (18 amino acids or less), about 75% 
of 1000 Da or less (10 amino acids or less) while about 55% had a molecular weight of 
500 Da or less (5 amino acids or less). Approximately 25 to 30% of the peptides had a 
molecular weight less than 200 Da, which represented small dipeptides and free amino 
acids (data obtained from Firmenich Bjørge Biomarin AS, Ålesund, Norway).  
 
The CPH was analysed for allergenicity, and it was found to be so low that it was 
regarded safe for those with fish allergy to consume (Report from Firmenich Bjørge 
Biomarin AS, analysis performed by the Section for Protein and Allergy Analysis, 
Laboratory for Clinical Biochemistry, Haukeland University Hospital, data on file).     
 
The amino acid and taurine composition of the CPH used in all of the three clinical 
studies included in this PhD-project is shown in Table 3. Composition of the different 
test materials used in the three different interventions, all provided as powders to be 






Table 3. Amino acid and taurine composition of the cod protein hydrolysate (CPH) used in the three 
clinical studies included in this PhD-thesis.  
 
Amino acid Total amino acid (mg/g) 
Alanine 47.8 
Arginine 51.1 
Aspartic acid 73.3 
Aspargine 0.38 


























3.3 Statistical analyses 
 
SPSS data package (IBM SPSS Statistics 24), Stata v15.1 (StataCorp LLC, Texas, USA) 
and GraphPad Prism version 7.0 (GraphPad Software, Inc., San Diego, CA, USA) were 
used for the statistical analysis included in the current thesis. All graphical work was 
conducted in GraphPad. P-values <0.05 were considered statistically significant.  
 
3.3.1 Paper I and II 
A multivariable, repeated measures linear mixed-effects regression analysis was 
conducted to evaluate the difference between the CPH and control arms. The data for 
insulin, GLP-1 and acylated ghrelin was not normally distributed, thus it was log-
transformed before analysis. The analyses were adjusted for BMI and gender. Total area 
under the curve (tAUC) for postprandial glucose concentration, differences in baseline 
characteristics between genders, acylated ghrelin and postprandial scores for satiety and 
the feeling of fullness were compared using unpaired t-tests. Paired t-test was used to 
evaluate the differences in nutrient intake between the two study days. 
 
3.3.2 Paper III 
To estimate the effect of the dose, the maximum observed value and the AUC of each 
outcome variable for each combination of person and dose was calculated. Mixed effects 
models were fitted with the outcome measure (max value or AUC) as dependent 
variable, fixed effects of dose and random intercepts across persons. Potential carry-
over effects were assessed using a standard likelihood-ratio test, to test for interaction 
between ordering and dose.  
 
3.3.3 Paper IV 
Paired two-sided t-tests were used to compare differences between the baseline and after 
intervention measures for each group, whereas unpaired two-sided t-tests were used to 
compare differences between the CPH group and the placebo group. Correlations were 





All the clinical studies were conducted according to the guidelines laid down in the 
Declaration of Helsinki and the Regional Committee for Medical and Health Research 
Ethics of Central Norway approved all procedures involving human subjects. Written 
informed consent was obtained from all subjects. 
 
Paper I and II: The study was approved by the Regional Committee for Medical and 
Health Research Ethics of Central Norway (2017/1794). The trial was registered at 
clinicaltrials.gov as NCT03669796. 
 
Paper III: The study was approved by the Regional Committee for Medical and Health 
Research Ethics of Central Norway (2017/1795). The trial was registered at 
clinicaltrials.gov as NCT03526744. 
 
Paper IV: The study was approved by the Regional Committee for Medical and Health 
Research Ethics of Central Norway (2018/1825). The trial was registered at 









A summary of the most important findings in each paper is presented in the following 
sections.  
 
4.1 Paper I 
 
Forty-one participants (age 51±6 years), of whom twenty-six females, completed the 
trial. Mean energy intake before the two study visits did not differ and mean fasting 
blood glucose concentrations were equal on both study days. At the first study visit, 
eighteen participants were allocated to CPH and twenty-three were allocated to control. 
At the second study visit they were all allocated to the opposite intervention to the one 
received the first study day.  
 
The peak in glucose concentration occurred 20 minutes after the breakfast both after 
CPH and control, and was numerically higher after CPH drink than control, however 
did not differ significantly. After CPH, the insulin concentration peaked at a lower level 
and after 20 minutes, whereas the peak after control was higher and occurred 40 minutes 
postprandially. The insulin concentration was significantly lower after CPH 
supplementation than after control. Mean plasma GPL-1 concentrations were equal 
before each study day, and the concentrations dropped right after the meal, with lower 
concentrations observed after CPH than after control. No differences between CPH 





4.2 Paper II 
 
The included participants and allocation to supplement is similar to that presented for 
Paper 1. No significant differences were observed between CPH and control for acylated 
ghrelin concentrations postprandially in a mixed-effects regression analysis. No effects 
were seen for BMI or gender when adjusting for these parameters in the analysis. Mean 
fasting acylated ghrelin levels were comparable before the CPH intervention and the 
control intervention. The concentration of acylated ghrelin was lowest 80 minutes 
postprandially after CPH and 20 minutes postprandially after control. No correlation 
was observed between body weight (kg) and concentrations of acylated ghrelin at 
baseline. When comparing the tAUC for postprandial acylated ghrelin and postprandial 
scores for satiety and the feeling of fullness, no differences were observed between CPH 
and control. 
 
4.3 Paper III 
 
Thirty-three older adults were included, of whom 31 subjects (18 females) completed 
the study (age 67.8±4.9 years) and were included in the analysis. Energy and 
macronutrient intake did not change during the study period. No differences in estimated 
maximum levels of glucose, insulin or GLP-1 were observed when comparing the 
lowest dose of CPH (10 mg/kg body weight) to the higher doses (20, 30 or 40 mg/kg 
body weight). Estimated maximum value of glucose was on average 0.28 mmol/L lower 
when the participants had been given the highest dose (40 mg/kg body weight CPH) 
compared to the lowest dose (10 mg/kg body weight CPH). Estimated maximum level 
of insulin was on average 5.14 mIU/L lower when the participants had been given the 
highest dose compared to the lowest dose. Estimated maximum level of GLP-1 was on 
average 0.34 pmol/l lower when given the highest dose compared to the lowest dose. 
No statistically significant differences in AUC between the four different doses were 
observed for either glucose, insulin or GLP-1 when comparing the lowest dose of 10 
mg/kg body weight of CPH with the higher doses of 20, 30 or 40 mg/kg body weight. 





4.4 Paper IV 
 
Thirty-one IBS patients were included of whom 28 patients (23 women and 5 men) 
completed the trial (age 42.7±11.9 years). Three patients withdrew after randomization, 
one patient due to disliking the supplement and two patients due to experiencing 
increased diarrhoea. Thirteen patients were allocated to CPH supplementation whereas 
15 patients received placebo. The groups were comparable at baseline. Total IBS-SSS 
scores and scores for quality of life were reduced in both the CPH group and the placebo-
group in response to intervention, with a significant reduction only in the placebo group. 
End of study scores did not differ between groups. Concentrations of gut integrity 
markers, pro-inflammatory cytokines and SCFAs did not change in response to 
intervention for any of the groups. Baseline measures for the whole group showed that 
the total SCFA concentration was significantly inversely correlated with the total IBS-
SSS score. No correlations were found between baseline total IBS-SSS score or any of 





5. Methodological considerations  
 
5.1 The cod protein hydrolysate 
 
5.1.1 Rationale for choice of doses 
The scientific rationale behind the choice of amount of CPH (20 mg/kg body weight), 
administered in Study 1 (Paper I and II) is limited. Unpublished data from studies with 
the CPH performed in rats and a small number of human subjects have indicated that 
the hydrolysate may induce a metabolic response when given in low concentrations. A 
cross-over trial including 12 healthy males found premeal supplementation with 20 
mg/kg body weight CPH to reduce postprandial blood glucose and insulin 
concentrations when compared to casein and whey protein. In addition, a study in 9 
healthy subjects found one premeal supplementation with 20 mg/kg body weight CPH 
to increase postprandial secretion of GLP-1 and PYY, reduce the postprandial secretion 
of ghrelin as well as reduce the feeling of hunger and increase the feeling of fullness 
after the test meal according to included questionnaires (unpublished data from studies 
performed at Clinical Trial Consultants AB, University Hospital, Uppsala University, 
Sweden, provided by Einar Lied, former scientific advisor for Firmenich Bjørge 
Biomarin AS).  
 
Of note, these unpublished trials included few subjects and the tendencies reported were 
not analyzed according to statistical significance. Anyhow, they suggested a metabolic 
effect when the CPH was given in concentrations of 20 mg/kg body weight, hence this 
dose was chosen as a starting point of investigation in Study 1.  
 
Due to limited knowledge and few published papers on the effect of fish protein 
hydrolysates in the human body, we consider  Study 1 to be an explorative trial regarding 
the unique effect of such a low dose. Based on the previously described literature 
reporting on the effect of fish protein hydrolysates in human subjects, the suggested 
effective daily dose ranges from 1 to 6 g a day.61,63,64 Taken together, results from these 





hydrolysate may beneficially affect glucose metabolism and hormones related to 
appetite and suggests that bioactivity from fish protein hydrolysates may be obtained at 
supplementary dosages of around 1.5 g a day, equivalent to about 15-20 mg hydrolysate 
per kg body weight in an individual with a body weight of 70-80 kg.  
 
Of note, the specific mechanisms behind the reported effects are not known. However, 
we chose to further investigate the potential effect of low doses of CPH in both the 
following interventions (Study 2 and 3). As the results from Paper III (the dose-range 
study) was not ready during the planning of the third study in IBS patients, we found it 
appropriate to decide on a set dose of 2.5 g of CPH a day for all individuals included. 
Overall, it is possible that the different doses investigated in the studies included in the 
current PhD-project were too low to observe an effect, and that the low doses 
investigated might partly explain the lack of distinct effects.   
 
5.1.2 Hypothesized mechanistic effects  
The recommended lowest daily dietary protein intake of a healthy individual is 0.8-1.0 
g protein per kg body weight per day,42 equal to 65-80 g protein per day with a body 
weight of 80 kg and on average e.g. 20 g protein per meal. Consequently, the 
hypothesized effect of the CPH is not due to the added consumed protein per se, which 
is negligible compared to the average daily protein intake. The mechanism of action of 
any effects of the CPH investigated in this project is still unclear. A low dose of fish 
protein hydrolysate is presumed to be effective due to the content of bioactive peptides 
with unique amino acid sequences, possibly capable of rapid absorption and distribution 
in the body,44 however the CPH investigated in the current project is not analyzed for 
the content of bioactive peptides.   
 
We postulated that the hydrolysate investigated in the project would have an effect 
beyond being a source of amino acids and protein, and that a possible effect of this 
specific hydrolysate could be attributed to the high content of branched chained amino 
acids (BCAAs) present as di- or tripeptides. BCAAs act as signal molecules affecting 
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protein synthesis, glucose metabolism and regulation of body weigh through pathways 
such as the PI3K/Akt and mTOR pathway.155 High levels of circulating BCAAs are 
suggested to be closely related to several adverse metabolic outcomes, and increasing 
evidence suggests that insulin resistance, obesity and T2D can be linked to dysregulation 
of the BCAA metabolism, resulting in elevated circulating levels of these.156,157 Hence, 
high levels of circulating BCAAs have been found to serve as biomarkers for insulin 
resistance and risk of developing T2D, and pharmacological treatment strategies have 
aimed to target the dysregulated signaling network including the BCAAs, such as the 
PI3K/Akt and mTOR pathway.156  
 
Although recent studies have indicated that the circulating levels of BCAAs are elevated 
in obese and insulin-resistant individuals, the literature is currently unclear regards to 
whether supplementation with additional BCAAs in the diet will further impair the 
glucose metabolism. Both animal and human trials have demonstrated that dietary 
BCAAs may contribute to impaired glucose regulation.158,159 However, this is not 
consistent, and a large Japanese cohort study suggested that a high intake of dietary 
BCAAs may be associated with a decreased risk of diabetes.160 In addition, a recent 
study in twelve obese and prediabetic individuals reported that 4 weeks of 
supplementation with 20 g BCAA a day did not impair glucose metabolism.161 Also, it 
has previously been demonstrated that postprandial plasma levels of BCAAs can be 
correlated with a beneficial insulin response and the release of the gut hormones GLP-
1 and GIP after a meal with different protein sourses.162 Interestingly, intragastric 
administration of the BCAAs leucine and isoleucine before a mixed nutrient drink has 
been demonstrated to reduce blood glucose response postprandially in healthy 
subjects.163  In addition, cell studies have suggested that protein hydrolysates containing 
BCAAs present as mixed dipeptides in low concentrations stimulate glucose uptake in 
muscle cells by the PI3K/Akt pathway.163,164 Taken together, these results suggests that 
dietary supplementation with a low dose of a protein hydrolysate containing BCAAs, 






The CPH investigated in the current project had a high concentration of BCAAs, and 
about 10% of the di- and tripeptide fraction of the supplement was present as peptides 
containing leucine and/or isoleucine (Table 3). In summary, we postulate that these 
peptides might constitute a unique, bioactive effect even when given in low 
concentrations. 
 
5.1.3 Interventions with food versus supplements 
The present thesis investigated the effect of a dietary supplement on several different 
metabolic outcomes. Overall, it is much easier to conduct an intervention study with a 
supplement than with actual food, both according to practical and scientific reasons. A 
dietary supplement can be taken without changing the baseline diet, meaning that if an 
effect was to be observed, it is more likely to be attributed to the intervention material. 
When using whole foods in an intervention study, for instance lean fish to investigate 
the effect of fish proteins, several issues have to be considered when interpreting the 
results, such as bioavailability of the amino acids in the food, other nutrients in the food 
and possible nutrient interactions, change of energy intake and distribution of 
macronutrients due to the intervention. As an example, in interventions with lean fish, 
one has to acknowledge that the fish provided is eaten instead of another food, in many 
cases most likely meat. This adds an uncertainty to the design, as one can question if an 
effect then can be related to consumption of lean fish or rather just a reduction in meat 
intake. These factors, leading to a potentially biased result, is easier to standardize when 
the intervention consists only of a dietary supplement, not leading to a change in the 





5.2 Choice of control material  
 
5.2.1 Study 1 
In Study 1, whole casein was chosen as control ingredient to facilitate an iso-caloric and 
iso-nitrogenic control material. The use of casein as control can be a limitation to the 
design. The metabolic response to casein is well investigated, and casein is reported to 
be a slowly digestible protein capable of delaying gastric emptying.165,166 In addition, 
the digestion pattern of casein has been suggested to hold distinct differences from other 
proteins when investigated in animals.150,167,168 Casein has been shown to affect gut 
hormones involved in the glucose regulation as well as affect the absorption rate of 
different amino acids, when compared to other food proteins in healthy subjects.162  
Importantly, the most distinct differences between casein and other proteins has been 
reported when casein is investigated in high-protein diets as well as served as a 
hydrolysate,150,167,168 which was not the case in the current trial.  
 
One could argue that the control drink should have been a true placebo and only 
contained glucose. However, then it would have been possible that an observed effect 
would simply occur due to the differences in caloric or nitrogen content, and not to the 
effect of the CPH. Both test drinks contained equal amounts of protein, in total 
approximately 1.5 g (dependent on the participants´ body weight). This amount of 
protein is negligible when compared to the effect of the proteins given in the breakfast 
meal (12.5 g), thus a potential effect can possibly be attributed the content of bioactive 
peptides and not the protein per se.  
 
Whole casein was chosen as control because it has been proven not to affect the glucose 
metabolism when administered in low concentrations.165,169 Based on the issues 






5.2.2 Study 2 
The protocol for Study 2 originally included a baseline test day without CPH 
supplement. Here, a glass of orange juice was chosen as control to facilitate an iso-
caloric breakfast each test day, and because we aimed to investigate the effect of 
different doses of CPH compared to no protein. As described in detail in section 6.3.2 
the baseline test day with orange juice as control was not included in the manuscript, 
according to a methodological mistake. Of note, a maltodextrin powder identical to the 
implemented powder-doses, but without CPH, could arguably be a more proper and 
comparable control than orange juice, and should have been implemented if one were 
to choose control material again.  
 
5.2.3 Study 3 
The placebo material used in Study 3 was maltodextrin. Maltodextrin is an easily 
absorbed polysaccharide, often used as a sugar replacement. It is thought to be a well-
tolerated carbohydrate in IBS and is commonly used as placebo material in dietary 
interventions including IBS patients, hence can be considered a safe placebo 
material.170,171 As we aimed to investigate the effect of CPH compared to a control 
without protein (as it was no need for an iso-nitrogenic control), we found maltodextrin 





5.3 The test meals 
 
Study 1 and 2 included a meal tolerance test with serving of a standardized breakfast 
meal (described in section 3.1.1 and 3.1.2), to investigate changes in postprandial blood 
glucose metabolism. A meal tolerance test is not a standardized tool and can vary greatly 
in terms of nutrient composition and total energy content. A standardized test to evaluate 
blood glucose response is the oral glucose tolerance test (OGTT), consisting of 75 g 
glucose resolved in water. This method is frequently used in clinical trials when 
investigating postprandial glucose regulation and is a recommended test in the diagnosis 
of diabetes mellitus.172 However, it is suggested that a mixed meal with proper food 
might be a more physiologically relevant test than an OGTT for postprandial measures, 
as it provides a mix of macronutrients, including both proteins and fats, which is likely 
to influence the glucose regulation.173,174  
 
We chose to use a “normal Norwegian breakfast” consisting of two semi-dark slices of 
bread with butter, cheese and jam, as we wanted to investigate the metabolic effect of 
CPH after consumption of a regular meal with complex sources of both carbohydrates, 
fat and protein (representative for a normal everyday breakfast), and not only glucose. 
Other studies investigating effects of fish proteins on glucose regulation have 
implemented similar meals to the one we included.34,39,47 As the test drinks differed 
slightly in composition between Study 1 and Study 2, the total content of carbohydrate 
was 77 g and 63,5 g, respectively. The use of the same meal in both Study 1 and 2 can 
arguably be regarded a strength and make the results more valid for comparison. 
 
In line with the body-weigh-adjusted doses of CPH, one could argue that individually 
weight-adjusted meals, with a set distribution of energy and nutrients according to body 
weight, should have been implemented to strengthen the design. This was evaluated as 
an option when planning the study. However, we chose not to implement these 
individual adjustments in the breakfast meal, as it would have made the practical 






5.4 Study populations 
 
5.4.1 Healthy middle-aged to elderly adults (Study 1 and 2) 
Study 1 and 2 were designed to investigate the effect of the CPH on postprandial blood 
glucose metabolism. In Study 1 and 2 we chose to include healthy individuals with a 
BMI from 20-30 kg/m2, corresponding to normal weight to overweight. The rationale 
for including healthy individuals with a BMI corresponding to normal weight to 
overweight, and not obesity, was the aim of primarily investigate the effect in subjects 
supposed to have a normal blood glucose regulation. Hence, we did not expect a great 
effect on the postprandial blood glucose levels, as this is supposed to be adequately 
regulated in a healthy individual. But, if an effect was to be observed in other outcomes 
in healthy individuals, it could arguably be an effect more distinct if investigated further 
in individuals with an abnormal blood glucose response, such as metabolic syndrome or 
T2D.  
 
Previous studies investigating the effect of fish protein hydrolysate supplements on 
blood glucose metabolism have included healthy overweigh and obese individuals with 
a BMI (mean/median) range from 31-35 kg/m2.47,61,62 Although these individuals were 
characterized as “healthy overweight and/or obese”, they may arguably be more likely 
to have a slightly dysregulated blood glucose metabolism than those subjects included 
in our trial.  
 
 In study 1, we included individuals aged 40-65 years, as it was a study in “normal 
adults” to establish a potential effect. In study 2 we included healthy individuals aged 
60 to 80 years. The glucose metabolism changes with increasing age, and many elderly 
adults are affected by impaired glucose metabolism.175 The skeletal muscle is the major 
site of insulin-stimulated glucose uptake in the human body, and aging leads to a gradual 
decline in muscle mass.176 Therefore, we found it relevant to explore the potential 
favourable effects of CPH on parameters of glucose metabolism, as these are closely 




5.4.2 IBS patients (Study 3) 
Study 3 was designed to investigate the effect of a CPH supplement on gut health in 
patients with IBS. Patients with predominantly diarrhea or mixed bowel habits (IBS-D 
or IBS-M) were chosen, as these subgroups previously have been reported to benefit the 
most from dietary interventions, such as reported for the low-FODMAP diet.177 In 
addition, by restricting the inclusion of IBS-patients to these two subgroups and not 
include patients with constipation as the predominant symptom, we aimed to reduce the 
risk of selection bias by comparing individuals with similar symptomatic problems. In 
addition, levels of SCFAs are suggested to differ between IBS-D/M and IBS-C,178 hence 
the inclusion of patients with constipation-predominant IBS could potentially have 
affected this outcome. However, it can be argued that inclusion of all subtypes of IBS 
might could have strengthen the design, as the effect of different dietary interventions 









5.5 Estimation of sample size  
 
The number of participants to include in the three clinical trials included in this PhD-
project was not calculated according to a power analysis, due to lack of similar studies 
and knowledge on which effects to expect. Available studies investigating the effects of 
cod proteins in humans, published before the planning of the study presented in Paper I 
and II, are based on whole fish38 or long-term use of fish protein supplement.47,61 Thus, 
we had no suitable data as basis for a power analysis according to our study design. 
Accordingly, it is possible that too few participants to be able to observe an effect were 
included in the studies. We decided to include between 30 and 40 subjects in the trials, 
a number higher or similar to previously reported in studies on cod protein.38,47,61 In the 
last trial in IBS patients we intended to include 30 patients according to protocol. To our 
knowledge, no previous trials have reported on the effect of a cod peptide supplement 





5.6 Fecal fermentation (Study 3) 
 
One of the secondary outcomes of Study 3 was concentration of SCFAs in feces. SCFAs 
are produced by microbial fermentation in the colon and serve as the main source of 
energy for the colonocytes. In addition, the SCFAs hold a broad spectrum of diverse 
physiological functions, such as influence on the colonic blood flow and the intestinal 
pH, of which the latter influence the absorption of nutrients.179 SCFAs are also suggested 
to serve as mediators in the microbiota-gut-brain crosstalk, hence influence 
psychological functioning.122 
 
The primary source for colonic production of SCFAs by the gut microbiota is dietary 
fibres. It is well established that the presence and production of SCFAs in the colon is 
important for health, and that the gut microbiota composition affects the production of 
SCFAs.122 Although most of the SCFAs are absorbed by the colonocytes in the proximal 
colon and only a small fraction is left in feces, several studies have suggested that the 
SCFAs present in the distal gut may contribute to the regulation of motility and 
sensitivity,180 as well as modulate inflammation.181 Of note, the concentration of SCFAs 
in feces might also be affected by transit time, and concentrations of the major SCFAs 
in feces are suggested to be higher in patients with IBS-D compared to other IBS 
subtypes.130 
 
A dietary FODMAP restriction has previously been shown to significantly modulate 
fecal fermentation and composition of SCFAs in patients with IBS. A 4-week low 
FODMAP diet in sixty-three IBS patients reported reduced concentration of total 
SCFAs after the diet, in addition to reduced concentrations of butyric acid and acetic 
acid.130 These findings are supported by an intervention in 20 IBS patients, who found 
a low-FODMAP diet to significantly reduce the total concentration of SCFAs as well as 
butyrate.139 In addition, a recent meta-analysis investigating the implication of 
alterations in fecal SCFAs in IBS patients suggested that the levels of butyrate and 





Of note, the clinical relevance and importance of changes in levels of SCFAs is currently 
not known.130  
 
In accordance with the previously reported effect of a low-FODMAP diet on fecal 
fermentation and concentrations of SCFAs in IBS patients, we chose to include analysis 
of fecal SCFAs concentrations in our study including IBS patients. We hypothesised 
that if the CPH had an effect on the function and composition of the gut microbiota, the 
concentrations of SCFAs would serve as a marker for this. The carbohydrate intake of 
the participants was not supposed to change during the trial, hence if a change in SCFAs 
was to be observed we hypothesized that it could potentially be attributed to alterations 












6. Discussion of results 
 
 
The overall aim of the current thesis was to investigate the potential health effects of a 
dietary supplement with a protein hydrolysate from cod. Effects on glucose metabolism 
and  appetite in healthy individuals and gut health in patients with IBS were the primary 
outcomes. Three intervention studies were conducted in this thesis to investigate the 
effect of CPH supplementation on glucose metabolism (Paper I) and appetite (Paper II), 
the effect of increasing doses of CPH supplementation on glucose metabolism (Paper 
III) as well as the effect of CPH supplementation in IBS patients (Paper IV). In 
summary, our findings suggests that a low dose of CPH beneficially affect glucose 
metabolism by decreasing the postprandial insulin concentration in healthy adults 
(Paper I), and that a beneficial postprandial effect may seem to be more distinct if the 
supplement is given in a dose corresponding to 40 mg/kg body weight, compared to 
lower doses (Paper III). No distinct effects of CPH supplementation were observed for 
outcomes related to appetite regulation or gut health in IBS patients (Paper II and IV).  
 
Previous studies have investigated the effect of lean fish and cod protein consumption 
in humans, as well as the effect of fish protein hydrolysates on several metabolic 
markers in animal models, but only a small amount of data exists on the specific effect 
of different fish protein hydrolysates on human metabolism. Thus, results from the 
presented studies add knowledge to the effects of CPH as a dietary supplement in 
humans and can be regarded valuable in further investigations of the effect of potentially 
bioactive fish peptides in individuals with abnormal glucose metabolism as well as the 
effect of peptides in patients with IBS. Of note, the effect of a supplement with fish 
peptides, or peptides from other protein sources, in an IBS population, has to our 
knowledge not previously been investigated. Hence, this study can be considered 
valuable as basis for further research on the effect of peptides in IBS, despite the lack of 
distinct findings.  
 
In the following section, the main finding in the four papers as well as limitations to the 





6.1 Effects on glucose metabolism (Paper I)  
 
Paper I is based on the primary outcomes in Study 1; The effect of CPH supplementation 
on postprandial glucose metabolism. We reported that the postprandial insulin 
concentration was significantly lower after a single preprandial intake of CPH compared 
to control (casein), whereas no effect was observed for concentrations of glucose or 
GLP-1.  
 
The trial included healthy normal- to overweight subjects with HbA1c levels within the 
normal range, hence the blood glucose regulation was supposed to be normal. 
Accordingly, the lack of observed effect on blood glucose regulation due to the CPH 
was not surprising. Previous trials investigating fish protein hydrolysates on glucose 
regulation have included overweight and/or obese individuals with higher BMI than 
those subjects we included,47,61,62 hence these study populations were more likely to 
have an abnormal glucose metabolism making the findings more distinct. We chose to 
include individuals presumed to have a normal blood glucose response in the current 
study, hence the lack of effect on postprandial blood glucose levels were as expected. 
The observed effect on the postprandial insulin concentrations in healthy subjects can 
arguably be relevant for further investigations, preferably in studies lasting over a period 
of time and in individuals with impaired blood glucose regulation.  
 
As highlighted in the introduction, few studies have reported on the specific effect of a 
fish protein hydrolysate on glucose metabolism. Hence, our results adds new knowledge 
to the field of research regarding novel utilisation of marine recourses and residual 
material from the fishing industry. Of note, several studies investigating the effects of 
supplementing the diet with low doses of protein hydrolysates from other protein 
sources than fish (such as the milk protein casein) have reported promising results of 
protein hydrolysate supplementation both in patients with T2D182-184 and gestational 
diabetes.185 Ingestion of a supplement with hydrolysed casein together with a meal rich 
in carbohydrates has been reported to reduce postprandial glucose concentrations and 
improve glycaemic control in several trials with T2D patients.182-184  
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In addition, supplementation with a drink containing 8.5 g casein protein hydrolysate 
twice a day for 8 days in 26 women with gestational diabetes, did moderately reduce 
plasma glucose levels postprandially when compared to placebo.185 These findings 
highlight the interest of further investigations of a fish protein hydrolysate supplement 
in target groups with impaired glucose metabolism. Based on the several disadvantages 
of pharmacological treatment of diabetes, such as risk of weight gain and 
hypoglycaemia, alternative approaches to achieve glycaemic control is of great 
interest.186  
 
6.1.1 Interpretation of the reduced postprandial insulin concentration 
 
Of note, it has to be highlighted that the differences between the postprandial insulin 
concentrations after CPH and after control in the current study are quite moderate, and 
the clinical implications of our findings can be discussed. It is likely that the statistically 
significant difference observed (p=0.032) is not clinically relevant, however it implies 
an effect of interest for further investigation targeting a study population with an 
abnormal glucose regulation, such as patients with metabolic syndrome or T2D. Based 
on previous findings on glucose regulation related to cod protein intake in animal 
studies,27,187 we hypothesize that the CPH might increase the insulin-stimulated glucose 
uptake in the muscle by enhance mechanisms involved in the glucose transporter 
system, such as increase translocation of GLUT4 to the cell surface. This hypothesis 







6.2 Effects on outcomes related to appetite (Paper II) 
 
Paper II is based on the secondary outcomes in Study 1; Evaluation of the effect of CPH 
on outcomes related to appetite regulation. We observed no effect of the CPH for any 
of the outcomes related to appetite, neither postprandial concentrations of acylated 
ghrelin or self-reported sensation related to hunger, satiety and feeling of fullness. 
Accordingly, we were unable to confirm our hypothesis that one low dose of CPH would 
suppress the ghrelin concentrations postprandially and contribute to a reduced feeling 
of hunger.  
 
Based on our findings in Paper I, were a reduced postprandial insulin concentration after 
one supplementation with CPH before a meal was observed, we aimed to investigate 
whether the alterations in insulin concentrations could be linked to, or be caused by, 
altered ghrelin concentrations. As we discuss in Paper II, the major effects of ghrelin is 
linked to mechanisms involved in promoting food intake and avoid starvation to prevent 
hypoglycemia, such as suppress insulin secretion and stimulate growth hormone 
secretion to restrict peripheral glucose uptake,188 and it has previously been reported an 
inverse correlation between postprandial insulin and plasma ghrelin concentrations.189 
Hence, we found it relevant to investigate whether the observed alterations in insulin 
concentrations could be partly linked to, or explained by, alterations in concentrations 
of ghrelin.  
 
6.2.1 Dietary protein and satiety 
The effects of protein intake in relation to appetite is a well investigated topic, based on 
the substantial interest from both the industry and consumers to identify specific 
substances, foods and/or diets that can generate increased satiety and improve weight 
management.190 It is acknowledged in the literature that high-protein diets can be used 
as successful strategies to prevent and/or treat overweight and obesity, through 




Replacing fats and carbohydrates with proteins in the diet, is suggested to have 
beneficial effect on satiety. High-protein ad-libitum diets have led to reduced energy 
intake due to increased satiety, causing unintentional weight loss, when investigated in 
several clinical trials.192,193 A meta-analysis reporting on the effect of a high-protein 
meal on postprandial ghrelin levels concluded that the consumption of a meal high in 
proteins increased satiety compared to meals high in either fat or carbohydrates.194 In 
addition, proteins from fish have been reported to increase satiety in a greater extent 
than other dietary protein sources when investigated in postprandial studies.195,196  
  
Only one small pilot study in fifteen overweight women has previously reported on the 
specific hunger-regulating effect of a fish protein hydrolysate.64 Zair et al. found daily 
supplementation with 2 g protein hydrolysate from blue whiting for fourteen days to 
significantly reduce sweet-cravings, in addition to glucose levels postprandially.64 Of 
note, this study is comparable to our intervention, as they investigated the effect of a 
low dose of a protein hydrolysate from lean fish. Thus, the effect cannot be attributed a 
change in nutrient intake, as seen in dietary interventions where more protein are added 
to the diet, substantially leading to a reduced intake of fats and carbohydrates and hence 
a change in the dietary composition of nutrient intake. When supplementing the diet 
with additional protein in form of a hydrolysate in a low dose, one reduce the risk of a 
potential effect to occure simply due to a change in the composition and nutrient 
distribution of the diet. The effects reported by Zair et al. suggest that we might would 
have observed an effect of the CPH if it was investigated in a higher dose and 
supplemented over a period of time.  
 
6.2.2 Limitations to the study design 
As the outcomes related to appetite were secondary outcomes, several aspects of the 
study design could explain the lack of findings. One could arguably have improved the 
design by include a more standardized and thorough evaluation of self-experienced 
hunger as measured by the questionnaires. In addition, inclusion of an ad libitum meal 





the breakfast meal, could have strengthen the design and made it possible to measure 
the actual caloric intake after CPH versus control. In addition, it would have been of 
interest to include measurements of other hunger regulating GI hormones, such as ISL5 
and GIP, as these hormones also affect appetite and can be related to the insulin 
concentrations postprandially.  
 
6.2.3 Interpretation of acylated ghrelin concentrations 
In addition to the limitations to the design already presented in Paper II, it has to be 
highlighted that our measurements of acylated ghrelin might hold a methodological 
weakness. Plasma for the analysis of acylated ghrelin was obtained by centrifugation of 
full blood, sampled in 4 ml EDTA-K3/Aprotinin blood collecting tubes. As acylated 
ghrelin is quite rapidly degenerated in plasma, it has been suggested that the best method 
for quantifying clinical plasma acylated ghrelin levels is to pretreat plasma samples with 
4-(2-aminoethyl) benzenesulfonyl fluoride hydrochloride (AEBSF).197 The guidelines 
from the manufacturer of the equipment used for samples and analysis of acylated 
ghrelin in the current study did not include recommendations on addition of AEBSF, 
thus we did not include pretreatment of AEBSF to the plasma samples in our protocol. 
Hence, it is possible that the levels we detected in our samples were lower than reality 
due to degeneration prior to analysis. This should be taken into consideration when 
interpreting the result. Data for acylated ghrelin values measured at baseline and 
postprandially after the intake of CPH/control drink and the breakfast meal is shown in 
Table 4.  
 
In human individuals, the circulating concentrations of ghrelin are presumed to be high 
right before a meal, and then drop to the lowest within 1 hour after food intake before a 
new rise. This fluctuation is thought to result in a two- to threefold variation in 
circulating levels of ghrelin in plasma.198 In our data, we did not include a measure 60 
minutes postprandially, hence it is possible that we have missed the lowest level. In 
addition, the levels of acylated ghrelin varied greatly between individuals, leading to 
large standard deviations, and we did not observe a two- to threefold rise or decrease in 
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concentrations. Of note, the concentrations of acylated ghrelin was numerically highest 
180 minutes postprandially, and not at baseline after the overnight fasting. 
 
Table 4. Plasma acylated ghrelin concentration of the 41 participants included in the study 
evaluating the effect of CPH on postprandial acylated ghrelin concentrations after intake 
of one dose of CPH and control (casein) drink. 
 
 
Acylated ghrelin  
CPH  Control 
(pg/ml) Mean SD  Mean SD 
Baseline 97.4 196.3  90.0 194.0 
0 min 91.1 202.5  89.7 193.0 
20 min 84.3 199.6  84.7 198.4 
40 min 86.1 204.8  84.2 199.7 
80 min 83.4 189.3  86.2  201.7 
180 min 101.4 199.5  95.4 192.7 
CPH, cod protein hydrolysate; SD, standard deviation 
 
 
It has been suggested that ghrelin levels may change according to pathologic states 
related to body weight. Several studies have suggested that the fasting levels of ghrelin 
in plasma are lower in obese than lean individuals,199,200 and increased levels have been 
reported in anorexia nervosa and cachexia.201 Of note, reported ghrelin concentrations 
seems to vary greatly in existing literature, and no clear reference limits are reported. In 
addition, the suggested possible actions of which ghrelin affect body weight include not 
only overproduction or low concentrations, but also increased receptor sensitivity to 
ghrelin action,202 a hypothesis making the concentration of less relevance. Wang et al. 
recently reported that obesity alters the adrenergic and chemosensory signaling 
pathways that regulate ghrelin secretion in the human gut.203 They found that  obesity 
altered the sensitivity of the ghrelin secreting cells to glucose in the small intestines, but 
not in the fundus of the stomach, and that activation of the sweet taste receptors in the 
gut inhibited the bitter taste signaling of the ghrelin secreting cell. These findings 






Accordingly, today there is a lack of knowledge to clearly interpret the relevance of 
ghrelin concentrations. We did not observe differences in acylated ghrelin 
concentrations between genders, a correlation between body weight and the baseline 
values or differences in postprandial response for those with BMI < 25 compared to 




6.3 Effects of different doses of CPH (Paper III) 
 
In Paper III we aimed to investigate the effect of increasing doses of CPH to create a 
basis for further protocols. Although no statistically significant differences were 
observed between the four different doses of 10, 20, 30 and 40 mg/kg body weight on 
postprandial glucose metabolism, our results suggest that the highest dose of 40 mg/kg 
body weight was more effective than the lower doses. As presented in the introduction, 
existing literature reporting on the effects of fish protein and fish protein hydrolysate 
supplements on metabolic outcomes in human individuals have investigated the effects 
of different set doses of proteins or peptides ranging from 1 to 6 g per day.61,63,64  
 
6.3.1 Interpretation of results 
To our knowledge, no previous publications have reported on effects of different 
weight-adjusted doses of fish protein hydrolysates in a dose-range design as presented 
in the current trial. Hence, the study can be regarded explorative in this manner. 
Although no clear conclusions can be drawn based on our findings, we suggest that a 
metabolic effect can be observed in response to a dose corresponding to 3-4 g of fish 
protein hydrolysate a day. This can be regarded a valuable foundation for further 
investigations, however there is need for further evaluation of these results before one 
can suggest a beneficial dose level, if any.   
 
The results presented in Paper III have to be interpreted taking certain limitations in the 
design into account. Limitations not discussed in detail in the paper are addressed below.  
 
6.3.2 Limitations with the baseline study visit 
The study design originally included an additional primary study visit, with baseline 
measures from a meal without test material (CPH). This visit would be the first of five 
identical test days including postprandial measures after a breakfast meal. Instead of the 
test drink with the last dose of CPH from the current week given at the next four study 





was chosen as it contains the same number of calories (100 kcal) and carbohydrate (20 
g) as the drinks containing test material. However, due to a mistake in the 
implementation of the study, the juice serving as control were given together with the 
breakfast, whereas the test drinks with CPH  provided the additional four test days were 
given 10 minutes before the breakfast meals was served. Accordingly, when analyzing 
the postprandial measures, the postprandial curve after the baseline/control study visit 
with orange juice (planned as a control curve) was displaced for both glucose, insulin 
and GLP-1, when compared to the postprandial curves for these measures after the four 
different doses. Figure 6 show the postprandial curves for glucose concentrations, 
including the control curve not reported in paper III.   
 
 
Figure 6. Postprandial glucose concentrations after intake of a glass of orange juice 
served together with a standardized breakfast meal (control, red curve), and after 
intake of the test drink with four different doses of CPH given 10 minutes before the 
standardized breakfast meal (n=31). BW: body weight.  
 
We presume this  shift to the right occurred due to the 10 minutes difference in serving 
of juice (control) and the four test drinks. This could obviously have been avoided by 
serving the control juice 10 minutes before the breakfast, however this mistake was 
observed after the study had ended. As this mistake made the control curve non-
comparable with the curves after the four doses, we chose to remove the control visit 
from the results reported in Paper III. Hence, the four different doses is compared to 
each other, and not to a control. The lack of a control measurement in Paper III can 
arguably be regarded a limitation, as a placebo or control measure would have 
strengthened the results. 
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6.4 Effects on gut health in IBS (Paper IV) 
 
In Paper IV we aimed to investigate whether a supplement with a low dose of CPH could 
affect gut health in patients with IBS. We observed no effect of the CPH 
supplementation compared to placebo, when evaluating the outcomes related to 
symptom severity, gut integrity markers, inflammation and fecal fermentation.  
 
Based on the hypothesis that the CPH contains bioactive peptides capable of induce a 
local effect in the GI tract, we found it interesting to evaluate the possible effect on gut 
health in patients with IBS. As it has previously been reported that a diet with lean 
seafood (including cod) beneficially modulates the gut microbiome composition when 
compared to a non-seafood diet,153 we postulated that the CPH supplement could 
improve symptoms in IBS by influence the gut microbiota composition and function, 
leading to altered concentrations of fecal metabolites such as SCFAs. In addition, we 
postulated that supplementation with CPH could reduce the gut permeability and degree 
of inflammation, measured by altered levels of gut integrity markers and pro-
inflammatory cytokines. Our findings do not support these assumptions. According to 
our knowledge, this is the first trial reporting on the effect of a fish peptide supplement 
in an IBS population. Despite the lack of distinct results, our findings can be regarded 
important as they contribute to increased knowledge on this field of research.  
 
6.4.1 Symptom severity and the placebo effect in IBS 
According to our results regarding the severity of IBS symptoms as measured by IBS-
SSS and scores for quality of life, we observed a reduction of symptoms in both the 
CPH and the placebo group, with a significant reduction of symptoms after the 
intervention only in the placebo group. Interventions in IBS patients are known to be 
influenced by a strong placebo effect.204 Meta-analyses estimating the placebo response 
rate in RCTs investigating the effects of pharmacological therapy, dietary interventions, 
psychological interventions and alternative medicine in patients with IBS all suggests a 





highlight the importance of interpreting symptom-based results in IBS patients with 
caution. As no effects of the supplement was observed according to the secondary 
outcomes (gut integrity markers, inflammatory markers and SCFAs), we assume that 
the observed reduction in symptom scores in both the CPH group and the placebo group 
most likely can be attributed a placebo effect, caused by a biased expectation of 
experiencing symptom relief when participating in a clinical trial and taking a provided 
supplement.  
 
6.4.2 Amino acids and gut health 
There is growing evidence suggesting that dietary proteins can modulate the 
composition and metabolic activity of the gut microbiota, and that the amino acid 
composition and digestibility of the proteins in the diet is of great importance for the 
outcome.151 The GI tract is the organ in the body with the highest levels of immune 
activity, and alterations in gut microbiota composition and gut barrier function leading 
to destruction of the intestinal homeostasis is closely related to the development of 
several diseases, including GI disorders such as IBD and colorectal cancer.209,210 
Increasing evidence from both animal and human trials highlight the role of amino acids 
as key regulators of intestinal health, capable of regulating the mucosal barrier function 
and integrity of tight junctions in the intestines, as well as influence anti-oxidative 
responses and the gut microbiota composition and activity.156,211  
 
As presented in Table 3 and discussed in paragraph 5.1.2, the CPH supplement 
investigated in this PhD-project contains a relative high concentration of the essential 
BCAAs leucine, isoleucine and valine. It is suggested in the literature that optimizing 
the dietary BCAA levels can have a beneficial effect on parameters related to several 
health outcomes, including intestinal health.156 BCAA-supplementation in piglets 
resulted in improved gut barrier function and intestinal immune defense, suggesting that 
BCAAs might serve as a regulator capable of promote intestinal development and 
improve gut health,212 whereas BCAA-supplementation in rats caused structural 
changes in the gut microbiota considered to be beneficial for health.213 Whether BCAAs 
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provided in the form of a hydrolyzed protein are capable of affecting pathways in GI 
tract of importance for gut health when supplemented to human subjects in low doses, 
has to our knowledge previously not been investigated.  
 
A few studies have highlighted and suggested a role of amino acid deprivation in IBS 
pathogenesis, focusing on the essential amino acids’ glutamate and tryptophan, in 
particular. Depletion of these are shown to lead to atrophy of intestinal epithelial cells 
and increased intestinal permeability,214 as well as reduced serotonin production and 
suggestively disruption in the tryptophan-kynurenine balance causing altered interaction 
between oxidants and antioxidants,215 respectively. Although the CPH investigated in 
this project has a low concentration of both glutamate and tryptophan, the suggested 
mechanisms pose interesting ideas for further investigations of effects of different amino 
acids in IBS pathogenesis, as well as effects on gut health in general.  
 
6.4.3 Markers in IBS 
As discussed in Paper IV, the significant inverse correlation observed between the total 
baseline symptom scores and SCFA concentrations should be interpreted with caution, 
as this connection cannot be concluded on based on previous research, and the literature 
pose conflicting results.130,149 Although the relevance of SCFAs as a marker for IBS is 
still unclear, the existing literature suggests that the SCFA pattern is different for the 
different IBS-subtypes.149,178 A study comparing IBS patients to healthy controls 
reported that the total concentration of SCFAs did not differ between the groups, 
however when looking into the different subtypes, the total SCFA level was 
significantly lower in IBS-C patients than those with IBS-D and IBS-M.178 
 
There is a lack of literature reporting on “normal” levels of the implemented gut integrity 
markers in an IBS population, and the use of these as biomarkers are discussed.142,146 
Interestingly, novel results from Linsalata et al. suggest that alterations in the small-
intestinal permeability might contribute to the pathogenesis of diarrhea predominant 





study comparing IBS-D patients with healthy controls, they managed to identify two 
distinct subtypes of IBS-D according to degree of intestinal permeability, as measured 
by increased or normal ratio of lactulose/mannitol in urine. They reported that the IBS-
D subtype with increased small-intestinal permeability had significantly higher levels 
of iFABP, LPS and IL-6 than those IBS-D patients with normal intestinal 
permeability.137 Of note, other markers than the ones included in our study could have 
been of interest when investigating gut integrity, such as the tight junction proteins 
occludin and claudin-1, in addition to excretion of different carbohydrate/sugar ratios in 
urine.216  
 
Despite the lack of observed effects in response to supplementation with CPH in the IBS 
population, our findings in Paper IV contribute with new knowledge and data regarding 
fecal fermentation and gut integrity markers in an IBS population. Although more 
research is needed before the value of these markers IBS can be concluded on, this study 
can be used as a basis for designing future studies investigating the effect of other 






• Preprandial supplementation with 20 mg/kg body weight CPH reduced the 
postprandial insulin concentration in healthy, middle-aged to older adults without 
affecting postprandial glucose concentration, GLP-1 levels, concentration of 
acylated ghrelin or self-reported sensations associated with appetite when 
compared to control.  
 
• When investigating the effect of four different doses of CPH given to older adults 
for seven days, no significant differences were observed between the doses 
corresponding to 10, 20, 30 and 40 mg/kg body weight CPH per day. However, 
the tendency was that the highest dose of 40 mg/kg body weight to a greater 
extent decreased postprandial glucose and insulin concentrations than the lower 
doses.  
 
• When 2.5 g CPH was supplemented to IBS patients for six weeks, no significant 
effects were observed in response to the CPH intervention when compared to 
placebo, either for symptom severity, gut integrity markers, inflammatory 
markers or fecal fermentation measured by concentrations of SCFAs. 
 
These findings only partly confirm our hypothesis suggesting that CPH would 
beneficially affect glucose metabolism and appetite regulation in healthy, middle-aged 
to older adults, that it would be a dose-response relationship between different doses of 
CPH supplementation and changes in the glucose metabolism, and that supplementation 
with CPH would beneficially affect gut health in patients with IBS.  
 
In summary, we observed beneficial alterations in insulin concentrations after 
supplementation with CPH and a dose of 40 mg/kg body weight is likely to be more 
effective than lower doses, but supplementation with CPH was not found to influence 
outcomes related to hunger regulation in healthy subjects or gut health in patients with 





8. Future perspectives 
 
The three clinical trials included in the current PhD-thesis were designed to investigate 
the health effect of a protein hydrolysate from cod, focusing on outcomes related to 
glucose metabolism and appetite in healthy individuals and gut health in patients with 
IBS. Our results pose novel opportunities for further research:  
 
• As an optimal supplementation dose with a hydrolysate from lean fish cannot be 
concluded on based on our findings, future trials should arguably investigate the 
effect of higher doses than the ones included in the studies presented here.  
 
• According to our findings reported on insulin concentrations in Paper I, we 
suggest to further evaluate the effect of a CPH supplement in a target group with 
impaired glucose metabolism, preferably over a period. Patients with metabolic 
syndrome and/or diet-controlled T2D would be of particular interest.  
 
• We did not analyze the CPH for the content of specific bioactive peptides. The 
identification of sequences with known bioactive effects could be of interest if 
the supplement was to be investigated in future clinical trials.  
 
• If further investigating the effect of a similar supplement or other suggested 
bioactive peptides on gut health in patients with IBS and/or other GI disorders, 
one should aim to evaluate the effect of peptides holding sequences with known 
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Abstract
The increased prevalence of lifestyle diseases, such as the metabolic syndrome and type 2 diabetes mellitus (T2DM), calls for more knowledge on dietary
treatments targeting the specific metabolic pathways involved in these conditions. Several studies have shown a protein preload before a meal to be effective
in lowering the postprandial glycaemic response in healthy individuals and patients with T2DM. The aim of the present study was to assess the effect of a
marine protein hydrolysate (MPH) from Atlantic cod (Gadus morhua) on postprandial glucose metabolism in healthy, middle-aged to elderly subjects. This
double-blind cross-over trial (n 41) included two study days with 4–7 d wash-out in between. The intervention consisted of 20 mg of MPH (or casein as
control) per kg body weight given before a breakfast meal. The primary outcome was postprandial response in glucose metabolism, measured by samples of
serum glucose, insulin and plasma glucagon-like peptide 1 (GLP-1) in 20 min intervals for 180 min. In a mixed-model regression analysis, no differences
were observed between MPH and control for postprandial glucose concentration (mean difference: −0·04 (95 % CI –0·17, 0·09) mmol/l; P= 0·573) or
GLP-1 concentration (mean difference between geometric means: 1·02 (95 % CI 0·99, 1·06) pmol/l; P = 0·250). The postprandial insulin concentration
was significantly lower after MPH compared with control (mean difference between geometric means: 1·067 (95 % CI 1·01, 1·13) mIU/l; P= 0·032). Our
findings demonstrate that a single dose of MPH before a breakfast meal reduces postprandial insulin secretion, without affecting blood glucose response or
GLP-1 levels, in healthy individuals. Further studies with repeated dosing and in target groups with abnormal glucose control are warranted.
Key words: Marine protein hydrolysate: Fish protein: Marine peptides: Glucose metabolism
The proportion of the population with health problems related
to overweight and obesity is constantly increasing worldwide,
and this constitutes a great risk factor for several lifestyle
diseases such as insulin resistance, the metabolic syndrome
and type 2 diabetes mellitus (T2DM)(1). The ability of the
body to control postprandial glucose metabolism is decisive
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for health. Several dietary treatments for the prevention of
postprandial hyperglycaemia in both diabetic and non-diabetic
individuals have been suggested, but the necessary lifestyle and
diet changes are challenging, and continue to lack adherence(2).
There is a need for more knowledge on dietary treatments tar-
geting the specific metabolic pathways involved in overweight,
obesity, the metabolic syndrome and T2DM.
Diets relatively high in protein (18–30 % energy) have been
shown to be effective in the management of obesity due to
suppression of appetite(3), and are further suggested to reduce
postprandial blood glucose in both healthy individuals and
patients with impaired glucose metabolism(4). Several trend
diets have over the last decades included high-protein diets
to reduce weight and suppress insulin response(5,6), but the
long-term effects of high-protein diets are unknown(7,8).
Furthermore, several studies have shown a protein preload
before a meal to be effective in lowering the postprandial gly-
caemic response both in T2DM patients and healthy
subjects(9–13).
Due to limited access to high-quality protein in the world, it
is neither sustainable nor possible for the world’s population
to increase the proportion of protein in the diet. Thus, the
potential benefit of altering the source and quality of protein,
rather than increasing the amount, is of great interest. Marine
resources in excess should be evaluated as a possible high-
quality protein source for human consumption(14).
Previous studies in rats and human subjects have shown
that the intake of both fish proteins and marine protein hydro-
lysates (MPH), even in low doses, has a desirable effect on
insulin sensitivity and postprandial glucose(7,15–19), lipids in
serum and adipose tissue, bile acids, fatty acid composition
and growth, and possibly has antihypertensive and immune-
modulating effects(14,19–23). It is indicated that MPH may con-
tain marine bioactive compounds with potentially important
biological effects in humans, beyond the known effect of pro-
tein as a source of amino acids(24,25). The use of MPH as a
dietary supplement with similar or better health benefits than
a regular fish meal could be both cost-effective, environmen-
tally friendly and sustainable. A low dose of MPH is presumed
to be effective due to the content of bioactive peptides not
equally present in other protein sources.
Thus, the present study was designed to assess the effect of
a single, low dose of MPH before a meal on postprandial glu-
cose metabolism in healthy, middle-aged to elderly subjects.
Subjects and methods
Trial design
The study was a double-blind cross-over trial, including two
different study days, with a 4–7 d wash-out period in between.
The intervention implemented 20 mg of MPH per kg body
weight (test material) or control (casein). MPH or casein pow-
der (identical, both flavoured with lemon) was mixed with
water and taken before a standardised breakfast meal, in ran-
domised order. The primary outcome was postprandial
response in glucose metabolism, measured by venous samples
of serum glucose and insulin, and plasma glucagon-like
peptide 1 (GLP-1). The secondary outcome was adverse
events measured by symptom questionnaires.
This study was conducted according to the guidelines laid
down in the Declaration of Helsinki and all procedures involv-
ing human subjects were approved by the Regional
Committees for Medical and Health Research Ethics of
Central Norway (2017/1794). Written informed consent was
obtained from all subjects. The trial was registered at clinical-
trials.gov as NCT03669796.
Participants
Participants were recruited through advertisements on the
Internet and posters at Haukeland University Hospital and
Ålesund Hospital between October 2017 and February
2018. Potential participants were interviewed for general eligi-
bility and compliance with inclusion and exclusion criteria, and
suitable candidates were invited for a further screening visit. A
total of forty-one healthy and active individuals between 41
and 64 years old were included in the study (male, n 15; female,
n 26). The inclusion process is depicted in Fig. 1.
Inclusion criteria were aged 40–65 years old and BMI 20–
30 kg/m2. Exclusion criteria were fish allergy, pharmacologic-
ally treated diabetes mellitus, elevated blood pressure, chronic
diseases (that might affect the evaluation of the study end-
points) and acute infections. The participants were instructed
not to take any nutritional supplements containing n-3 fatty
acids for 1 week before the study start, and while participating
in the study.
Study protocol
The participants came to the research units on two different
occasions, with a 4–7 d wash-out period (Fig. 2). A clinical
examination by a physician, baseline biochemistry and mea-
sures of height, weight and blood pressure were done before
inclusion. The level of physical activity was assessed, and par-
ticipants were instructed not to change the level of physical
activity or diet composition during the study period.
A 3-d and 1-d prospective dietary record was filled out prior
to study days 1 and 2, respectively. On the day preceding each
study day, the participants were provided with a standardised
evening meal (oatmeal, rice or barley porridge) instructed to
be eaten before 20.30 hours, followed by fasting until the
next morning.
On study days, the participants came to the research units
between 08.00 and 09.00 hours. After blood samples, they
were served a drink with MPH or control, before a breakfast
meal was given. The first post-meal sample (0 min sample) was
taken 15 min after the breakfast was served.
The standardised breakfast meal consisted of two slices of
semi-coarse bread (50 % whole wheat, 80 g bread), 10 g mar-
garine, 20 g strawberry jam and 20 g white cheese, providing a
total of 355 kcal (1485 kJ), 41 g carbohydrate, 12·5 g protein
and 15 g fat. The drink provided on average 35·9 g carbohy-
drate and 145 kcal (607 kJ). Thus, including the drink, the
breakfast provided in total 500 kcal (2092 kJ) and 77 g carbo-
hydrate. The amount of energy and carbohydrates in the
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Fig. 1. Flowchart depicting the inclusion process for the study evaluating the effect of a marine protein hydrolysate (MPH) from Atlantic cod (Gadus morhua) on
postprandial glucose metabolism in healthy individuals aged 40–65 years. Participants were recruited through advertisements on the Internet and posters at
Haukeland University Hospital and Ålesund Hospital between October 2017 and February 2018.
Fig. 2. Study protocol for the evaluation of the effect of a marine protein hydrolysate (MPH) from Atlantic cod (Gadus morhua) on postprandial glucose metabolism.
We included forty-one healthy subjects (age range 40–64 years).
3
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breakfast was calculated to induce an adequate blood glucose
response. No coffee or tea was served, but water ad libitum.
The participants spent 4 h at the research units to allow for
repeated sampling of blood, at 20 min intervals until 180 min,
and monitoring of blood pressure.
Assessments
Assessment of the participants’ medical history, and measure-
ment of biochemical variables and safety parameters were con-
ducted at baseline.
During the study days, serum glucose and serum insulin
were measured at baseline and every 20 min for 2 h (120
min), with a final sample at 180 min. GLP-1 was measured
at baseline, time 0, 20, 40, 80 and 180 min. Blood pressure
was measured at baseline, after 40 min and after 180 min, as
a safety parameter.
Two questionnaires evaluating the participants’ self-
experienced symptoms were implemented to identify possible
adverse events during each study day. A visual analogue scale
was filled out six times during the study day, and a question-
naire validated for the evaluation of gastrointestinal symptoms
(Kane) was filled out at baseline and at the end of each study
day(26).
Estimation of nutritional intake
Calculations of energy and macronutrient intake were per-
formed using Kostholdsplanleggeren (Norwegian Food Safety
Authority and The Norwegian Directorate of Health, Oslo,
Norway)(27). The dietary records were used to evaluate the
composition of the baseline diet, to map the participants’ regu-
lar meal pattern and to compare the days prior to each study
day according to energy intake.
Test materials
The MPH and casein powder were delivered from the manu-
facturer (Firmenich Bjørge Biomarin AS) in neutral bottles
coded with participant number and study day. The bottles
were coded by a person not involved in the implementation
of the study and randomised according to a randomisation
list. Both study participants and all persons involved in
study conduction and analysis were blinded. The powder con-
tained 4 % protein (MPH raw material or casein) and 96 %
carbohydrate (maltodextrin). It was flavoured with lemon,
but otherwise neutral. It was not possible to identify the active
ingredient from the control, according to flavour or appear-
ance. Each participant was given 20 mg/kg body weight of
MPH or control. The drinks were made isonitrogenous, and
equal amounts of N in the form of casein were added to
the control drink. This was done to avoid any bias due to dif-
ference in N content between the MPH drink and the control
drink. The amount of protein (N x 6·25) in both drinks was on
average 1·6 g, constituting only a small fraction of the total
protein content of the standardised breakfast meal. Casein
was chosen as the control as it has previously shown to not
affect blood glucose or insulin sensitivity when compared
with proteins from cod and soya(28).
The MPH powder was made by Firmenich Bjørge Biomarin
AS by hydrolysing fish meat of Atlantic cod (Gadus morhua)
with Protamex® (Novozymes AS) followed by spray drying
of the soluble part of the enzyme digest. The MPH raw mater-
ial contained approximately 89 % protein by weight, <0·2 %
fat, 0 % carbohydrate, <3·0 % water, 10 % ash, 0·1 % NaCl,
1·7 % Na and 0·07 % chloride. Free amino acids accounted
for 4·77 % of total amino acids in the MPH, and the essential
amino acids:non-essential amino acids ratio was 0·70. Analysis
of the molecular weight distribution (Table 1) shows that
about 90 % of the peptides in the fish protein hydrolysate
have a molecular weight of 2000 Da or less (eighteen amino
acids or fewer), about 75 % of 1000 Da or less (ten amino
acids or fewer) while about 55 % have a molecular weight of
500 Da or less (five amino acids or fewer). Approximately
25 to 30 % of the peptides have a molecular weight less
than 200 Da, which represents small dipeptides and free
amino acids.
The casein contained approximately 88 % protein. The
amino acid composition of MPH and casein used as control
is presented in Table 2 (data obtained from Firmenich
Bjørge Biomarin AS).
The MPH was analysed at the Allergy Laboratory
(Haukeland University Hospital, Bergen, Norway) for allergen-
icity of the hydrolysate. Direct ELISA showed insignificant
reactivity of specific IgG and IgE to the hydrolysate in com-
parison with the reactivity against cod allergen. The allergen-
icity of the hydrolysate was so low that it was considered
unsignificant.
Analysis of blood samples
Baseline biochemistry was analysed according to standard
accredited methods at the Laboratory for Clinical
Biochemistry, Haukeland University Hospital (Bergen,
Norway) and the Department of Medical Biochemistry,
Ålesund Hospital (Ålesund, Norway).
Glucose and insulin were measured in serum according to
standard accredited methods at the Laboratory for Clinical
Biochemistry, Haukeland University Hospital (Bergen,
Norway). Serum was obtained by centrifugation of full
Table 1. Molecular weight distribution in the dry and solubilised marine








g/100 g in the
spray-dried powder
>10 000 – <0·1 <0·1
10 000–8000 88–71 0·1 0·1
8000–6000 70–53 0·6 0·5
6000–4000 52–36 2·1 1·9
4000–2000 35–18 7·2 6·3
2000–1000 17–10 14·8 13·0
1000–500 9–5 21·0 18·5
500–200 4–2 27·0 23·8
<200 ≤2 27·2 24·0
4
journals.cambridge.org/jns
blood at 2000 g at room temperature (20°C) for 10 min after
30–60 min of coagulation, using serum separator cloth activa-
tor tubes. Samples were aliquoted and stored frozen at −80°C
prior to analyses.
Plasma for GLP-1 determination was obtained by centrifu-
gation of EDTA full blood at 1800 g at −4°C for 10 min
within 20 min after blood sampling. To EDTA blood sam-
pling tubes were added 10 µl dipeptidyl peptidase-4 inhibitor
(DPP4-010; DRG Diagnostics) per ml EDTA blood prior
to sampling. GLP-1 plasma was aliquoted and stored frozen
at −80°C prior to analysis. The GLP-1 analyses were per-
formed using an ELISA kit from IBL International GmbH
(GLP-1 (7–36) active ELISA, reference RE53121).
Statistical analysis
Statistical analysis was performed using SPSS software (IBM
SPSS Statistics 24) and GraphPad Prism version 7.0
(GraphPad Software, Inc.). The Shapiro–Wilk test was used
to assess normal distribution. Mixed-model regression analysis
was conducted to evaluate the difference between MPH and
control. Non-normally distributed data were log-transformed
before analysis (insulin and GLP-1) and are presented as log
mean and back-transformed values. Paired t tests were used
to evaluate differences in nutrient intake between study days.
Two-way ANOVA with repeated measures was used to evalu-
ate differences between each time point. Graphical work was
conducted in GraphPad Prism. P values <0·05 were consid-
ered statistically significant.
The sample size was not calculated according to a power
analysis, due to lack of similar studies. Previous research
reporting on the effect of cod proteins in human subjects is
based on whole fish(16) or long-term use of fish protein sup-
plement(17,29); thus we did not find any data adequate for mak-
ing a basis for a power analysis representative for our design.
We decided to include forty participants (forty-one were
included), a number higher or similar to previously reported
in studies on cod protein(16,17,29).
Results
Participant characteristics
Overall, forty-one participants completed the trial, of whom
twenty-six were female. Mean age was 51 (SD 6) years, range
40–64 years. Mean BMI was 25·2 (SD 3) kg/m2. The recorded
mean energy intake (2084 (SD 504) kcal/d; 8719 (SD 2109) kJ/
d) was lower than the estimated energy need (2605 (SD 392)
kcal/d; 10899 (SD 1640) kJ/d) at baseline. The standardised
breakfast provided on the study days (500 kcal (2092 kJ)) cov-
ered 19·6 (SD 2·9) % of the participants’ total energy need. All
baseline biochemistry was within the current reference values.
Baseline characteristics are presented in Table 3.
Energy intake
Mean energy intake before study day 1 was 2030 (SD 550)
kcal/d (8494 (SD 2301) kJ/d). Mean intake before study day
2 was 2110 (SD 534) kcal (8828 (SD 2234) kJ/d). The energy
intake did not differ before the two study days (P = 0·201).
Postprandial measurements
Data at each time point are presented in Table 4. In a multi-
variable, repeated-measures linear mixed-effects regression
analysis, no differences were observed between MPH and con-
trol for glucose concentration (mean difference: −0·04 (95 %
CI –0·17, 0·09) mmol/l; P = 0·573). Mean fasting glucose
levels were numerically equal on both study days (5·1 (SD
0·4) mmol/l; P> 0·999). The peak in glucose concentration
Table 2. Amino acid and taurine composition of the marine protein
hydrolysate (MPH) from Atlantic cod (Gadus morhua) and the casein
control used in the present study
Amino acid




Aspartic acid 73·3 70·8
Asparagine 0·38 N/A


















* Branched-chained amino acids.
Table 3. Baseline characteristics of the forty-one participants included in
the study at Haukeland University Hospital and Ålesund Hospital between
October 2017 and February 2018*
(Mean values and standard deviations)
Characteristics Mean SD
Age (years) 51·0 6·0
BMI (kg/m2) 25·2 3·0
Systolic blood pressure (mmHg) 125 18
Diastolic blood pressure (mmHg) 78 11




Energy intake at baseline
kcal/d 2084 504
kJ/d 8719 2109
Carbohydrates (g/d) 226·7 68·5
Fat (g/d) 90·2 33·0
Protein (g/d) 92·9 23·6
* Nutritional values are based on mean values from 3-d dietary records.
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(Cmax) occurred 20 min after the meal for both MPH and
control and was numerically higher after MPH than after
the control drink (7·6 (SD 1·8) v. 7·4 (SD 1·5) mmol/l,
respectively; P = 0·997). The AUC was compared for the
nine glucose measurements. The AUC for the glucose concen-
tration was numerically equal between MPH (1078 (95 % CI
956·0, 1199·0) mmol/l×min) and control (1068 (95 % CI
944·8, 1190·0) mmol/l×min; P= 0·910).
The insulin concentration was significantly lower after MPH
compared with control (mean difference between geometric
means: 1·067 (95 % CI 1·01, 1·13) mIU/l; P = 0·032). Mean
fasting insulin levels were numerically higher before MPH
(6·4 (SD 5·8) mIU/l) than control (6·1 (SD 5·6) mIU/l; P >
0·999), but the insulin concentration peaked at a lower level
and at 20 min (69·6 (SD 52·7) mIU/l) after MPH whereas
the peak after the control drink was numerically higher and
occurred at 40 min (70·3 (SD 53·6) mIU/l). Women had sig-
nificantly lower insulin concentrations than men (mean differ-
ence between geometric means: 0·65 (95 % CI 0·45, 0·93)
mIU/l; P= 0·020), irrespective of intervention.
Table 4. Descriptive statistics* of the forty-one participants included in a study at Haukeland University Hospital and Ålesund Hospital between October
2017 and February 2018, evaluating the effect of marine protein hydrolysate (MPH) from Atlantic cod (Gadus morhua) on postprandial glucose
metabolism measured by serum glucose, insulin and glucagon-like peptide 1 (GLP-1) during exposure to MPH and control (casein) drinks
(Mean values and standard deviations)
MPH Control
Outcome Time Mean SD Log mean SD GM Mean SD Log mean SD GM
Glucose (mmol/l) Baseline 5·1 0·4 5·1 0·4
0 min 6·5 0·9 6·7 0·8
20 min 7·6 1·6 7·4 1·5
40 min 6·5 1·8 6·2 1·9
60 min 5·4 1·4 5·4 1·6
80 min 4·9 1·2 5·1 1·4
100 min 4·6 1·1 4·7 1·2
120 min 4·5 1·1 4·4 1·0
180 min 4·4 0·6 4·3 0·6
Insulin (mIU/l)† Baseline 6·4 5·8 1·6 0·7 4·9 6·1 5·6 1·5 0·7 4·6
0 min 33·8 34·3 3·2 0·9 23·8 34·9 30·4 3·3 0·7 27·5
20 min 69·6 52·7 4·0 0·6 57·1 68·0 47·7 4·0 0·6 56·3
40 min 64·8 51·1 4·0 0·6 52·0 70·3 53·6 4·0 0·7 55·1
60 min 57·2 46·2 3·8 0·6 45·7 61·4 49·0 3·9 0·6 49·3
80 min 42·9 33·9 3·6 0·6 35·0 51·7 47·3 3·7 0·7 39·7
100 min 36·4 39·3 3·3 0·7 26·9 40·8 42·0 3·4 0·7 31·3
120 min 28·6 31·3 3·0 0·8 20·6 30·1 37·9 3·0 0·8 21·1
180 min 12·2 17·7 2·1 0·9 8·0 12·4 15·1 2·2 0·8 8·7
GLP-1 (pmol/l) Baseline 6·2 9·5 1·5 0·6 4·4 6·2 9·5 1·5 0·6 4·4
0 min 8·1 9·1 1·9 0·6 6·5 8·8 9·9 1·9 0·6 7·0
20 min 8·0 9·4 1·9 0·5 6·4 7·9 9·3 1·8 0·6 6·2
40 min 7·2 9·1 1·7 0·6 5·6 7·3 9·0 1·7 0·6 5·7
80 min 6·9 10·3 1·6 0·6 5·0 7·0 9·6 1·6 0·6 5·2
180 min 6·8 10·1 1·6 0·7 4·8 6·5 0·8 1·6 0·6 4·8
GM, geometric mean (exp(log mean)).
* Log mean and GM are presented for non-normally distributed data (insulin and GLP-1). Glucose values are only presented as means and standard deviations due to approxi-
mately normal distribution.
† In a mixed-model linear regression analysis, the insulin levels were significantly lower after intake of MPH than control (P = 0·032).
Fig. 3. Metabolic response for serum glucose (a), serum insulin (b) and plasma glucagon-like peptide 1 (GLP-1) (c) concentrations after intake of a standardised
breakfast meal supplemented with a drink containing either marine protein hydrolysate (MPH; –○–) or control (casein; –●–). Results are presented for forty-one
healthy subjects. The study had a cross-over design and all subjects received both treatments in random order. Time point 0 min shows values measured right




No differences were observed between MPH and control
for GLP-1 concentration (mean difference between geometric
means: 1·02 (95 % CI 0·99, 1·06) pmol/l; P = 0·250). Mean
fasting GLP-1 levels were numerically equal on both study
days (6·2 (SD 9·4) pmol/l; P> 0·999). The peak occurred
right after intake of breakfast and test drink (0 min) and was
lower after MPH (8·1 (SD 9·1) pmol/l) than after control (8·8
(SD 9·9) pmol/l; P= 0·092). Results are presented in Fig. 3.
Adverse events
No adverse events were reported in the questionnaires or
otherwise observed.
Discussion
The study was designed to investigate the effect of a low dose
of MPH on postprandial glucose metabolism in healthy indivi-
duals. Our hypothesis was that supplementation with MPH
before a meal would beneficially affect the glucose response,
insulin and GLP-1 concentration compared with control. We
found that a single dose of 20 mg/kg body weight MPH pre-
meal supplement significantly lowered the postprandial insulin
response. Although we did not observe a reduction in post-
prandial blood glucose values and GLP-1 concentrations, we
postulate that our findings could indicate a potential beneficial
effect of MPH in individuals with reduced insulin sensitivity.
We hypothesise that MPH may enhance the insulin sensitivity
and affect other mechanisms involved in the blood glucose
uptake in peripheral tissue. The study participants were healthy
individuals with HbA1c levels within the normal range
(Table 2), thus one would expect normal blood glucose con-
centrations after a meal. We speculate that the effect of
MPH on postprandial glucose metabolism will be more dis-
tinct if further investigated in individuals with the metabolic
syndrome or T2DM.
The target of nutritional diabetic and pre-diabetic treatment
is to maintain a blood glucose level within the normal range.
Several studies have previously shown different sources of
protein preload before a meal to reduce the postprandial gly-
caemic response, both in healthy and diabetic individuals(9–13).
However, to our knowledge, data on the specific acute effect
of a fish protein hydrolysate supplement prior to a meal has
previously not been published.
Our finding is consistent with a previous study, showing
lower postprandial insulin C-peptide levels after a 7-d interven-
tion with cod(30). Furthermore, Ouellet et al.(16) have previously
demonstrated that a diet rich in cod improved insulin sensitiv-
ity in nineteen insulin-resistant individuals, when compared
with a diet rich in other animal protein sources. Also, it has
previously been demonstrated that cod protein-fed rats, in
comparison with casein-fed and soya-fed rats, are protected
against the development of insulin resistance and hypergly-
caemia induced by diets rich in fat and sucrose(28). This effect
was related to enhanced insulin-stimulated glucose uptake in
muscle cells, but not in adipose tissue. It is indicated that
amino acids derived from cod protein can increase the insulin-
stimulated glucose uptake in muscle cells by acting directly on
the glucose transport system(28). Investigations of the mechan-
isms promoting this positive effect of amino acids from cod
revealed that dietary cod protein restored insulin-induced acti-
vation of the phosphatidylinositol 3-kinase (PI3K)/protein
kinase B (Akt) pathway and improved translocation of
GLUT4 to the T-tubes in skeletal muscle cells(31). The glucose
transporter protein GLUT4 facilitates the uptake of glucose
into the cell when expressed at the cell surface, and it has
been proposed that a reduced translocation of GLUT4 to
the T-tubules leads to the development of insulin resist-
ance(31). It is proposed that the amino acids derived from
cod protein, in comparison with amino acids derived from
other protein sources, facilitate a unique pathway leading to
the increased expression of GLUT4 in the T-tubules and
enhanced insulin sensitivity(31).
The assumed beneficial effect of the amino acids derived
from cod can possibly be linked to the high concentration
of branched-chain amino acids (BCAA). It has previously
been demonstrated that serum levels of the BCAA leucine,
isoleucine and valine, as well as the amino acid lysine, is cor-
related with the insulin response(32). The effect has been linked
to the increase of hormones such as glucose-dependent insu-
linotropic polypeptide and GLP-1(33). Although it is estab-
lished that the BCAA leucine and isoleucine are the major
amino acids affecting blood glucose homeostasis, the effect
has not been observed when the amino acid concentration is
low(34). Interestingly, a significant stimulation of glucose
uptake in muscle cells by the PI3K/Akt pathway has been
observed when the BCAA were administered as dipeptides
in low concentrations(35). The MPH used in our trial have a
high concentration of BCAA (Table 1), and analysis of the
MPH used in the present study shows that about 10 % of
the di- and tripeptide fractions are present as leucine- and
isoleucine-containing peptides (data obtained from Firmenich
Bjørge Biomarin AS). Even though we did not observe an
increase of GLP-1 in relation to the intake of single, low
dose of MPH, our findings suggest that low concentrations
of MPH may increase insulin sensitivity. The casein used as
the control has higher concentrations of BCAA than the
MPH, but it differs from MPH regarding the fraction present
as di- or tripeptides. The casein used in the study is not a
hydrolysate, but present as whole protein, and does not con-
tain either peptides or free amino acids. Thus, we assume
that the BCAA-containing peptides present in MPH constitute
the unique, bioactive effect even when given in low concentra-
tions. We postulate that this is due to the rapid absorption of
intact bioactive leucine- and isoleucine-containing peptides via
peptide transporters in the upper jejunum and into the blood.
It has been shown that other sources of protein, such as casein
and whey, are necessary in much higher doses than MPH to
achieve significant alterations in the postprandial blood glucose
and insulin response(36,37).
One could argue that the control drink should be a true pla-
cebo and only contain glucose (maltodextrin), and no protein.
However, then it would be possible that the observed effect
could simply be due to differences in energy and N content.
To avoid this, the control drink contained casein, a protein
shown not to affect blood glucose response and insulin
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sensitivity when given in low concentrations(28,38,39), to facili-
tate an isoenergetic and isonitrogenic placebo material. Both
the MPH and casein control drinks contained an equal amount
of protein, in total on average 1·6 g. This amount is negligible
compared with the total protein content of the breakfast meal
provided (12·5 g protein); thus the effect of MPH can be
attributed to the content of bioactive peptides and not the pro-
tein per se. In a clinical study comprising of 120, slightly over-
weight (BMI between 25 and 30 kg/m2) male and female
subjects, Nobile et al.(40) showed that oral doses of 1·4 and
2·8 g MPH from the codfish species blue whiting
(Micromesistius poutassou) taken daily for 90 d increased the
blood concentrations of both cholecystokinin and GLP-1.
Further, body weight composition was improved in favour
of reduced body fat mass. Daily doses higher than 1·4 g did
not give any further effects, demonstrating that MPH may
show bioactivity in humans when taken orally in the range
of 15–20 mg per kg body weight.
Previous studies have investigated the long-term effect of
fish protein intake in overweight, obese and/or diabetic indivi-
duals. Improvement in postprandial glucose regulation after
intake of 750 g fatty fish/week (for 8 weeks) in overweight/
obese adults has been demonstrated, but this effect was not
observed after intake of lean fish(15). Similar findings have
been reported in T2DM patients; Zhu et al.(41) demonstrated
that treatment with a fish protein hydrolysate improved glu-
cose and lipid metabolism, resulting in reduced fasting blood
glucose, insulin and HbA1c, compared with placebo.
Vikøren et al.(17) were the first to investigate the specific effect
of a fish protein supplement on postprandial blood glucose.
They found that low doses of a fish protein supplement
from cod (3 and 6 g) for 4 weeks resulted in lower levels of
fasting and postprandial glucose, including lower AUC for glu-
cose when compared with placebo, in thirty-four overweight
individuals. Another recent study found that supplementation
with cod protein for 8 weeks in forty-two overweight and
obese individuals had a beneficial effect on postprandial con-
centration of serum NEFA, but no effect was observed in
postprandial glucose or insulin concentration compared with
control(29). The most obvious difference when comparing
these studies with our study design is that they evaluated
the long-term effect of fish intake/fish protein supplement
in overweight and obese patients, while we were interested in
the acute effect of a fish protein hydrolysate after a meal in
healthy individuals.
There are elements with our design that may have affected
the outcome. Previous studies in human subjects have investi-
gated the effect of fish or fish protein supplementation over a
longer period of time. Thus, it will be interesting to investigate
a potential effect using different doses given over a period of
time. Furthermore, we investigated the effect of MPH in
healthy individuals, assumed to have a normal glucose
response. Our findings indicate that further research should
aim to include individuals with hyperglycaemia or abnormal
postprandial glucose control. The participants in this study
might have been too healthy to find a meaningful effect.
The significant lower insulin concentration observed after
intake of MPH could be important in patients with reduced
insulin sensitivity, thus should be further investigated in a
group of patients with the metabolic syndrome and/or
T2DM. It has to be considered that 1 week of wash-out for
the use of n-3 supplements before inclusion might not have
been enough; thus the short wash-out period may be regarded
as a limitation to our design.
Most previous studies have been performed in rodents, and
few data exist on the specific effect of MPH supplement in
human individuals. The effect of a low dose of MPH on the
postprandial glycaemic response has previously just been
hypothesised, and our study is the first to investigate this pos-
sible association. Thus, this double-blinded cross-over trial
investigating the effect of MPH supplement in human subjects
can be regarded valuable for future studies. We suggest that
the potential effect of MPH should be investigated over a
longer period, with higher doses in patients with impaired gly-
caemic response and reduced insulin sensitivity.
In conclusion, our findings demonstrated that a single dose
of MPH before a breakfast meal reduced postprandial insulin
concentration without affecting blood glucose response or
GLP-1 levels when compared with control (casein), in healthy,
middle-aged individuals. The mechanism for this effect is
unknown, and further studies are warranted in target groups
with abnormal glucose metabolism.
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Abstract
Background: Fish protein hydrolysates are suggested to contain bioactive sequences capable of affecting met-
abolic pathways involved in the regulation of glucose metabolism and body weight when consumed in low 
doses. Modulation of the appetite-regulating hormone ghrelin may explain suppression of insulin secretion 
and weight loss observed in previous studies with fish protein hydrolysates.
Objective: This study aimed to assess the effect of a single, low dose of cod protein hydrolysate (CPH) before a break-
fast meal on postprandial acylated ghrelin concentration and sensations associated with appetite in healthy subjects.
Design: In this explorative trial with a crossover design, 41 healthy individuals (15 males and 26 females, age 
51 ± 6 years) completed 2 study days separated by 4–7 days of washout. On both study days, a test drink 
containing 20 mg CPH or casein (control) per kg body weight was given immediately before a standardized 
breakfast meal. Acylated ghrelin concentrations were measured before test drink/breakfast (baseline) and at 
time 0, 20, 40, 80, and 180 min postprandially. Sensations associated with appetite were measured by a Visual 
Analog Scale (100 mm) at baseline and 0, 20, 40, and 180 min postprandially.
Results: Statistically, no difference was observed between CPH and control for postprandial acylated ghrelin con-
centrations (mean difference geometric mean: 1.05 pg/mL, 95% confidence interval [CI]: 0.97–1.13, P = 0.266), 
or between the total area under the curve (tAUC) for acylated ghrelin after CPH (tAUC = 17518 pg/mL × min, 
95% CI: 0–47941) and control (tAUC = 17272 pg/mL × min, 95% CI: 0–48048, P = 0.991). No differences were 
found between CPH and control for sensation of appetite, according to tAUC of postprandial scores for satiety 
(P = 0.794) and the feeling of fullness (P = 0.996).
Conclusion: We did not find an effect of a single dose of CPH on postprandial concentrations of acylated 
ghrelin or sensations related to feeling of hunger, compared to control. Further studies should aim to evaluate 
the effect of a supplement with CPH given daily over a period of time.
Keywords: hunger; overweight; marine peptides; gastric hormones; nutrition supplement
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Popular scientific summary
• Ghrelin is an appetite-regulating hormone, with high concentrations before a meal and reduced 
concentrations after a meal. Compounds with the ability to suppress the action of ghrelin may be 
valuable for weight regulation.
• Fish protein hydrolysates are suggested to contain bioactive peptides capable of affecting glucose 
metabolism and body weight.
• In this study, no effect of a supplement with cod protein hydrolysate on postprandial ghrelin con-
centrations or sensations related to appetite was observed.
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Ghrelin is a gastric hormone, capable of stimulat-ing hunger and influence energy homeostasis (1). It is a small peptide consisting of 28 amino acids, 
secreted from neuroendocrine cells in the submucosal 
layer of the stomach (2). The circulating ghrelin concen-
tration gradually increases before a meal and decreases 
with feeding (3). Two forms of ghrelin are present in the 
circulation, acylated and non-acylated ghrelin, of which 
the acylated form is the one known to activate the ghrelin 
receptor (2).
Acylated ghrelin is a natural ligand binding to the 
growth hormone secretagogue (GHS) receptor, leading 
to stimulation of the secretion of growth hormone (GH), 
reduction in insulin secretion and glucose tolerance (4–6). 
Furthermore, it has been shown that acylated ghrelin holds 
potent adipogenic and orexigenic effects mediated through 
the GHS receptor located in the central nervous system 
(CNS) (4). Acylated ghrelin is known to directly activate 
pathways in the CNS controlling both parasympathetic 
and sympathetic nerve activity through GHS receptors 
(7) and possibly indirectly suppresses insulin secretion via 
neural signaling (8). These qualities have created the idea 
that compounds having the ability to suppress the action 
of ghrelin may be valuable for the prevention or treatment 
of overweight, obesity, insulin resistance, and abnormal 
lipid and glucose metabolism (9, 10).
In previous studies in rats and humans, it has been ob-
served that the intake of low doses of peptides from fish 
is capable of beneficially influencing glucose metabolism 
(11–14), reducing adipose tissue mass, and improving 
serum fatty acid composition (15, 16), when compared to 
placebo or casein. In addition, some recent studies have 
found fish protein hydrolysates to beneficially influence hor-
mones involved in the regulation of appetite, such as cho-
lecystokinin (CCK) and glucagon-like peptide 1 (GLP-1), 
as well as influence the subjective feeling of craving sweets 
(17, 18), when compared to placebo in human subjects. The 
suggested effective daily dose based on the current litera-
ture in human subjects ranges from 1 to 6 g per day (13, 18). 
Consequently, the hypothesized effect of a fish protein hy-
drolysate is not due to the consumed protein per se, which 
is negligible compared to the normal recommended total 
daily dietary intake of a healthy individual (e.g. 65–80 g 
protein per day with body weight 80 kg) (19). A possible 
mechanism for suppression of postprandial insulin concen-
tration and weight loss could be modulation of postpran-
dial ghrelin concentrations, and a low dose of fish protein 
hydrolysate is presumed to be effective due to the content of 
bioactive peptides with unique amino acid sequences (20). 
In the current trial, we hypothesize that a potential sup-
pressing effect on appetite and postprandial ghrelin levels 
can be attributed to a high fraction of di- and tripeptides 
with branched-chain amino acids in the cod protein hy-
drolysate (CPH), facilitating rapidly absorption from the 
gastrointestinal tract and possibly capable of influencing 
pathways involved in the regulation of appetite.
As metabolism and energy expenditure decrease with 
age, middle-aged individuals often experience weight 
gain. Thus, middle-aged individuals might benefit from 
an intervention targeting appetite and hunger regulation. 
Data on the specific effect of a dietary supplement with 
a fish protein hydrolysate on ghrelin concentrations and 
sensations associated with appetite have, to our knowl-
edge, previously not been published. The present study 
aimed to assess the effect of a single, low dose of CPH 
before a breakfast meal on postprandial acylated ghrelin 
concentration and sensations associated with appetite in 
healthy, middle-aged to elderly subjects.
Material and methods
Data on subjects and methods have been described in de-
tail in a previous publication (14).
Trial design
The study was a double-blind crossover trial, which in-
cluded two study visits for each subject, with 4–7 days of 
washout in between. The intervention included serving 
of a test drink containing 20 mg of CPH per kg body 
weight (test material) or control (casein) in randomized 
order, immediately before a standardized breakfast meal 
was served. The CPH and casein powder were mixed with 
cold water and served as a drink. The primary outcome of 
the intervention (postprandial response in glucose metab-
olism) is reported in a previous publication (14). Here, we 
report the secondary outcome: acylated ghrelin concen-
trations measured for 180 min postprandially and subjec-
tive sensations associated with appetite.
This study was conducted according to the guidelines 
laid down in the Declaration of Helsinki, and all pro-
cedures were approved by the Regional Committees for 
Medical and Health Research Ethics of Central Norway 
(2017/1794). Written informed consent was obtained from 
all subjects. The trial was registered at clinicaltrials.gov as 
NCT03669796.
Participants
Subjects were recruited at Haukeland University Hospital 
and Ålesund Hospital between October 2017 and February 
2018. Potential subjects were interviewed for general 
eligibility and compliance with inclusion and exclusion 
criteria by telephone. Candidates were invited for a fur-
ther screening visit.
Inclusion criteria were as follows: age 40–65 years and 
body mass index (BMI) 20–30 kg/m2. Exclusion criteria 
were fish allergy, pharmacologically treated diabetes mel-
litus, elevated blood pressure, chronic diseases that might 
affect the evaluation of the study endpoints, and acute 
infections.
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Study protocol
The screening visit included a clinical examination 
by a physician, biochemistry tests for safety purposes 
(leukocyter, trombocytes, hemoglobin, fasting glucose, 
long-term blood glucose, C-reactive protein, creatinine, 
sodium, potassium, kidney function estimate, liver en-
zymes and muscle enzymes) and compliance with in-
clusion criteria, measuring of  height, weight, and blood 
pressure, as well as assessment of  the level of  physical 
activity. The level of  physical activity was assessed by 
asking the participants two questions regarding moder-
ate physical activity and vigorous activity (self-reported). 
The participants were instructed not to change the diet 
composition or the level of  physical activity during the 
study period. On the day preceding each study day, the 
participants received a standardized porridge evening 
meal to be eaten before 8:30 pm. After this, the subjects 
were instructed to fast until the next morning and were 
only allowed to drink water. On study days, the partici-
pants came to the research units in a fasting state between 
08:00 am and 09:00 am. After the first blood sample, the 
subjects were served the test drink, before the breakfast 
meal was provided. Fifteen minutes after the breakfast 
was served, the first post-meal sample (0 min sample) was 
taken.
The standardized breakfast meal consisted of two slices 
of bread (50% whole wheat, 80 g bread), 10 g margarine, 
20 g strawberry jam, and 20 g white cheese. This provided 
a total of 355 kcal (1,485 kJ, 41 g carbohydrate, 12.5 g 
protein, 15 g fat). The drink contained on average 35.9 g 
carbohydrate and 145 kcal (607 kJ). Thus, including the 
drink, the breakfast provided in total 500 kcal (2,092 kJ) 
and 77 g carbohydrate, equal at both study days. Water 
was given ad libitum, but no coffee or tea was allowed. 
The subjects spent 4 h in the research units, and repeated 
sampling of blood was conducted before serving of the 
test drink and breakfast, and at time 0, 20, 40, 80, and 
180 min postprandially.
Assessments
Assessment of medical history, measurement of biochem-
ical variables and safety parameters were conducted be-
fore randomization. During the two study visits, acylated 
ghrelin was measured in plasma samples taken before 
serving of the test drink and breakfast (baseline), at time 
0, 20, 40, 80, and 180 min postprandially. The subjects 
had 15 min to finish the breakfast before the 0 min sam-
ple was taken. Blood pressure was measured before inter-
vention, after 40 and 180 min after the intervention, as a 
safety parameter.
Appetite sensation was assessed on a Visual Analog 
Scale (VAS) of 100 mm in length, addressing the feeling 
of fullness and satiety. The VAS questionnaire also in-
cluded three questions regarding adverse gastrointestinal 
symptoms (pain, discomfort, and nausea). The VAS was 
filled out five times during the study visit, at baseline, time 
0 and 20, 40, and 180 min after the breakfast meal. Ad-
ditionally, a questionnaire validated for the evaluation of 
different gastrointestinal symptoms was filled out before 
the breakfast meal and at the end of each study day (21). 
The questionnaire assessed nausea, bloating, stomach 
pain, constipation, and diarrhea, as well as hunger/satiety 
with a score from 0 to 10, of which the score 10 indicated 
severe symptoms and being fully satiated.
Test materials
The test material was a lemon-flavored powder provided 
from the manufacturer (Firmenich Bjørge Biomarin AS, 
Ålesund, Norway) in standardized bottles to be added 
150 mL cold water. The powder contained 4% protein 
(CPH raw material or whole casein) and 96% carbohy-
drate (maltodextrin). Thorough laboratory tests assured 
that it was not possible to identify the active ingredient 
from the control, according to flavor or appearance. Each 
subject was given individually adjusted doses of  20 mg/
kg body weight of  CPH or casein. The drinks were made 
isonitrogenous to avoid bias due to difference in nitro-
gen content, and equal amounts of  nitrogen in the form 
of casein were added to the control drink. Both drinks 
contained on average 1.6 g protein; thus it constituted 
only a small fraction of the total protein content of  the 
standardized breakfast meal. Casein was chosen as the 
control as it has previously shown to not affect blood glu-
cose or insulin sensitivity when compared with proteins 
from cod and soya (22). The casein used as control was 
present as whole protein and did not contain free amino 
acids or peptides. The production and composition of 
the test  materials has been described in detail in previous 
publication (14).
Analysis of blood samples
Samples of venous blood were repeatedly collected using 
an intravenous catheter from the antecubital vein. Sam-
ples were analyzed according to standard accredited 
methods at the Laboratory for Clinical Biochemistry, 
Haukeland University Hospital (Bergen, Norway) and 
the Department of Medical Biochemistry, Ålesund Hos-
pital (Ålesund, Norway).
Plasma ghrelin was obtained by centrifugation of full 
blood using 4 mL anticoagulant (EDTA-K3)/Aproti-
nin blood collecting tubes (VACUETTE®, Greiner Bio 
One International GmbH, cat # 454261, Kremsmünster, 
Austria) at 1800 × g at 4°C for 10 min within 20 min after 
blood sampling. Plasma was stored frozen at −80°C prior 
to analysis. The ghrelin analyses were performed using 
Acylated Ghrelin-Easy Sampling Enzyme Immunoassay 
kit (Bertin Pharma, Montigny-le-Bretonneux, France, ref: 
#A11306).
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Statistical analysis
SPSS data package (SPSS Statistics 24.0, IBM Company, 
Armonk, NY, USA) and GraphPad Prism version 7.0 
(GraphPad Software, Inc., San Diego, CA, USA) were 
used for statistical analysis. Shapiro–Wilk’s test was con-
ducted to assess normal distribution of data. A multivari-
able, repeated-measures linear mixed-effects regression 
analysis (adjusted for BMI and gender) was conducted 
in SPSS in order to evaluate the difference between the 
concentrations of acylated ghrelin after CPH and control. 
The data for acylated ghrelin were non-normally distrib-
uted; thus, it was log-transformed before analysis and 
presented as log mean and back-transformed values (geo-
metric means). Graphical work and total area under the 
curve (tAUC) analysis for acylated ghrelin concentrations 
and symptom VAS-scores were conducted in GraphPad. 
The difference in baseline and end-point scores for the 
additional questionnaire was evaluated by a paired t-test. 
Assessment of correlations was done with Pearson’s cor-
relation coefficient. P-values < 0.05 were considered statis-
tically significant.
The number of participants was not calculated accord-
ing to a power analysis, due to lack of similar studies. 
Previous research reporting on effect of cod proteins in 
humans is based on whole fish (23) or long-term use of 
fish protein supplement (12, 13); thus, we did not find any 
data suitable as basis for power analysis for our design.
Results
Subjects
Seventy-eight subjects were screened for inclusion and ex-
clusion criteria over telephone, of which 47 were enrolled 
to a screening visit. Six participants withdrew before the 
first study visit, and 41 participants completed the trial, of 
which 15 males and 26 females. The inclusion process has 
previously been described and illustrated (14). The mean 
age of the participants was 51 ± 6 years (range 40–64 
years). The mean body weight of the participants was 
77.3 ± 13.5 kg. Dependent on body weight, the subjects 
consumed CPH in a dose ranging from 1.2 to 2.3 g (mean 
1.5 g). Mean BMI was 25.2 ± 3 kg/m2. Twenty-three par-
ticipants had BMI ≤ 25 kg/m2, whereas 18 participants 
had BMI > 25 kg/m2. Baseline characteristics and com-
parison of gender distribution are presented in Table 1.
Acylated ghrelin concentrations
Mean fasting acylated ghrelin levels were higher before 
the CPH intervention than before the control interven-
tion (97.4 ± 196.3 pg/mL vs. 90.0 ± 194.0 pg/mL, respec-
tively), but the difference was not significant (P > 0.999). 
Suppression of acylated ghrelin (Cmin) was greatest: 80 
min postprandially after CPH and 20 min postprandially 
after control, with a Cmin mean difference from baseline of 
−14.0 ± 21.4 after CPH and −5.3 ± 22.8 after control, at 
these times, respectively (P = 0.681).
Statistically, no differences were observed between CPH 
and control for postprandial acylated ghrelin concentra-
tion in a mixed-effects regression analysis (mean differ-
ence of the geometric mean: 1.05 pg/mL, 95%  confidence 
interval [CI]: 0.97–1.13, P = 0.266) (Fig. 1). Additionally, 
Table 1. Baseline characteristics of the 41 participants (26 females and 15 males) included in the study at the Haukeland University Hospital 
and Ålesund Hospital
Characteristics Total subjects (n = 41) Female (n = 26) Male (n = 15) P
Mean Standard deviation Mean Standard deviation Mean Standard deviation
Age, years 51.0 6.0 52.1 6.2 49.0 5.0 0.104
Body weight 77.3 13.5 71.6 10.8 87.2 12.3 0.001
Body mass index, kg/m2 25.2 3.0 24.7 3.0 26.0 2.9 0.183
Acylated ghrelin, pg/mL 93.7 194.9 81.4 184.7 115.0 210.6 0.453
Baseline acylated ghrelin concentrations are merged values for the baseline value at both study visits.
Fig. 1.  Metabolic response in acylated ghrelin concentration 
after intake of a standardized breakfast meal supplemented 
with a drink containing a cod protein hydrolysate (CPH) or 
control (casein). Results are presented for 41 healthy sub-
jects. Time point 0 min shows values measured right after 
the intake of breakfast and test drink. Values are presented 
as mean + SD. Statistically, no differences were observed be-
tween CPH and control for acylated ghrelin concentration in 
a mixed-model regression analysis (P = 0.266).
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no difference was observed between the tAUC for acylated 
ghrelin concentrations after CPH (tAUC = 17518  pg/
mL  × min, 95% CI: 0–47941) and control (tAUC  = 
17272 pg/mL × min, 95% CI: 0–48048, P = 0.991).
No correlation was observed between body weight 
(kg) and baseline concentration of acylated ghrelin 
(mean baseline value before CPH and control) (r = 0.118, 
P = 0.463). When adjusting for BMI and gender in the 
mixed-effects regression analysis, no differences were ob-
served between subjects with BMI ≤ 25 kg/m2 compared 
to those with BMI > 25 kg/m2 (P = 0.681), or between 
genders (P = 0.627).
Sensation of appetite 
Baseline scores for satiety were numerically the same 
before each intervention (CPH: 37.4 ± 26.6, control: 
35.1 ± 23.9, P = 0.997). No difference was observed 
between the tAUC for the postprandial satiety scores 
after CPH (tAUC = 10989 mm × min, 95% CI: 6794–
15185) and control (tAUC = 11742 mm × min, 95% CI: 
8001–15483, P = 0.794). Data are presented in Fig. 2a.
Baseline scores for the feeling of  fullness were 
numerically the same before each intervention (CPH: 
7.1 ± 15.7, control: 7.3 ± 17.5, P > 0.999). No differ-
ence was observed between the tAUC for the post-
prandial feeling of  fullness scores after CPH (tAUC = 
1306 mm × min, 95% CI: 0–3257) and control (tAUC = 
1243 mm × min, 95% CI: 0–3418, P = 0.966). Data are 
presented in Fig. 2b.
The questionnaire addressing hunger did not reveal any 
differences in the feeling of satiety and hunger between 
CPH (3.4 ± 1.8) and control (3.4 ± 2.3) 180 min after the 
breakfast (P = 0.822). Baseline scores did not differ before 
each intervention (CPH: 3.7 ± 2.7 and control: 3.0 ± 2.5, 
P = 0.165).
Gastrointestinal symptoms
There were no reports of adverse gastrointestinal symp-
toms (e.g. nausea, bloating, stomach pain, constipation, or 
diarrhea) during the exposure for either CPH or control.
Discussion
This study revealed no differences in postprandial con-
centrations of acylated ghrelin after a meal supplemented 
with CPH compared to control. Thus, we were unable to 
confirm our hypothesis that a single dose of CPH sup-
plementation before a meal would suppress ghrelin con-
centrations postprandially, and thereby cause reduced 
feeling of hunger. Moreover, we found no differences 
between control and CPH drink in the feeling of satiety 
or feeling of fullness, as measured by the implemented 
questionnaires.
In a previous publication, we reported that supple-
mentation with 20 mg CPH per kg body weight before a 
breakfast meal reduced the postprandial concentrations 
of  insulin compared to control in healthy individuals 
(14). Although not affecting glucose levels or concen-
trations of  GLP-1, we found that pre-prandial supple-
mentation with one low dose of  CPH may beneficially 
alter the glucose metabolism. An inverse correlation be-
tween postprandial insulin concentrations and plasma 
ghrelin has previously been reported (24), and changes 
in ghrelin concentration after CPH might affect post-
prandial insulin secretion. The major effects of  ghrelin 
are linked to mechanisms involved in avoiding starvation 
and promoting food intake and include stimulation of 
GH secretion to restrict peripheral glucose uptake, pro-
mote lipolysis, and suppress insulin secretion to prevent 
hypoglycemia (25). Due to this close link between glu-
cose metabolism and appetite control, it can be hypoth-
esized that supplementation with CPH might influence 
Fig. 2.  Symptom scores from a VAS-questionnaire addressing satiety (a) and the feeling of fullness (b) after intake of a stan-
dardized breakfast meal supplemented with a drink containing either a cod protein hydrolysate (CPH) or control (casein). 
 Results are presented for 41 healthy subjects. Time point 0 min shows values measured right after the intake of breakfast and test 
material. Values are presented as mean + SD. Statistically, no differences were found between CPH and control for sensation of 
appetite, according to the tAUC of postprandial scores for satiety (P = 0.794) and the feeling of fullness (P = 0.966).
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postprandial ghrelin concentrations and the feeling of 
hunger and satiety.
Our results are partly in line with previous similar sin-
gle-dose studies; however, few studies are comparable in 
test material. Most studies investigating the relationship 
between ghrelin levels after meals with different macro-
nutrient composition have found that a high-protein meal 
causes the ghrelin levels to be suppressed for a longer 
time than after the intake of a meal high in carbohydrates 
(26–31). Furthermore, it causes higher satiety scores post-
prandially than a meal containing regular or low amount 
of protein (28, 32). The mechanisms suggested to facil-
itate these findings include slowing of gastric emptying, 
increase of plasma insulin, glucagon, ghrelin, CCK, 
gastric inhibitory polypeptide (GIP), and GLP-1 after a 
high-protein meal (33).
Only a few studies have reported on the specific acute 
postprandial effect of a meal with proteins from fish, 
compared to other protein sources (34–36). A compari-
son of the effects of isocaloric meals with proteins from 
beef, chicken, or fish revealed a significantly higher satiety 
score after the fish meal compared to the other protein 
sources (34). A study evaluating the effect on satiety when 
comparing a fish protein meal with a beef protein meal 
revealed that subjects receiving the fish-meal had lower 
hunger scores and consumed less energy in the subsequent 
evening meal (36). In contrast, a study investigating the 
acute effect of meals based on proteins from cod or veal 
in combination with carbohydrates high- or low-glycemic 
index did not find any differences in appetite sensation, 
energy intake, or postprandial response in glucose, insu-
lin, or ghrelin levels when comparing the two different 
protein sources (35). Although some previous studies have 
reported fish proteins to suppress appetite, no effect has 
this far been reported for the levels of ghrelin. One previ-
ous study has reported on the specific hunger-regulating 
effect of a fish protein hydrolysate from blue whiting 
(2 g/day) (17). The fish protein hydrolysate was reported to 
suppress appetite when compared to placebo in a 2-week 
crossover trial in overweight women. According to post-
prandial measures after a standardized breakfast meal, it 
was observed that the fish protein hydrolysate significantly 
reduced sweet-cravings, as well as plasma glucose levels 
compared to placebo. This study was based on observa-
tions made in both in vitro and in vivo models, showing 
that the fish protein hydrolysate was capable of enhancing 
the secretion of CCK and GLP-1, both hormones con-
tributing to the regulation of energy intake (37).
In the present study, we hypothesized that a potential 
suppressing effect on appetite and postprandial ghrelin 
levels would occur due to the CPH containing a high frac-
tion of di- and tripeptides with the branched-chain amino 
acids leucine and isoleucine. We hypothesize that these 
peptides work as biologically active substances, which 
are rapidly absorbed from the gastrointestinal tract and 
possibly capable of influencing pathways involved in the 
regulation of appetite. Thus, a single low dose of peptides 
was administered to the participants. The amount of pro-
tein provided was so low that it can be regarded negligible 
per se, compared to the amount of protein provided in 
the breakfast meal. Several factors could explain the lack 
of observed effect. First, it is possible that one acute ex-
posure of the low concentration is not enough to induce 
the wanted effect. A different effect could might have been 
observed if  the participants had taken the CPH supple-
ment daily for a period of time, for instance over a period 
of 6–8 weeks.
A similar dose of  CPH as the one administered in our 
trial, has previously been reported to increase concen-
trations of  CCK and GLP-1 compared to placebo in a 
study including 120 overweight individuals given either 
1.4 or 2.8 g protein hydrolysate from blue whiting or pla-
cebo, for 90 days (18). The fish protein hydrolysate was 
found to be effective compared to placebo, but no differ-
ence in effect was observed between the two doses. This 
demonstrates a potential effect when CPH is adminis-
tered orally in doses of  approximately 15–20 mg per kg 
body weight. In our study, the subjects consumed CPH 
in a dose range from 1.2 to 2.3 g (mean 1.5 g), dependent 
on body weight. Thus, if  an effect was to be observed, 
this could possibly have been attributed to the presence 
of  bioactive peptides.
The results have to be interpreted taking certain 
strengths and limitations into account. First, the random-
ized, crossover design as well as the successful blinding 
with similar test drink and control is a strength of this 
study. Furthermore, the adjustment of peptide dose ac-
cording to the body weight of each participant can be 
regarded as an improvement in accuracy compared to 
previous investigations of protein meals and the few stud-
ies investigating a marine protein hydrolysate, as this may 
reduce the effect of variation in body weight. It can be 
regarded a weakness of the design that the control drink 
contained casein in equal amounts as CPH, and that we 
did not include a true placebo without protein. However, 
as discussed above, the hypothesized effect is attributed 
to the presence of bioactive peptides and not protein per 
se. Whole casein was chosen as control, so the observed 
effect should not be simply due to differences in energy 
and nitrogen content. Casein has previously been shown 
to not affect glucose metabolism when given in low con-
centrations (38). We could arguably have investigated the 
effect of CPH on several different hunger-regulating hor-
mones, for instance, CCK, which has been measured in 
few other studies investigating the effect of a fish protein 
hydrolysate on appetite (17, 18). The assessment of ap-
petite could have been improved by using a more com-
prehensive instrument at all timepoints (39). However, 
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the use of VAS ratings in the evaluation of appetite in 
healthy subjects is a previously validated method (40). An 
ad libitum lunch meal with subsequent calculations of ac-
tual energy intake after CPH and control could have been 
included for a better and more detailed investigation of 
appetite. Furthermore, it is possible that the lack of suffi-
cient previous data to perform a power analysis could re-
sult in too few included participants to be able to observe 
an effect. We decided to include 40 participants, a number 
greater than or equal to previously reported studies on 
cod protein (12, 13, 23).
Further studies should aim to evaluate the impact of 
fish protein hydrolysates on different metabolic pathways 
involved in glucose metabolism and appetite control, such 
as regulation of different hunger-regulating hormones. In 
addition to ghrelin, insulin-like peptide 5 (INSL5) is quite 
recently suggested to be an orexigenic hormone influenc-
ing appetite and regulation of food intake (41). Thus, fu-
ture studies should aim to evaluate the appetite-regulating 
effect of CPH on several hormones, including INSL5. As-
sessments of such response can arguably contribute to the 
expansion of knowledge on the effects of CPH, as well as 
possibly reveal new preventive and treatment options for 
overweight and obesity. Based on the current literature, 
the effect could be more apparent if  the fish protein hy-
drolysate had been given daily over a period of time, and 
if  it had been investigated in a target group of overweight 
and obese individuals.Thus, the design of future studies 
should take this into account.
In conclusion, we did not find any effect of a single 
dose of CPH on postprandial concentrations of acylated 
ghrelin, or sensations-related appetite in healthy individu-
als, when compared to control after a standardized break-
fast meal.
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Abstract
A large proportion of older adults are affected by impaired glucose metabolism. Previous studies with fish protein have reported improved glucose regu-
lation in healthy adults, but the evidence in older adults is limited. Therefore, we wanted to assess the effect of increasing doses of a cod protein hydrolysate
(CPH) on postprandial glucose metabolism in older adults. The study was a double-blind cross-over trial. Participants received four different doses (10, 20,
30 or 40 mg/kg body weight (BW)) of CPH daily for 1 week with 1-week washout periods in between. The primary outcome was postprandial response in
glucose metabolism, measured by samples of serum glucose and insulin in 20 min intervals for 120 min. The secondary outcome was postprandial response
in plasma glucagon-like peptide 1 (GLP-1). Thirty-one subjects aged 60–78 years were included in the study. In a mixed-model statistical analysis, no dif-
ferences in estimated maximum value of glucose, insulin or GLP-1 were observed when comparing the lowest dose of CPH (10 mg/kg BW) with the
higher doses (20, 30 or 40 mg/kg BW). The estimated maximum value of glucose was on average 0·28 mmol/l lower when the participants were
given 40 mg/kg BW CPH compared with 10 mg/kg BW (P = 0·13). The estimated maximum value of insulin was on average 5·14 mIU/l lower with
40 mg/kg BW of CPH compared with 10 mg/kg BW (P= 0·20). Our findings suggest that serum glucose and insulin levels tend to decrease with increas-
ing amounts of CPH. Due to preliminary findings, the results require further investigation.
Keywords: Fish protein: Cod protein: Marine peptides: Marine protein hydrolysate: Glucose homeostasis
The human body is dependent on a tight regulation of blood
glucose levels to ensure normal function(1). Blood glucose
levels are regulated within a narrow range, and glucose homeo-
stasis is maintained through an intricate network of hormones
and neuropeptides that are released in the body(1,2). With
increasing age, glucose metabolism changes and a large pro-
portion of older adults are affected by impaired glucose
metabolism(3,4). Since skeletal muscle is the major site for
insulin-stimulated uptake of glucose(5,6), it has been suggested
that low skeletal muscle mass observed in some older adults
† Equal contribution.
Abbreviations: BW, body weight; CPH, cod protein hydrolysate; GLP-1, glucagon-like peptide 1.
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with reduced muscle mass and function might result in
reduced capacity for glucose disposal(7). Furthermore, higher
fasting and postprandial values of glucose and insulin have
been associated with lower muscle mass in older adults(8).
The gradual decline in muscle mass and function observed
with increasing age(9–11) is a major threat to healthy ageing,
and causes reduced mobility, increased disability, loss of inde-
pendence and overall reduced quality of life(12,13).
Several previous intervention studies have reported
improved insulin sensitivity(14,15) and glucose tolerance(14,16)
in humans and rodents after supplementation with fish pro-
tein. Furthermore, 3-month supplementation with a daily
dose of 1·4 g protein hydrolysate from blue whiting given to
overweight adults increased blood concentrations of glucagon-
like peptide 1 (GLP-1). No further effects were observed when
the participants were given a higher dose of 2·8 g, which might
indicate a plateau effect starting at 1·4 g(17). GLP-1 is released
from the enteroendocrine L-cells in response to food intake
and lowers blood glucose levels by stimulating insulin secre-
tion, suppressing glucagon secretion and slowing gastric
emptying(18). In general, fish protein and hydrolysates from
fish protein have a well-balanced distribution of amino acids
and should be considered a high-quality protein source, and
there is an increasing amount of evidence supporting a favour-
able effect of these proteins on metabolic health(19).
The evidence of health effects of cod protein as a nutritional
supplement is limited, and only a few studies in healthy and
overweight adults have been conducted. A recent study
reported that an 8-week supplementation with 6 g of residual
material from cod (press-cake meal) in a group of overweight
or obese adults resulted in decreased postprandial concentra-
tions of serum NEFA, which might indicate an effect on mar-
kers for glucose regulation(20). In addition, a small pilot study in
overweight adults observed improved glucose regulation after
daily supplementation with 2·5 g of protein from cod for 8
weeks(21). No changes in insulin, insulin C-peptide or NEFA
in serum were observed(21). Furthermore, we recently demon-
strated that supplementation with a single dose of 20 mg/kg
body weight (BW) of a protein hydrolysate from cod, given
before a breakfast meal, reduced postprandial insulin secretion
in forty-one healthy adults between 41 and 64 years, when com-
pared with control(22). We did not observe any effects on post-
prandial blood glucose response or on the levels of GLP-1.
Based on current knowledge, it is of interest to further
explore potential favourable effects of cod protein on para-
meters closely related to muscle health, including parameters
of glucose metabolism in an older population. To our knowl-
edge, no previous trial has evaluated the effect of increasing
doses of a supplement with cod protein hydrolysate (CPH)
on glucose metabolism in older adults. Therefore, the aim of
the present study was to investigate the effect of supplementa-
tion with four different weight-adjusted doses of a CPH on
postprandial glucose regulation in a group of older adults
aged 60–80 years. Based on the results from the study, we
hoped to create a basis for selecting an effective daily dose
of CPH for further use in clinical study protocols in patient
groups with muscle health issues, inflammatory conditions
or abnormal glucose metabolism.
Experimental methods
Study design
The study was a double-blind cross-over trial. The participants
received four different doses (10, 20, 30 or 40 mg/kg BW) of
CPH daily for 1 week with 1-week washout periods in between
the dose intervals. Each participant received all four different
dose intervals in random order. The participants were
instructed to take the supplement each morning before break-
fast for 7 d. After an initial screening visit, included partici-
pants came to the research unit on four different occasions,
separated by 2 weeks. In total, the study lasted for 7 weeks.
The primary outcome was postprandial response in glucose
metabolism, measured by venous samples of glucose and insu-
lin. Secondary outcomes were plasma GLP-1 and adverse
effects measured by symptom questionnaires.
The study was conducted according to the guidelines laid
down in the Declaration of Helsinki and all procedures involv-
ing human subjects were approved by the Regional Committee
for Medical and Health Research Ethics of Central Norway
(2017/1795). Written informed consent was obtained from
all subjects. The trial is registered at www.clinicaltrials.gov as
NCT03526744.
Participants
Participants were recruited by advertisement on the external
websites and on notice boards at Haukeland University
Hospital, Bergen and Ålesund Hospital, Ålesund.
Recruitment took place between March and July 2018, and
the study was conducted between April and November of
the same year.
Potential participants were screened for general eligibility by
telephone, and suitable candidates were invited for a baseline
evaluation visit, with further information and baseline blood
chemistry. The criteria for inclusion were age between 60
and 80 years, BMI between 20 and 30 kg/m2 and signed
informed consent. Criteria for exclusion were allergy and intol-
erances to fish and/or shellfish, pharmacologically treated dia-
betes mellitus, low or unstable blood pressure, chronic
diseases or medication that were likely to interfere with the
evaluation of the study endpoints, acute infections, substance
misuse (excessive alcohol consumption and/or narcotic sub-
stances assessed by physician) or unwillingness to comply
with the requirements of the study. The participants were
instructed to not take any nutritional supplements containing
n-3 PUFA for 2 weeks before study commencement and dur-
ing the course of the study.
Study protocol
The participants came to the research unit on five different
occasions, including a screening visit. Before inclusion, the
subjects underwent clinical examination by a physician, base-
line biochemistry and measurement of height, weight and
blood pressure.
A 3-d prospective diet diary was recorded prior to starting
the intervention, and at the end of the study period. The
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level of physical activity was assessed at baseline and at the end
of the study by asking the participants two questions regarding
moderate physical activity and vigorous activity (self-reported).
The participants were instructed not to change diet habits or
the level of physical activity during the study period.
The study consisted of four different intervention cycles.
Before each intervention cycle, the participants received six
bottles containing powder with CPH, labelled 1 to 6. We
instructed the participants to take one bottle each morning
during the intervention cycle. On days of study tests, day 7
in each intervention cycle, the participants came to the
research facility in a fasting condition between 08.00 and
09.00 hours. After baseline blood sampling, we gave the last
dosage of CPH followed by a standardised breakfast meal
10 min later. At 25 min after the CPH drink was served and
15 min after the breakfast meal had started, we took the
first postprandial blood sample (0 min sample). Thereafter,
the participants spent 2 h in the vicinity of the research unit
to allow for repeated sampling of blood, at 20 min intervals
until 120 min.
The standardised breakfast meal consisted of two slices of
semi-coarse bread (50 % whole wheat, 80 g bread), 10 g mar-
garine, 20 g strawberry jam and 20 g white cheese, providing a
total of 1485 kJ (355 kcal), 41 g carbohydrate, 12·5 g protein
and 15 g fat. The drink contained 22·5 g carbohydrate and
approximately 418 kJ (100 kcal), and including the drink, the
breakfast provided in total 1900 kJ (455 kcal). The amount
of energy and carbohydrates in the breakfast was calculated
to induce an adequate blood glucose response. No coffee or
tea was served, but water was given ad libitum.
We handed out the six bottles for the next intervention cycle
at the end of the test day and gave instructions for when to
start the next intervention cycle. Between intervention cycles,
the participants had a washout period of 7 d. All participants
received a text message on the morning of the day they
were to start the next intervention cycle.
Assessments
At the screening visit we assessed the participant’s medical his-
tory and measured biochemical parameters for nutritional sta-
tus (albumin, prealbumin, vitamins B12 and D). We measured
biochemical safety parameters at the screening visit and the
end of study visit.
During the test days, baseline fasting serum glucose and
serum insulin were measured 25 min before the first postpran-
dial blood sample (time (t) = 0 min postprandial).
Subsequently, serum glucose and insulin were measured
every 20 min for 2 h (t = 20, 40, 60, 80, 100 and 120 min post-
prandial). Baseline GLP-1 was measured and thereafter post-
prandially at t = 0, 20, 40, 80 and 120 min. Blood pressure
was measured at three time points during the test day as a
safety parameter (t = 0, 40 and 120 min).
Two questionnaires evaluating the participants’ symptoms
were used to identify possible adverse events during each
intervention period and on study visits. In each intervention
period, a visual analogue scale was filled out before the parti-
cipants took the first dose with CPH on day 1 and before the
last dose on day 7. Further, a questionnaire validated for the
evaluation of gastrointestinal symptoms(23) was filled out 2 h
after intake of CPH on day 1 and day 7 (end of test day,
t = 120 min).
Test material
The protein hydrolysate powder was delivered from the manu-
facturer (Firmenich Bjørge Biomarin AS) in neutral bottles
coded with participant number and dose level (1–4). The bot-
tles were coded by a person not involved in the performance
of the study and the different dose levels were randomly allo-
cated to the participants according to a central digital random-
isation list. Study participants and investigators were blinded to
the dose content in the bottles (double-blinded study). The key
of randomisation was provided to the investigators when the
trial had ended, and the statistical analysis was completed.
The powder contained 4 % protein (CPH raw material) and
96 % carbohydrate (maltodextrin) and was flavoured with
lemon. The CPH raw material contained approximately 89
% protein by weight, <0·2 % fat, 0 % carbohydrate, <3·0 %
water, 10 % ash, 0·1 % NaCl, 1·7 % Na and 0·07 % chloride.
The amino acid composition of CPH raw material is presented
in Table 1. The hydrolysation process has been presented in a
previous publication(22).
Estimation of energy intake
Calculations of energy and macronutrient intake were per-
formed using Kostholdsplanleggeren (Norwegian Food Safety
Authority and The Norwegian Directorate of Health, Oslo,
Norway)(24), based on the reported food and drink intake
data from the participants at baseline and at the end of the
study. Participants registered their intake of food and drink
Table 1. Amino acid and taurine composition of the cod protein
hydrolysate used in the present study






















* Branched-chain amino acids.
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for three consecutive days, preferably including one weekend
day, prior to the first dose and at the end of the study. The
dietary records were used to record the participants’ diet pat-
terns and to assess whether the participants made changes to
their diets during the study period.
Analyses of blood samples
Baseline biochemistry was analysed according to standard
accredited methods at the Laboratory for Clinical
Biochemistry, Haukeland University Hospital (Bergen,
Norway) and the Department of Medical Biochemistry,
Ålesund Hospital (Ålesund, Norway).
Glucose and insulin were measured in serum according to
standard accredited methods at the Laboratory for Clinical
Biochemistry, Haukeland University Hospital (Bergen,
Norway). Serum was obtained by centrifugation of full
blood at 2000 g at room temperature (20°C) for 10 min
after 30–60 min of coagulation, using serum separator cloth
activator tubes. Samples were aliquoted and stored at −80°C
prior to analysis.
Plasma for the determination of GLP-1 was obtained by
centrifugation of EDTA full blood at 1800 g at −4°C for
10 min, within 20 min after blood sampling. Prior to sampling,
to EDTA blood sampling tubes were added 10 µl dipeptidyl
peptidase-4 inhibitor (DPP4-010; DRG Diagnostics) per ml
EDTA blood. GLP-1 plasma was aliquoted and stored at
−80°C prior to analysis. The GLP-1 analyses were performed
using an ELISA kit from IBL International GmbH (GLP-1
(7–36) active ELISA, reference RE53121).
Statistical analysis
Statistical analyses were performed using Stata v15.1
(StataCorp LLC) and SPSS software (IBM SPSS Statistics
24). Graphical work was conducted in GraphPad Prism ver-
sion 7.0 (GraphPad Software, Inc.). Data are presented as
means and standard deviations for continuous variables, and
frequencies and relative frequencies for categorical variables.
To estimate the effect of dose we calculated the maximum
observed value and the AUC for the time course of each
outcome variable, for each combination of person and dose.
We then fitted mixed models with the outcome measure
(maximum value or AUC) as the dependent variable, fixed
effects of dose and random intercepts across persons.
Carry-over effects were assessed using a standard
likelihood-ratio test to test for interaction between dose and
ordering. Paired-samples t tests were used to compare changes
in energy intake and macronutrient intake from baseline to the
end of the study. P values <0·05 were considered statistically
significant.
The sample size was not feasible to calculate for power ana-
lysis, due to lack of similar studies. Possible health effects of
supplementation with residual material from cod as protein
hydrolysate has previously not been studied in a group of
older adults, and therefore we had no basis for calculating




From April to June 2018 we screened fifty-one subjects for
study participation and thirty-three were enrolled in the
study (Fig. 1). Two of the included participants were excluded
before the first test day due to difficulties with blood sampling.
Overall, thirty-one subjects aged 60–78 years completed the
trial (thirteen males and eighteen females). One participant
had to be excluded on the final study day due to difficulties
with blood sampling; therefore data on glucose, insulin and
GLP-1 are only available for three of the dose levels. Four
of the participants were excluded from the final statistical ana-
lysis of GLP-1 due to analytical errors. Baseline characteristics
of the participants are presented in Table 2.
Energy and macronutrient intake
No statistically significant differences were observed in energy
intake or macronutrient intake during the course of the study
(Table 3). One participant did not fill out the 3-d food record
at the end of the study. Based on the reported intake of protein
from the food diaries at baseline and at the end of the study,
an average intake of 1·2 g protein/kg BW at baseline was esti-
mated and this did not change during the study period (P =
0·36; estimated average intake at end of study 1·1 g protein/
kg BW).
Postprandial measurements
In a mixed-model analysis, no statistically significant differ-
ences in estimated maximum value of glucose, insulin or
GLP-1 were observed when comparing the lowest dose of
10 mg/kg BW of CPH with 20, 30 or 40 mg/kg BW
(Table 4). The estimated maximum value of glucose was on
average 0·28 mmol/l lower when the participants were given
the highest dose of 40 mg/kg BW CPH compared with the
lowest dose of 10 mg/kg BW (P = 0·13). The estimated
maximum value of insulin was on average 5·14 mIU/l lower
after participants were given the highest dose of 40 mg/kg
BW of CPH compared with the lowest dose of 10 mg/kg
BW (P = 0·20). The estimated maximum value of GLP-1
was on average 0·34 pmol/l lower when given the highest
dose (40 mg/kg BW) compared with the lowest dose of
CPH (10 mg/kg BW) (P= 0·48). No carry-over effect was
observed for glucose (P= 0·19), insulin (P = 0·21) or GLP-1
(P = 0·08).
No statistically significant differences in AUC between the
four different doses were observed for any of the outcome
measures when comparing the lowest dose of 10 mg/kg BW
of CPH with the higher doses of 20, 30 or 40 mg/kg BW.
For glucose, AUC was calculated from t = baseline until
t = 80, excluding t = 100 and t = 120 (Fig. 2), based on the
assumption that for the majority of individuals, glucose levels
had returned to their baseline levels. The AUC for glucose was
on average 1·16 mmol/l ×min higher when given 20 mg/kg
BW of CPH (P = 0·14), on average 0·27 mmol/l ×min higher













Attended the screening visit
(n 39)
Randomly contacted and 




































screening visit (n 12)
Fig. 1. Flowchart depicting the inclusion and randomisation process. BW, body weight.
Table 2. Baseline characteristics of the thirty-one participants





Age (years) 67·8 4·9
Weight (kg) 76·6 11·3
BMI (kg/m2) 26·0 2·6
Systolic BP (mmHg) 137 15
Diastolic BP (mmHg) 82 10
HbA1c (mmol/mol) 36·7 4·3
Fasting glucose (mmol/l) 5·4 0·6
BP, blood pressure; HbA1c, glycated Hb.
Table 3. Dietary intake at baseline and at the end of the study*
(Mean values and standard deviations)
Baseline End of study
P†Mean SD Mean SD
Energy intake (kJ) 7765 1586 7807 1506 0·84
Protein (g) 86·9 20·6 84·2 18·1 0·32
Fat (g) 73·1 19·3 75·2 18·6 0·50
Carbohydrates (g) 215·2 65·4 213·8 55·8 0·95
* Food and drink intakes were registered for 3 d at baseline and at the end of the
study.
†Paired-samples t tests were used to compare changes in energy intake and
macronutrient intake from baseline to the end of the study. No significant differences
were observed during the course of the study.
5
journals.cambridge.org/jns
mmol/l ×min lower when given 40 mg/kg BW (P= 0·32),
when compared with the lowest dose of 10 mg/kg BW of
CPH. If all measuring points were included in the statistical ana-
lysis of glucose, also including t = 100 and t = 120, the
significance of the results did not change (Fig. 2). For insulin,
the AUC was on average 11·3 mIU/l ×min higher
when given 20 mg/kg BW of CPH (P = 0·49), on average
6·84 mIU/l ×min higher when given 30 mg/kg BW of CPH
(P= 0·67) and on average 7·4 mIU/l ×min lower when given
40 mg/kg BW (P = 0·65), when compared with the lowest
dose of 10 mg/kg BW of CPH. For GLP-1, the AUC was on
average 1·38 pmol/l ×min lower when given 20 mg/kg BW
of CPH (P = 0·36), on average 0·01 pmol/l ×min lower
when given 30 mg/kw BW of CPH (P = 0·99) and on average
1·09 pmol/l ×min lower when given 40 mg/kg BW of CPH
(P= 0·47), when compared with the lowest dose of 10 mg/kg
BW of CPH. A graphical representation of the metabolic
response for serum glucose, serum insulin and plasma GLP-1
concentration on the test day, the last day in the four different
intervention cycles, is presented in Fig. 2. A bar chart showing
total AUC for serum glucose, serum insulin and plasma GLP-1
is presented in Fig. 3.
Adverse effects
No adverse effects were reported in the questionnaires, from
the biochemical safety parameters or from the biochemical
parameters for nutritional status.
Discussion
The overall objective of the present study was to evaluate the
effect of increasing doses of a supplement with CPH on glu-
cose metabolism in older adults, aiming to find a dose
response and creating a basis for an optimal daily dose for
future clinical use. We investigated the effect on postprandial
glucose regulation of four different doses of a CPH supple-
ment (10, 20, 30 and 40 mg/kg BW) taken daily for 1 week.
Although no statistically significant differences were observed
between the postprandial measurements after the four differ-
ent doses, our results indicate that the highest dose of CPH
(40 mg/kg BW), equal to 3·2 g/d in an individual with a
BW of 80 kg, is the most efficient in lowering postprandial
blood glucose levels and insulin concentrations, when com-
pared with the lower doses (10, 20 and 30 mg/kg BW).
In a previous publication, we reported that a single dose of
20 mg/kg BW CPH significantly reduced postprandial insulin
concentrations in healthy, middle-aged to older individuals,
without affecting postprandial glucose levels or GLP-1 levels,
compared with control (casein)(22). We hypothesised that the
CPH might enhance the insulin sensitivity and affect other
mechanism involved in blood glucose uptake in peripheral tis-
sue. The significantly lower insulin concentration after intake
of CPH may be of more interest in patients with reduced insu-
lin sensitivity.
To our knowledge, only one small pilot study has been con-
ducted with fish protein hydrolysate in an older population(25).
In this double-blind, randomised controlled study, a daily diet-
ary supplement of 5·2 g fish protein hydrolysate from blue
whiting, or placebo, was given to twenty-four nursing home
residents daily for 6 weeks. No differences in serum concen-
trations of glucose or insulin after 6-week supplementation
with fish protein were observed, when compared with pla-
cebo(25). However, since this was a study population with
Table 4. Estimated maximum values of glucose, insulin and glucagon-
like peptide 1 (GLP-1) derived from a mixed model





difference 95 % CI P
Glucose (mmol/l) 10 0 (Reference)
20 0·33 −0·04, 0·70 0·08
30 0·09 −0·29, 0·46 0·65
40 −0·28 −0·65, 0·08 0·13
Insulin (mIU/l) 10 0 (Reference)
20 3·59 −4·34, 11·5 0·38
30 3·42 −4·60, 11·4 0·40
40 −5·14 −13·1, 2·79 0·20
GLP-1 (pmol/l) 10 0 (Reference)
20 −0·66 −1·59, 0·28 0·17
30 −0·11 −1·06, 0·84 0·83
40 −0·34 −1·28, 0·59 0·48
BW, body weight.
Fig. 2. Metabolic responses for serum glucose (a), serum insulin (b) and plasma glucagon-like peptide 1 (GLP-1) (c) concentrations after intake of a standardised
breakfast meal and the last dosage of the cod protein hydrolysate (CPH). Dose levels were 10, 20, 30 and 40 mg/kg body weight (BW). Results for serum glucose
and insulin are presented for all thirty-one subjects, whereas for GLP-1 the results are presented for twenty-seven subjects (four participants were excluded from the
statistical analysis due to analytical errors). Values are means. Time point 0 min is the first postprandial blood sample, taken 25 min after the drink was served and 15
min after the breakfast meal started. BL, baseline.
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older adults who lived in a nursing home setting, the results are
not directly transferable to our study population with home-
dwelling older adults.
Based on a few previous studies investigating the effect of
supplements containing protein hydrolysates from fish on
metabolic health(17,26), we hypothesised that small doses of
CPH may be effective due to the content of small, easily
absorbable bioactive peptides. These are capable of rapidly
affecting different metabolic pathways involved in glucose
regulation and hence leading to a more rapid glucose response
in the body. Thus, we presume that a potential observed effect
on postprandial glucose metabolism can be attributed to the
content of small, bioactive peptides in the supplement, and
not the protein intake per se, which is negligible compared
with overall protein content in a normal meal. Previous studies
investigating supplements with fish protein or hydrolysates of
fish proteins have reported doses in the range of 1 to 6 g per d
to beneficially influence blood glucose metabolism when com-
pared with control(16,17,21,26).
The results have to be interpreted taking certain limitations
in the design into account. The use of a cross-over design
always implies a risk of a carry-over-effect. According to ana-
lysis of all possible interaction effects between doses and time
periods, the results in this cross-over trial are not biased by a
carry-over effect. We included a washout period of 7 d
between each week of peptide supplementation. We presume
1 week to be a sufficient washout period, as dietary protein
in general has a high turnover rate and the investigated
doses of protein hydrolysate were low(27). On study days, the
supplement was given to the participants 10 min before break-
fast and 25 min before the first postprandial blood sample was
taken. This design might have caused a metabolic response
even before the breakfast was served. As a result, we may
have missed some early information on postprandial glucose
response. Furthermore, a 2-week washout period for the use
of supplements containing n-3 PUFA before starting on the
first dose of CPH may not have been enough and a longer
washout period could arguably have strengthened the design.
It is possible that the short supplementation period of 1
week could have affected the results, and that a longer period
would have been preferable. However, we have previously
observed an effect after only one acute supplementation (20
mg/kg BW) in healthy middle-aged adults(22). A longer inter-
vention period would have made it more challenging to
include participants and avoid drop-outs, due to a long time-
frame of the study. Therefore, due to practical implementa-
tions of the study, 1 week of supplementation (7 d) for each
dose was chosen. Finally, the design could have been strength-
ened by including a postprandial blood sampling at day 0 for
each intervention cycle or a control group (0 mg/kg BW
CPH). However the study was performed based on a previous
study, where we report that a low dose of CPH (20 mg/kg
BW) significantly reduced the postprandial insulin concentra-
tion(22), and we therefore aimed to further evaluate the effect
of different doses in the present study. An additional study day
in each intervention period would also have made it more
challenging to include participants and avoid a high drop-out
rate, and would be difficult to implement due to limited
resources. Based on this, we chose to only include postpran-
dial blood sampling at the end of each intervention period.
To our knowledge, no previous publication has reported on
the metabolic effect of different low doses of fish protein
hydrolysate in an older adult population. Although no signifi-
cant differences were observed in this trial, our findings sug-
gest that low doses of fish protein hydrolysate might be
effective and capable of improving blood glucose regulation
in older adults. According to our findings, further studies
investigating effects of supplements containing hydrolysates
of fish proteins should be able to observe a metabolic effect
from doses starting around 40 mg/kg BW, equal to 3·2 g
per d in an individual with a BW of 80 kg. Based on this,
we suggest that a dose ranging from 3 to 4 g per d is a reason-
able starting point for future clinical studies. Due to prelimin-
ary findings, these results require further investigation.
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Abstract: Peptides from fish may beneficially a↵ect several metabolic outcomes, including gut health
and inflammation. The e↵ect of fish peptides in subjects with irritable bowel syndrome (IBS) has
not previously been investigated, hence this study aimed to evaluate the e↵ect of a cod protein
hydrolysate (CPH) supplement on symptom severity, gut integrity markers and fecal fermentation in
IBS-patients. A double-blind, randomized parallel-intervention with six weeks of supplementation
with 2.5 g CPH (n = 13) or placebo (n = 15) was conducted. The outcomes were evaluated at baseline
and the end of the study. The primary outcomes were symptom severity evaluated by the IBS
severity scoring system (IBS-SSS) and quality of life. The secondary outcomes included gut integrity
markers and pro-inflammatory cytokines in serum, fecal fermentation measured by concentration of
short-chain fatty acids (SCFAs) and fecal calprotectin. The groups were comparable at baseline. The
total IBS-SSS-scores were reduced in both the CPH-group (298 ± 69 to 236 ± 106, p = 0.081) and the
placebo-group (295 ± 107 to 202 ± 103, p = 0.005), but the end of study-scores did not di↵er (p = 0.395).
The concentrations of serum markers and SCFAs did not change for any of the groups. The baseline
measures for the whole group showed that the total SCFA concentrations were inversely correlated
with the total IBS-SSS-score (r =  0.527, p = 0.004). Our study showed that a low dose of CPH taken
daily by IBS-patients for six weeks did not a↵ect symptom severity, gut integrity markers or fecal
fermentation when compared to the placebo group.
Keywords: irritable bowel syndrome; bioactive fish peptide; short-chain fatty acids; low-grade
inflammation; gut integrity markers
1. Introduction
Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder a↵ecting between 10–20%
of the population [1], characterized by abdominal pain, bloating and/or distention, constipation and/or
Nutrients 2019, 11, 1635; doi:10.3390/nu11071635 www.mdpi.com/journal/nutrients
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diarrhea [2,3]. The pathophysiological mechanisms behind the condition are not fully understood
but are suggested to include a combination of genetics, diet, abnormal gut microbiota, abnormal gut
endocrine cells, increased intestinal permeability and low-grade inflammation [4,5].
Diet is considered as an important factor in IBS,with over half of the patients reportingworsening of
symptoms in relation to intake of certain foods [6]. The e↵ects of di↵erent sources of carbohydrates have
been investigated in patients with IBS. Further, a diet low in fermentable oligo-, di-, monosaccharides
and polyols (FODMAPs) is currently one recommended dietary treatment [2]. FODMAPs are poorly
digested in the small intestine. When reaching the colon fermentation of these carbohydrates by colonic
bacteria, this leads to the generation of gases and short chain fatty acids (SCFAs). The levels of these
metabolic end-products are altered in patients with IBS, conceivably causing symptoms [7,8]. The
SCFAs exert several important physiological functions, such as influencing pathways involved in the
gene regulation of the metabolism, inflammation and disease, as well as protect against diseases in
the gastrointestinal tract [9]. A diet low in FODMAPs is associated with distinct alterations in the
composition and function of the gut microbiota, and hence the levels of SCFAs. The long-term e↵ect of
the diet has not been well established [10,11].
Some dietary proteins are a source of bioactive peptides, exerting specific e↵ects extending beyond
the mere nutrient supply. These peptides can occur naturally by digestion in the gut or be consumed
as already hydrolyzed proteins in dietary supplements [12]. Several animal studies have suggested
that bioactive peptides from hydrolyzed fish proteins may beneficially influence health by improving
the lipid profile, body composition and glucose metabolism [13–16]. This is supported by increasing
evidence from recent clinical trials in human subjects, suggesting that supplements containing fish
protein hydrolysates may beneficially influence several metabolic outcomes [17–21]. In addition, it
is suggested that fish protein hydrolysates may have an immune-modulating e↵ect with beneficial
properties in the gut [22,23]. A chronic low-grade mucosal inflammation and increased intestinal
permeability have been assumed to contribute to symptom generation in IBS patients, and several gut
integrity markers have been investigated as potential biomarkers. These include zonulin, a physiologic
regulator of intercellular tight junctions and suggested as amarker for impaired gut-barrier function [24];
lipopolysaccharide-binding protein (LBP), an acute phase protein suggested as a marker of bacterial
translocation [25] and an intestinal fatty acid binding protein (iFABP), a marker for intestinal epithelial
cell damage [26]. The clinical implications of these gut integrity markers in IBS have not been
established. However based on the hypothesis of fish protein hydrolysate as a possible modulator of
the gut, they can be relevant for evaluation in combination with pro-inflammatory cytokines.
The evidence and knowledge are limited on the specific impact of di↵erent sources of proteins
in patients with IBS. According to clinical experience, IBS symptoms are most often linked to the
digestion of carbohydrates, and further, dietary proteins are normally well tolerated. Investigations of
di↵erent dietary sources of protein in healthy individuals have indicated that they a↵ect the diversity
and composition of the human gut microbiota in di↵erent degrees [27]. Recent results indicate that
the presence of fish proteins in the diet have an impact on the composition and activity of the gut
microbiome, influencing the microbiota composition [28]. To the authors’ knowledge, the e↵ect of a
peptide supplement in IBS patients has previously not been reported. The environmental and economic
benefits of expanding the utilization of by-products from the fishing industry, in addition to the need
for novel, additional dietary treatment strategies for patients with IBS, make this study warranted.
The aim of this studywas to evaluate the e↵ect of a supplementwith cod protein hydrolysate (CPH)
on inflammation and gastrointestinal health, including changes in IBS symptoms. For this purpose,
this study assessed symptom severity and analyzed gut integrity markers, including pro-inflammatory
cytokines in serum, fecal fermentation products (SCFAs) and fecal calprotectin in patients with IBS.
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2. Materials and Methods
2.1. Patients
The patients were recruited through advertisements on the internet between December 2018 and
January 2019. The potential subjects answering the online recruitment form were interviewed for
general eligibility and compliance with inclusion and exclusion criteria by telephone. The suitable
candidates then received more information and signed the informed consent form. A 3-day dietary
record and equipment to collect a baseline stool sample was sent by post to the participants prior to
the baseline visit at the hospital.
The inclusion criteria were age 20–70 years, BMI 18–30 kg/m2 and IBS diagnosis according to Rome
IV criteria with predominant diarrhea (IBS-D) or mixed bowel movements (IBS-M). The exclusion
criteria were fish allergy, diabetes mellitus, elevated blood pressure, chronic diseases (that might
a↵ect the evaluation of the study outcomes), acute infections, substance abuse, immunocompromised
patients defined as taking immuno-suppressive medications, patients eating a strict low-FODMAP
diet, use of antibiotics during the last 4 weeks before the inclusion or use of medications for the
IBS diagnosis.
2.2. Study Design and Protocol
The study was a double-blinded, randomized parallel group trial, and included a six-week
intervention with a drink containing 2.5 g CPH (test material) or 2.5 g maltodextrin (placebo). CPH or
placebo powder was delivered to the patients in sealed bags containing doses for one day. The patients
mixed the powder with water and drank it at least 10 min before breakfast each morning.
The baseline visit included assessment of medical data, IBS-diagnosis and biochemical variables.
The Rome IV criteria were used to confirm the clinical diagnosis of IBS [29]. The study outcomes were
evaluated at baseline and at the end of the study. The primary outcomes were symptom severity
evaluated by IBS severity scoring system (IBS-SSS) and quality of life (QoL). The secondary outcomes
included gut integrity markers and pro-inflammatory cytokines in serum, fecal fermentation measured
by a concentration of short-chain fatty acids (SCFAs) and fecal calprotectin. All subjects completed a
dietary record for three days prior to taking the fecal sample at baseline and at the end of the study.
The subjects were instructed not to make any changes in the diet while attending the study, and not to
take any nutritional supplements containing omega-3 or pre- or probiotics for 6 weeks before the study
start, and during the study.
The study was conducted according to the guidelines laid down in the Declaration of Helsinki
and the Regional Committees for Medical and Health Research Ethics of Central Norway (2018/1825)
approved all procedures involving human. All subjects gave written informed consent and the trial
was registered at clinicaltrials.gov as NCT03801057.
2.3. Test Material
The test material was a lemon-flavored powder provided from themanufacturer (Firmenich Bjørge
Biomarin AS, Ålesund, Norway) in standardized sealed plastic-coated aluminum bags containing 8 g
powder to be mixed with 100 mL cold water. Each powder bag contained 5 g glucose monohydrate,
0.0025 g Tastegram Powder Flavor, 0.1 g Lemongrass Durarome taste and 0.7 g citric acid, in addition to
2.5 g of CPH or maltodextrin (placebo). The thorough tests assured that it was not possible to identify
the active ingredient from placebo, according to the flavor or the appearance.
The cod protein hydrolysate powder was made by Firmenich Bjørge Biomarin AS by hydrolyzing
fish meat of Atlantic cod (Gadus morhua) with Protamex® (Novozymes AS) followed by spray drying of
the soluble part of the enzyme digest. The CPH raw material contained approximately 89% protein by
weight, <0.2% fat, 0% carbohydrate, <3.0%water, 10% ash, 0.1%NaCl, 1.7% sodium and 0.07% chloride.
The free amino acids accounted for 4.77% of the total amino acids in the cod protein hydrolysate (CPH),
and the ratio essential amino acids/non-essential amino acids was 0.70. The analysis of the molecular
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weight distribution showed that approximately 90% of the peptides in the CPH had a molecular weight
of 2000 Daltons (Da) or less (18 amino acids or less), approximately 75% of 1000 Da or less (10 amino
acids or less), while approximately 55% had a molecular weight of 500 Da or less (5 amino acids or less).
Approximately 25 to 30% of the peptides had a molecular weight less than 200 Da, which represents
small dipeptides and free amino acids. The production process and composition of the CPH raw
material has been described in detail in a previous publication [17].
The patients were randomly assigned to the experimental (CPH) or the control (placebo) group.
Randomization was completed using a computer-based automated sequence implemented in the
digital central case-report file (webCRF). The randomization sequence was generated by a person
blinded to the assignment of patients to the study groups. The random assignment order was created
using block randomization. The powder bagwas coded by a person blinded to the allocation of patients.
Both patients and study investigators were unaware of the study-group allocation (double-blinded
study). The key of randomization was provided to the investigators when the trial had ended, and the
statistical analysis was completed.
2.4. Blood Samples
The blood samples were taken at baseline and after the six-week intervention. General
biochemical tests were taken for safety purposes (albumin, prealbumin, vitamin-B12, vitamin-D,
leucocytes, thrombocytes, hemoglobin, HbA1c, CRP, sodium, potassium, ALAT, ALP, creatinine and
ASAT). The samples were analyzed according to standard accredited methods at the Laboratory
for Clinical Biochemistry, Haukeland University Hospital and Department of Medical Biochemistry,
Ålesund Hospital.
The gut integrity markers measured in the serum included iFABP, LBP and zonulin. In addition,
this study analyzed the following pro-inflammatory cytokines in serum—tumor necrosis factor alpha
(TNF-↵), interferon gamma (INF- ) and interleukins (IL-4, 6, 8, 10). The serum was obtained by
centrifugation of full blood at 2000⇥ g in room temperature (20  C) for 10 min after 30–60 min of
coagulation, using serum separator cloth activator tubes. The samples were aliquoted and stored at
 80  C until analysis. The analyses of cytokines were performed by a cytokine human ultrasensitive
magnetic 10-plex panel for LuminexTM platform, Cat# LHC6004 (Invitrogen, Thermo Fisher Scientific,
Waltham, MA, USA). Furthermore, iFABP was analyzed by Human FABP2 (intestinal) ELISA kit Cat#
EHFABP2 (Invitrogen, Thermo Scientific, Waltham, MA, USA), LBP was analyzed by Human LBP
(Lipopolysaccharide-binding protein) ELISA kit, Cat# EKH3120 (Biosite, Taby, Sweeden) and zonulin
was analyzed by IDK® Zonulin ELISA, Ref# K5601 (Immun diagnostic, Bensheim, Germany).
2.5. Fecal Samples
The fecal samples for analyses of calprotectin and SCFAs were collected before and after the
six-week intervention. The patients were instructed to freeze the samples immediately after collection
at home ( 20  C freezer) and bring the samples frozen to the hospital visits. The samples were stored
at  20  C until analysis.
The fecal samples for evaluation of calprotectin were collected in Calpro Easy Extract containers
(Calpro AS, Oslo, Norway) and calprotectin content was measured using CALPROLABTM Calprotectin
ELISA (ALP) CALP0170 (CALPROLAB, Calpro AS, Oslo, Norway).
The fecal samples for evaluation of SCFAs were collected in designated containers (Sarstedt AG
& Co., product No. 80.734.301, Numbrecht, Germany). Upon analysis, 0.5 g of the fecal material
was added to distilled water containing 3 mmol/L of 2-ethylbutyric acid (as internal standard) and
0.5 mmol/L of H2SO4. 2.5 mL and then homogenized. After homogenization, 2.5 mL of the sample was
vacuum distilled, according to the method of Zijlstra et al. [30], as modified by Hoverstad et al. [31].
The distillate was analyzed with gas chromatography (Agilent 7890 A, Calif., USA), using a capillary
column (serial No. USE400345H, Agilent J&W GC Columns, Calif., USA) and quantified using internal
standardization. Flame ionization detection was employed. The fecal samples were analyzed for both
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major SCFAs (acetic, propionic and butyric) and minor SCFAs (iso-butyric, valeric, iso-valeric, capronic
and iso-capronic acids). The results were expressed in mmol/kg wet weight.
2.6. Symptom Questionnaires
The symptoms related to the IBS diagnosis were assessed by symptom questionnaires at baseline
and after the six-week intervention. The severity of abdominal symptomswas assessed by the validated
IBS severity scoring system (IBS-SSS). The maximum score is 500 points, with the following grading:
Mild (75–175 points), moderate (175–300) and severe (>300 points). A reduction of 50 points or more
in the IBS-SSS questionnaire is regarded as clinically relevant [32]. The Quality of life (QoL) was
evaluated by the validated Short Form-Nepean Dyspepsia Index (SF-NDI) with a maximum sum score
of 50 points [33].
2.7. Estimation of Nutritional Intake
The calculations of energy and macronutrient intake, as well as FODMAP content in the diet, were
performed using the Nordic nutrient calculation program Dietist Net Pro (Bromma, Sweden). The
estimations reported were the mean daily intake based on three days of dietary records registered at
baseline and during the last days of the six-week intervention. The total FODMAP content is the sum
of calculated fructose, fructose in excess of glucose, lactose, fructans, polyols, fructo-oligosaccharides
(FOS) and galacto-oligosaccharides (GOS).
2.8. Statistical Analysis
The statistical analyses were conducted in SPSS data package (SPSS Statistics 24.0, IBM Company,
Armonk, NY, USA) and GraphPad Prism version 7.0. (GraphPad Software, Inc., San Diego, CA,
USA). For all graphical work, this study used GraphPad Prism. The data are presented as the
mean ± SD, unless otherwise stated. To compare the di↵erences between the baseline and the end
of the study measures for each subject, paired t-tests, and unpaired t-tests were used comparing
di↵erences between the CPH and the placebo group. The assessment of correlations was completed
with Pearson’s correlation coe cient. All tests were two-sided and p-values < 0.05 were considered
statistically significant.
A power calculation for estimation of the sample size was not performed. According to protocol,
this study intended to include 30 patients.
3. Results
3.1. Patient Characteristics
Thirty-one eligible patients were included, of whom 28 patients (23 women and 5 men) completed
the trial and were included in the analyses. Three patients withdrew after randomization, one patient
due to disliking the supplement and two patients due to experiencing increased diarrhea. The inclusion
process is showed in Figure 1. According to the Rome IV phenotype definition, 19 patients were
classified as diarrhea-predominant (IBS-D) and 9 patients as mixed bowel habits (IBS-M). Ten patients
reported to avoid specific high-FODMAP food items they experienced as problematic (e.g., lactose,
apples, wheat and/or garlic). In accordance with the inclusion criteria, no subjects followed a strict low
FODMAP diet. According to total IBS-SSS scores at baseline, IBS severity was classified as mild in 2
patients, moderate in 9 patients and severe in 17 patients. The groups were comparable at baseline,
except for a significant di↵erence in BMI. Table 1 elucidates the baseline characteristics.
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Figure 1. Flow-chart describing the inclusion process of the 28 irritable bowel syndrome (IBS) patients
completing the six-week trial and included in the analysis.
Table 1. The baseline characteristics of 28 irritable bowel syndrome (IBS) patients randomly allocated
to six weeks supplementation with either cod protein hydrolysate (CPH) or placebo.
Characteristics CPH (n = 13) Placebo (n = 15) p-Value
Age, years 42.7 (11.9) 45.1 (14.8) 0.647
Gender (male/female) 1/12 4/11 -
BMI, kg/m2 24.1 (2.8) 27.2 (3.9) 0.025 *
IBS-D/IBS-M 8/5 11/4 -
IBS severity 1 mild 0 2 -
moderate 5 4 -
severe 8 9 -
IBS-SSS sum score (0–500) 295 (107) 298 (69) 0.928
Energy intake, kcal/day 1750 (500) 1950 (395) 0.245
Protein intake, g/kg BW/day 1.2 (0.4) 1.0 (0.3) 0.185
Carbohydrates, g/day 140.0 (68.1) 180.2 (53.6) 0.093
Fiber, g/day 18.9 (7.6) 17.9 (5.7) 0.697
Total FODMAP 2, g/day 11.2 (6.6) 13.0 (11.3) 0.623
Alcohol, g/day 5.3 (6.8) 6.2 (8.6) 0.760
Fat, g/day 130.0 (190.5) 91.7 (22.6) 0.445
BW: body weight; BMI, Body Mass Index; IBS-D, IBS with diarrhea; IBS-M, mixed IBS; FODMAP, fermentable oligo-,
di-, monosaccharides and polyol; IBS-SSS, IBS severity scoring system. 1 IBS severity based on the baseline IBS-SSS
sum score: mild (75–175 points), moderate (175–300) and severe (>300 points); 2 Total FODMAP content in the diet
based on mean daily intake from 3-days dietary records. * Statistically significant di↵erence between the groups.
3.2. Irritable Bowel Syndrome Symptom Scores and Quality of Life
Table 2 reports symptom scores. According to total IBS-SSS scores, IBS symptoms improved from
baseline to after six weeks of intervention in both the CPH-group (from 298 ± 69 to 236 ± 106, p = 0.081)
Nutrients 2019, 11, 1635 7 of 13
and the placebo-group (from 295± 107 to 202± 103, p = 0.005) (Figure 2). Regarding themean di↵erence
from baseline to after the intervention, the total IBS-SSS score did not di↵er significantly between the
CPH-group ( 62 ± 118) and the placebo-group ( 93 ± 108, p = 0.471) (Figure 3). After the intervention,
the scores did not di↵er significantly between the groups (p = 0.395).
All IBS-SSS sub scores (pain severity, pain frequency, bloating, bowel habit dissatisfaction and life
interference) declined from baseline to the end of the study in both groups. For the placebo-group,
all symptoms declined significantly, whereas for the CPH-group, only bloating and life interference
significantly declined. Significant di↵erences between the groups for any other of the reported
symptoms, either at baseline or at the end of the study, did not occur. The baseline measures for the
whole group (n = 28) showed no significant correlations between total IBS-SSS scores and the calculated
total FODMAP content in the diet.
The scores for QoL declined in both groups from baseline to the end of the study, with a significant
reduction in the placebo-group (Table 2). The scores did not di↵er between the groups either at baseline
(p = 0.191) or after the intervention (p = 0.094).
Table 2. Symptoms scores at baseline and after the six-week intervention for IBS patients in the cod
protein hydrolysate (CPH) group and the placebo-group.
CPH (n = 13) Placebo (n = 15)
Symptom Scores Baseline End of Study p-Value Baseline End of Study p-Value
IBS-SSS Sum score 298.1 (68.9) 236.0 (105.9) 0.081 294.9(106.6) 201.7 (103.6) 0.005 *
Pain severity 45.0 (25.1) 39.2 (25.3) 0.096 43.3 (33.3) 25.0 (32.3) 0.016 *
Pain frequency 45.4 (34.3) 39.2 (25.3) 0.446 47.3 (35.5) 25.3 (28.5) 0.018 *
Bloating 65.9 (18.5) 46.0 (27.5) 0.046 * 59.3 (35.9) 37.0 (31.1) 0.038 *
Bowel habit
dissatisfaction 77.1 (20.1) 62.3 (30.8) 0.059 73.7 (26.2) 54.0 (30.1) 0.034 *
Life interference 78.5 (17.1) 57.4 (30.4) 0.023 * 71.3 (23.6) 60.3 (22.2) 0.034 *
SF-NDI Sum score 28.0 (7.1) 23.9 (9.1) 0.104 24.1 (7.9) 18.3 (7.9) 0.042 *
IBS-SSS: Irritable bowel syndrome severity scoring system, SF-NDI: Short Form-Nepean Dyspepsia Index, *
Statistically significant di↵erence between the baseline score the and end of study score.
Figure 2. IBS-SSS scores at baseline and after the six-week intervention for the cod protein hydrolysate
(CPH) group (n = 13) and the placebo-group (n = 15). The horizontal lines show the mean values.
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Figure 3. The reduction in total IBS-SSS scores from baseline to after the six-week intervention for the
cod protein hydrolysate (CPH) group (n = 13) and the placebo-group (n = 15) expressed as the mean
di↵erence from baseline.
3.3. Gut Integrity Markers and Pro-Inflammatory Cytokines in Serum
The values for gut integrity markers and pro-inflammatory cytokines in serum are shown in
Table 3. No significant changes in concentrations of LBP, iFABP or zonulin (ng/mL) were observed
between baseline and the end of the study, in either the CPH-group or the placebo-group. The levels of
zonulin were significantly lower for the CPH-group than the placebo-group at baseline (p = 0.011), but
no other di↵erences were observed between the groups. For the analyzed pro-inflammatory cytokines,
only IL-8 showed values within detectable range, thus no data are reported for IL-4, 6 10, TNF-↵ and
INF- . The concentration of IL-8 (pg/mL) increased from baseline to the end of the study in both
groups, but the increase was not significant, and no di↵erences were observed between the groups.
The baseline measures for the whole group (n = 28) showed no significant correlations between
the serum markers and the total IBS-SSS score.
Table 3. The concentrations of gut integrity markers and pro-inflammatory cytokines in serum samples
collected before and after six weeks of supplementation with cod protein hydrolysate (CPH) or placebo.
CPH (n = 13) Placebo (n = 15)
Inflammatory Marker Baseline End of Study p-Value Baseline End of Study p-Value
iFABP (ng/mL) 68.3 (43.2) 58.2 (28.0) 0.432 55.5 (20.1) 56.2 (28.7) 0.940
LBP (ng/mL) 6097 (2630) 6446 (2043) 0.355 6931 (3023) 6884 (3274) 0.925
Zonulin (ng/mL) 40.5 (5.6) 42.5 (6.3) 0.125 46.6 (5.9) 45.7 (5.3) 0.286
IL-8 (pg/mL) 8.8 (11.8) 11.4 (10.1) 0.185 7.4 (6.5) 8.9 (9.1) 0.413
iFABP: Intestinal fatty acid binding protein, LBP: Lipopolysaccharide binding protein, IL: Interleukin.
3.4. Fecal SCFAs
This study observed no significant changes in concentrations of any SCFAs between the baseline
and the end of the study measures, either in the CPH-group or the placebo-group. Table 4 outlines
the values. No significant di↵erences were observed between the groups for any of the measured
SCFAs, either at baseline or the end of the study. The fecal total SCFA concentrations at baseline for the
whole study population were inversely correlated with the IBS-SSS baseline sum score (r =  0.527,
p = 0.004) (Figure 4). No correlations were observed between the total SCFA concentration and the
serum markers or the total FODMAP content in the diet for the whole group at baseline.
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Table 4. Short-chain fatty acid (SCFA) concentrations (mmol/kg) in fecal samples collected before and
after six weeks of supplementation with cod protein hydrolysate (CPH) or the placebo.
CPH (n = 13) Placebo (n = 15)
Parameter Baseline End of Study p-Value Baseline End of Study p-Value
Total SCFA 51.8 (22.4) 55.7 (24.1) 0.591 62.6 (19.5) 62.4 (23.1) 0.997
Acetic acid 30.4 (12.3) 32.2 (14.5) 0.705 36.3 (11.9) 35.9 (11.3) 0.921
Propionic acid 9.9 (6.3) 10.4 (6.7) 0.768 10.7 (3.8) 10.8 (6.0) 0.963
Butyric acid 7.4 (3.9) 8.5 (5.0) 0.473 10.3 (4.5) 10.0 (5.1) 0.827
Iso-butyric acid 1.1 (0.5) 1.3 (0.6) 0.257 1.3 (0.7) 1.4 (0.8) 0.595
Valeric acid 1.1 (0.8) 1.2 (0.6) 0.785 1.7 (0.9) 1.8 (1.0) 0.805
Iso-valeric acid 1.6 (0.8) 1.9 (1.0) 0.322 1.9 (1.1) 2.0 (1.3) 0.554
Caproic acid 0.3 (0.5) 0.3 (0.4) 0.992 0.5 (0.5) 0.6 (0.8) 0.425
Iso-caproic acid 0.0 (0,0) 0.0 (0.0) - 0.01 (0.04) 0.01 (0.04) 0.670
Figure 4. The relationship between the total concentration of SCFAs and the total IBS-SSS score at
baseline for 28 patients with IBS. * The fecal total SCFA concentrations at baseline were statistically
significant inversely correlated with the IBS-SSS baseline sum score.
3.5. Fecal Calprotectin
No significant changes in concentration of fecal calprotectin was observed between the baseline
and the end of the study measures, either in the CPH-group (baseline: 137 ± 213 mg/kg, after
intervention: 129 ± 134 mg/kg, p = 0.216) or the placebo-group (baseline: 117 ± 248, end of study:
99 ± 157, p = 0.525). Numerically, the mean value decreased slightly from baseline to the end of the
study for both groups. No significant di↵erences were observed between the groups either at baseline
(p = 0.525) or at end of the study (p = 0.496).
3.6. Dietary Records
The comparison between the mean daily nutrient intake (kcal, proteins (g/kg body weight),
carbohydrates (g), fiber (g), total FODMAPs (g), fat (g) and alcohol (g)) revealed no di↵erences between
the two groups either at baseline or at end of the study. No significant changes in nutrient intake from
baseline to the end of the study were observed within each group.
3.7. Adverse Events
Three subjects allocated to CPH supplement withdrew after inclusion. One did not like the smell
of the supplement, thus reported nausea associated to consumption. Two subjects reported an increase
in IBS symptoms related to diarrhea and/or pain, of which one related the increase in symptoms to the
supplement, whereas one acknowledged the symptoms as a regular bad IBS period.
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4. Discussion
To the authors’ knowledge, this is the first study reporting on the e↵ects of a fish peptide
supplement in IBS patients. The study was designed to investigate the e↵ect of a dietary supplement
with cod protein hydrolysate, hypothesized to contain bioactive peptides with potentially beneficial
properties in the gut. This study observed no significant e↵ects of the supplement for any of the
outcome measures, when compared to the placebo.
The lack of e↵ects could be explained by several factors. It was a reduction in symptom scores
(primary outcome) during intervention in both the CPH and the placebo group, with a significant
reduction in the total score only in the placebo group, and no significant di↵erences between groups.
Interventions in IBS patients are likely to be influenced by a strong placebo or nocebo e↵ect [34]. As this
study did not observe any changes in secondary outcomes to support an e↵ect of the CPH supplement,
it was assumed that the symptom reduction in both groups can be attributed a placebo e↵ect, caused
by the patients’ expectations on symptom improvement when taking a dietary supplement in a clinical
trial. It is possible that a di↵erent e↵ect may have been observed if the hydrolysate was given in a
higher dose. Previous studies investigating the health e↵ects from a supplement containing hydrolyzed
proteins from fish in human individuals have reported beneficial metabolic e↵ects in a low dose range
of 1 to 6 g a day [17–20]. Based on this, the authors chose an intervention with 2.5 g per day. This dose
is negligible per se when put in context with the total daily dietary protein intake. Thus, if an e↵ect
were to be observed, our hypothesis was that it could have been attributed to the CPH.
According to our findings, no changes were observed in SCFA concentration after the intervention,
but there was an inverse correlation between the total SCFA concentration at the baseline and the total
IBS-SSS score when looking at the whole study population. This indicated that those with higher
concentrations of SCFAs have less IBS-related symptoms. Previous studies investigating alterations
in SCFA concentrations in IBS patients have reported inconsistent results. However, di↵erences in
fecal SCFA concentrations have been reported between IBS patients and healthy controls [35]. In
addition, altered concentrations of both SCFAs and cytokines have been observed in response to a
low-FODMAPdiet in IBS patients [36,37]. The clinical relevance of a change in fecal SCFA concentration
is currently not known. The fecal fermentation is dependent on both diet and gut microbiota, and the
primary source for colonic production of SCFAs is low-digestible carbohydrates [37]. As the intake of
carbohydrates did not change during the intervention, the lack of distinct findings in the current trial
was not surprising.
The authors hypothesized that the CPH might influence inflammation and gut permeability,
hence pro-inflammatory cytokines and gut integrity markers were evaluated. A change in either gut
integrity markers or pro-inflammatory cytokines in response to intervention was not observed. Based
on the theory of increased gut permeability and low-grade inflammation as a central contributor to
IBS etiology, several studies have compared a broad range of gut integrity markers and inflammatory
markers in IBS patients to healthy controls, aiming to identify possible biomarkers. To date, the
findings have been inconsistent, but a reported tendency has been altered levels of gut integrity
markers [24,26,38] and higher levels of pro-inflammatory cytokines [39–41] in IBS patients compared to
healthy controls. Interestingly, of the analyzed cytokines, only IL-8 showed values within a detectable
range at baseline, suggesting that neither IL-4, IL-6, IL-10, TNF-↵ or INF-  are relevant as inflammatory
markers for our IBS population with predominant diarrhea or mixed bowel habits. However, the
measured levels of fecal calprotectin, with the mean baseline levels of above 100 mg/kg and levels
above 50 mg/kg regarded as a positive value, support the assumption of low-grade inflammation as a
contributor to disease. Hence, other inflammatory markers other than the cytokines investigated in
this trial might be of interest in future studies.
The potential beneficial e↵ects of dietary supplements with peptides and amino acids are in
general not well investigated in IBS populations. Interestingly, Zhou et al. recently reported that
dietary supplementation with the essential amino acid glutamine significantly improved symptoms in
patients with post-infectious, diarrhea-predominant IBS [42]. Supplementation with glutamine (5 g per
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day for eight weeks) was found to restore the intestinal permeability, leading to a reduction of diarrhea
and abdominal pain, compared to the control (whey protein). Notably, the CPH used in our study
holds a low concentration of glutamine, 0.78 mg/g CPH, corresponding to 1.95 mg glutamine per day
with a dose of 2.5 g CPH (data on composition of the CPH are reported in a previous publication [17]).
The design holds some limitations. The cohort of the patients studied included only IBS-D and
IBS-M subtypes. The absence of the e↵ect of the intervention could be due to either the small cohort of
the patients studied or to the low dose used. A larger cohort, including all the IBS subtypes, is needed
before drawing any conclusion.
5. Conclusions
In summary, no e↵ects of a supplement with 2.5 g CPH given daily for six-weeks was observed on
symptom severity, gut integrity markers, pro-inflammatory cytokines or fecal fermentation products in
a small group of patients with IBS, when compared to the placebo. Future studies should aim to target
low-grade inflammation and evaluate the potential e↵ect of supplementation with peptides containing
bioactive sequences with known anti-inflammatory properties in IBS patients.
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